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Replication of many positive-strand RNA viruses have been shown to occur within 
intracellular membrane-associated compartments termed replication complexes. 
Replication of viral RNA occurs within these intracellular compartments as a way for 
the virus to concentrate the structural and non-structural components into a small 
area to facilitate replication as well as protecting the virus components from host-
cell pathogen recognition and innate immune responses. Using immunofluorescent 
confocal and electron microscopy, foot-and-mouth disease virus (FMDV) has been 
shown to dysregulate Golgi and ER-derived membranes, but to date, no distinct 
membrane-bound replication complex comprised of viral RNA, structural and non-
structural proteins, and host-cell proteins have yet to be identified for FMDV. 
The FMDV RNA-dependent RNA polymerase, 3Dpol, is the primary protein involved in 
virus genome replication and has been previously shown to form higher-order fibril-
like structures in vitro in the presence of RNA. These 3Dpol fibril structures could act 
to ‘scaffold’ replication complex formation. Here, several mutations were made in 
3Dpol to assess their role in higher-order complex formation. The ability for the 
different 3Dpol mutations to function was assessed biochemically, structurally and in 
cell culture. The results point towards the necessity for a fully functional (catalytically 
active) polymerase in the formation of the higher-order structures. Furthermore, 
complementation studies indicate that 3Dpol has two distinct functions necessary for 
replication within cells. 
Additionally, it was pertinent to investigate the role of membrane-associated kinases, 
such as PI4K, as a number of related viruses utilise this cellular pathway to form an 
v 
 
optimal environment within which viral replication can occur by upregulating the 
formation of lipids used in the building of intracellular membranes. Investigation of 
translation and replication of FMDV RNA within cells show that FMDV does not 
appear to utilise the PI4K pathway. These results highlight differences between 
FMDV and other related picornaviruses and provide a basis to investigate alternative 
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Chapter 1  
Introduction 
1.1 Picornaviruses 
1.1.1 Classification and genome structure 
Picornaviruses are a diverse family of small RNA viruses. The family consists of 35 
genera and over 80 species of single-stranded positive sense RNA (+ve ssRNA) viruses 
as classified by the International Committee on Taxonomy of Viruses (ICTV) in 2016 
(ICTV, 2016; Adams et al., 2017). Many of these viruses (summarised in Table 1.1) are 
significant causative agents of human and animal disease. Members include 
poliovirus (PV), human rhinovirus, bovine enterovirus, hepatitis A virus and, foot-
and-mouth disease virus (FMDV). PV, belonging to the genus Enterovirus, is one of 
the most well-defined viruses; much of the research on the replication processes of 
Picornaviridae is due to the discovery that PV could be propagated in cell culture 
(Enders et al., 1949) and for review see Racaniello, 2007. 
The term “picornavirus” is derived from “pico”, meaning small, and “RNA”, which 
refers to the ribonucleic acid contained within the non-enveloped, icosahedral capsid 
of all picornaviruses. Picornaviruses measure between 18-30 nm in diameter and 
contain a +ve ssRNA genome between ≈7.5-8.5 kb in length (reviewed in Racaniello, 
2007).  Despite being a diverse family, picornaviruses share a very similar genome 
structure and organisation (as highlighted in Fig. 1.1). The FMDV RNA encodes for a 
large single polyprotein that can be separated into three regions: P1 (1A-1D) that 
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encodes for the structural (capsid) proteins, P2 (2A-2C) and P3 (3A-3D) which encode 
for the non-structural proteins necessary for the replication of the genome and the 
manipulation of the host-cell environment. The genome is flanked by two highly 
structured untranslated regions (UTR) located at the 5ʹ and 3ʹ termini of the genome. 
The 5ʹ UTR is covalently linked to protein VPg, and contains a number of highly-
structured RNA elements including an internal ribosome entry site (IRES). The 3ʹ UTR 
is polyadenylated (Rueckert et al., 1984; Stanway, 1990) and contains two stem-loop 
structures preceding the poly-A tract. The two stem-loops at the 3ʹ UTR have been 
shown, through studies using FMDV infectious clones and passaging in cell culture, 
to be involved in the replication ability of the RNA. Exchanging the 3ʹ UTR with the 
equivalent region of swine vesicular disease virus, or deleting the 3’ UTR region 
abrogated virus replication (Sáiz et al., 2001). The FMDV 3ʹ UTR has also been shown 
to be involved in the circularisation of the genome by interacting with structural 
elements in the 5ʹ UTR (Serrano et al., 2006). 
Figure 1.1 Schematic representation of the FMDV genome organisation. Most 
picornaviruses share a similar genome structure and organisation. FMDV contains a 
very long 5ʹ UTR, a ‘leader’ protease (Lpro) coloured in light blue, and three tandem 
copies of the 3B protein. Adapted from (Forrest et al., 2014). 
Upon entry into the cell and after capsid uncoating, the FMDV RNA genome is 
translated in a cap-independent mechanism using the IRES located in the 5ʹ UTR. 
Following translation, the polyprotein is cleaved into the structural and non-
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structural proteins by two viral-encoded proteases: leader (Lpro) (present in some 
picornaviruses) and 3C, and by a region termed 2A that results in cleavage of the 
polyprotein through due to ribosome skipping (see section 1.2.3.5.1). 2A cleaves the 
structural P1 proteins away from the non-structural P2 and P3 regions, and 3C 
cleaves the remaining non-structural proteins into their active forms (Stanway, 1990; 
Lin et al., 2009). 
Despite sharing a similar genome organisation, a number of picornavirus species 
differ in some of their genomic constituents. A major difference between some 
picornavirus family members is located in the 5ʹ UTR. Cardioviruses and 
aphthoviruses have a significantly larger 5ʹ UTR than enteroviruses and rhinoviruses 
(1300 bp compared to 600 bp) as they contain a large poly-C tract. Other differences 
can be found within Lpro, 2A and in the number of 3B protein copies they contain 
(Palmenberg, 1987; Stanway, 1990). These are discussed in more detail in 
subsequent sections. 









Bovine rhinitis A virus EU236594 
Equine rhinitis A virus DQ272578 
Aquamavirus Seal aquamavirus AY593829 





Cardiovirus Encephalomyocarditis virus KC614703 
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Cosavirus Human cosavirus FJ438902 
Dicipivirus Canine picodicistrovirus JN819202 
Enterovirus 
Coxsackievirus A16 AY421760 
Coxsackievirus B3 M88483 
Poliovirus V01149 
Enterovirus D68 AY426531 
Rhinovirus A FJ445111 
Erbovirus Equine rhinitis B virus X96871 
Gallivirus Gallivirus JQ691613 
Harkavirus Falcovirus KP230449 
Hepatovirus Hepatitis A virus M14707 
Hunnivirus Hunnivirus JQ941880 
Kobuvirus Aichi virus AB040749 
Kunsagivirus Kunsagivirus KC935379 
Limnipivirus Carp picornavirus KF306267 
Megrivirus Turkey hepatitis virus HM751199 
Mischivirus Mischivirus JQ814851 
Mosavirus Mosavirus JF973687 
Oscivirus Oscivirus GU182408 
Parechovirus Human parechovirus S45208 
Pasivirus Pasivirus JQ316470 
Passerivirus Passerivirus GU182406 
Potamipivirus Eel picornavirus KC843627 
Rabovirus Rabovirus KP233897 
Rosavirus Rosavirus JF973686 
Sakobuvirus Feline sakobuvirus KF387721 
Salivirus Salivirus GQ179640 
Sapelovirus Avian sapelovirus AY563023 
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Genus Species examples Accession number 
Porcine sapelovirus AF406813 
Simian sapelovirus AY064708 
Senecavirus Seneca Valley virus DQ641257 
Sicinivirus Sicinivirus KF741227 
Teschovirus Porcine teschovirus AF231769 





Table 1.1 Summary of the 35 confirmed genera in the family Picornaviridae (as of 
2016). Adapted from ICTV 2016 Master Species List (ICTV, 2016). 
1.1.2 Aphthoviruses 
Aphthoviruses are a genus of picornaviruses, members include FMDV, bovine rhinitis 
A virus (BRAV), bovine rhinitis B virus (BRBV) and equine rhinitis A virus (ERAV), 
according to the ICTV (Knowles et al., 2012; Knowles, 2017) (Fig. 1.2). FMDV has 
seven serotypes that are prevalent globally (A, O, C, Asia-1 and South African 
Territories (SAT) 1, 2 and 3). FMDV is the causative agent of foot-and-mouth disease 
(FMD) in cloven hooved animals. BRAV has two serotypes, and BRBV only has one 
serotype. Both infect cattle, as their name suggests. ERAV contains one serotype and 
is the causative agent of upper respiratory infection in horses (Knowles, 2017). The 
different aphthovirus members contain a poly-C tract within the 5ʹ UTR, and an Lpro 
sequence marking the start of the polyprotein open reading frame (ORF). FMDV is 
the only aphthovirus species that contains three non-identical tandem repeats of 




Figure 1.2 Neighbour-joining phylogenic tree of the aphthovirus genus members. 
The P1 (1A-1D) amino acid sequences were used to show the relationship between 
the different serotypes of each species. The FMDV serotypes compared here are O, 
A, C, Asia-1, SAT1, SAT2 and SAT3. Accession numbers of each serotype is shown. 
Adapted from (Knowles, 2017).  
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1.2 Foot-and-Mouth Disease Virus 
1.2.1 History, Taxonomy and Epidemiology 
Foot-and-mouth disease (FMD) is a highly infectious, vesicular disease of both 
domestic and wild cloven-hooved animals including cattle, sheep, swine, goats, 
buffalo and deer (Otto, 1994; Pacheco et al., 2003; Grubman et al., 2004; García-
Briones et al., 2006). The first written description of FMD in cattle is believed to have 
been documented by Hieronymus Fracastorius in 1514, and later published in his 
major work “De contagione et contagiosis morbis et eorum curatione” (Infectious and 
contagious diseases and their treatment) where he also outlined the concept of 
epidemic disease in 1546 that identifies the transmission of a vesicular disease in 
cattle (Grubman et al., 2004). In 1897, at the dawn of the “virology era”, German 
scientists Loeffler and Frosch identified that the causative agent of FMD was 
filterable. This later led to the characterisation of foot-and mouth-disease virus 
(FMDV) (Loeffler et al., 1897; Modrow, 1929; Grubman et al., 2004). 
There are seven different serotypes of FMDV (A, O, C, Asia-1, SAT1, 2, and 3). The 
large number of FMDV serotypes contributes to the difficulty in the development of 
effective FMDV vaccines as there is no cross-protection. There is a global prevalence 
of FMDV and there is a propensity for regions to be endemic to a number of different 
serotypes, which can be classified as pools (Fig. 1.3) (Di Nardo et al., 2011; Jamal et 
al., 2013). Serotypes O, A and C were considered the most widely distributed 
(Knowles et al., 2005), however, it is believed that serotype C is no longer extant 
outside of laboratories with the last reported outbreak being in Ethiopia in 2005 
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(Rweyemamu et al., 2008), and the last reported outbreak of serotype A was in 
eastern Asia in 2010 (Park et al., 2013). Asia-1, SAT1 and SAT2 have a more limited 
geographic distribution. SAT3 is only present in pools identified in southern Africa. 
Figure 1.3 Map showing the geographical distribution of the seven different FMDV 
serotypes highlighted in pools. Map from (Jamal et al., 2013). 
1.2.2 Virus Transmission and Control 
FMDV is highly contagious and has multiple known routes of transmission. The 
known routes of transmission are by respiratory transmission, by direct contact of 
infected animals through the fluid from blisters, blood, saliva and milk, through 
fomite contact including via agricultural trucks and loading ramps, and from feed 
containing products from infected animals (reviewed in Grubman and Baxt, 2004; 
Racaniello, 2007).  
FMDV has been classified as a zoonosis, although transmission and manifestation of 
clinical symptoms in humans are extremely rare. Since the characterisation of the 
virus in 1897, only one confirmed and 40 unconfirmed human cases of FMDV have 
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been documented worldwide (Bauer, 1997). The only confirmed case of a human 
infected with FMDV in the UK was recorded in 1966. The infection resulted in the 
development of clinical symptoms, virus recovery from the lesions and antibody 
production (Armstrong et al., 1967). However, humans have been shown to be 
carriers of the virus; following contact with infected animals the virus was recovered 
from the nose, throat and saliva of the individuals, however no clinical symptoms 
were identified, nor was there any increase in antibody production resulting from 
exposure to the virus (Sellers et al., 2009). Humans are also able to physically 
transport the virus via fomite transmission to susceptible animals. No human-to-
human transmission has been documented (Brown, 2001; Sellers et al., 2009). 
The threat of FMDV infection in cloven-hooved livestock is increased by the ability 
for the virus to replicate rapidly within the target cells, and by the high levels of 
excreted virions. These characteristics contribute to the production of highly 
antigenic variability and a quasispecies nature of the virus which poses a challenge 
to vaccine production. Upon infection, FMDV mediates efficient host-cell protein 
synthesis shut down by cleavage of the essential cap-dependent translation initiation 
factor eIF4G. As a result of this shut down, infected cells struggle to mount an 
effective antiviral response based on de novo protein synthesis (Domingo, Escarmís, 
et al., 2005; Domingo, Pariente, et al., 2005; Summerfield et al., 2009). 
Due to the need to produce an efficient vaccine against FMDV, knowledge of the 
adaptive immune response against FMDV infection has been well-characterised. 
FMDV has been shown to elicit a rapid humoral response followed by effective 
clearance through phagocytic cells. Within 3-4 days post-infection high levels of 
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neutralising antibodies can be detected in infected livestock (McCullough et al., 1988; 
Doel, 2005). However, the innate immune response to FMDV infection and viral 
replication is less well understood. Recent studies have attempted to shed light on 
these interactions particularly when considering novel antiviral strategies 
(Summerfield et al., 2009). 
As with most viral infections, FMDV-infected non-immunological cells induce the 
production of interferons (IFNs), chemokines and cytokines, however, due to the 
effective host-cell protein synthesis shut-down mediated by FMDV, the production 
IFN, chemokines and cytokines from mRNA is limited resulting in a downregulation 
of MHC-I-mediated antigen presentation (Sanz-Parra et al., 1998; Ku et al., 2005; de 
Los Santos et al., 2006; de los Santos et al., 2007). Studies by de los Santos et al. 
demonstrated that FMDV can also interfere with NFκB signalling, and result in the 
down-regulation of the p65/RelA subunits of the molecule even at later times during 
infection (de los Santos et al., 2007). The generation of a rapid, and well-established 
adaptive immune response points to an active innate response being present within 
infected cells.  
FMDV was responsible for the slaughter of over 7 million livestock in the UK alone 
during two major national outbreaks in 1967 and 2001. The spread and control of the 
virus had an unprecedented economic impact of over £8 billion. Other countries 
including Taiwan, Ireland, France, South Africa and the Netherlands have had similar 
outbreaks with comparably devastating effects on their tourism, agricultural and 
financial economies (reviewed in Sobrino et al., 2001; Sáiz et al., 2002). There are a 
number of vaccines against FMDV already available, however they are only 
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economically viable in regions and farms that are endemic to FMDV (Sobrino et al., 
2001; Sáiz et al., 2002). There are a number of limitations associated with the 
vaccines despite their success, making them counter-productive in an emergency 
outbreak situation. Some of the concerns include the need for a high-containment 
facility to produce the vaccines and the use of cell suspensions to grow virus for the 
vaccine. The use of cell suspension for vaccine production can result in a high 
concentration of contaminating non-structural proteins resulting in the animals 
producing antibodies against these proteins making it difficult to serologically 
distinguish between vaccinated animals and infected animals. Modern methods of 
production of these vaccines have, however, improved and contamination of the 
vaccine with non-structural proteins has been reduced. 
Additionally, the current inactivated vaccines do not induce a rapid immune response 
and vaccinated animals have the potential to become carriers of the virus and 
experience long-term asymptomatic infection but still able to shed virus to naïve 
animals; animals may remain in a carrier-state for up to 4 years (Brown, 2001; 
reviewed in Grubman and Baxt, 2004). However, recent studies have defined 
methods such as ELISA-based assays and diagnostic assays targeting non-structural 
viral proteins, that allow for easier differentiation of vaccine-derived and virus-
infected animals (reviewed in Sáiz et al., 2002; Alexandersen et al., 2002). The most 
widely-used method of containing an outbreak in the UK and the European Union is 
by the inhibition of movement and the slaughter of infected and in-contact 
susceptible livestock (Grubman et al., 2004); this could potentially be prevented by 
the development of therapeutic drugs and alternative vaccine strategies. 
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There have been recent developments in the field of alternative vaccines that do not 
require infectious virus. A vaccine using the highly immunogenic VP1 capsid protein 
(encoded for by 1D) has been developed; however, when tested in a bovine 
population, the vaccine produced limited protection against a challenge. It is believed 
that the quasispecies nature of the virus resulted in the selection of antigenic variants 
as a response to the vaccine, which can make the development of an effective 
vaccine challenging (Kleid et al., 1981; Taboga et al., 1997; Tami et al., 2003). More 
recently, studies have shown that the antigenic region of the VP1 (termed the G-H 
loop) may have been necessary for protection against challenge in cattle. As such, by 
removing a portion of the VP1 G-H loop, a ‘negative vaccine’ could be developed 
which could both protect cattle from challenge as well as differentiate vaccinated 
and infected animals (through the detection of antibody production against the 
modified G-H loop sequence) (Fowler et al., 2008; Fowler et al., 2010; Fowler et al., 
2011). Live-attenuated vaccines have also been developed and tested, although they 
provide good protection in the bovine population, there were concerns that the 
attenuated strains may still be virulent in other host populations (e.g. porcine) in 
addition to the risk that live attenuated vaccines may revert back to the wildtype 
phenotype (Beck et al., 1987; Sobrino et al., 2001; Grubman et al., 2004). Empty viral 
capsids and virus-like particles consisting of the co-expression of the capsid proteins 
VP0, VP1 and VP3 (encoded for by 1D, 1A-B and 1C, respectively) on a plasmid in E. 
coli, have also been developed for the use as a vaccine. To date, they have been the 
most successful alternative form of vaccination, inducing complete protection when 
challenged at seven days (Grubman et al., 2004; Porta, Xu, et al., 2013; Porta, 
Kotecha, et al., 2013; Xiao et al., 2016).  
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However, in an emergency situation, a method is needed to rapidly reduce virus 
shedding and contain an outbreak. To do this, antiviral approaches could be 
developed. It has been shown that interferon effectively inhibits virus production and 
induces an innate immune response in the infected cells. If delivered prophylactically 
and in combination with the current vaccine, the interferon treatment could allow 
time for the adaptive immune response induced by the vaccine to activate and clear 
the infection (Ahl et al., 1976; Almeida et al., 1998; Chinsangaram et al., 2001; 
Grubman et al., 2002). However, trials using interferon in combination with the 
empty viral capsids failed to completely clear the challenged animals of the virus (Wu 
et al., 2003). 
For a successful antiviral drug to be developed, a better understanding of the innate 
immune response, particularly in ruminants, needs to be established. The production 
of an effective antiviral requires a target that is conserved in all serotypes of the virus 
and inhibit the ability of the virus to replicate and spread to other cells. Key targets 
include the major viral protease, 3C and the viral polymerase, 3Dpol, responsible for 
the replication of the viral genome and highly conserved among all serotypes. 
Understanding and inhibiting the function of these proteins could lead to the 
development of an effective broad-spectrum and fast-acting antiviral therapeutic. 
1.2.3 Genome Structure  
The FMDV virion is composed of an 8.3 kb +ve ssRNA genome encapsidated in a 
simple pseudo-icosahedral capsid approximately 25 nm in diameter. The capsid is 
composed of 60 copies of four structural proteins VP1-4, encoded by 1D, 1B, 1C and 
1A, respectively (protomer). VP1, VP2 and VP3 are exposed on the surface of the 
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capsid, whereas VP4 is internalised (Fig. 1.4). The viral RNA that is packaged within 
the capsid is arranged in a single ORF, organised like a cellular mRNA, which is 
translated as a single polyprotein that is co- and post-translationally cleaved by three 
virus-encoded proteases (Lpro, 2A and 3C) into intermediate and mature structural 
and non-structural proteins  (Burroughs et al., 1971; Robertson et al., 1985; Grubman 
et al., 2004; Jamal et al., 2013; Gao et al., 2016). The viral genome is flanked by 5ʹ and 
3ʹ UTRs that contain regulatory elements of replication and translation.   
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Figure 1.4 Schematic of the FMDV genome organisation and capsid protein 
structure. The structural proteins 1A-1D encoding for VP1-4 are colour coded in 
yellow, blue, pink and green, respectively and their organisation within the protomer, 
pentamer and pseudo-icosahedral capsid are depicted. VP4, encoded by 1A is not 
visible as it is internalised. Non-structural proteins are depicted in dark blue. Arrows 
show the major cleavage sites between Lpro (turquoise) and the P1 region, 2A 
between the P1 and P2-P3 region and 3C that cleaves between the non-structural 
proteins in the P2-P3 region. Adapted from (Jamal et al., 2013).  
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1.2.3.1 The 5ʹ UTR 
Figure 1.5 Schematic depicting the location and organisation of the FMDV 5ʹ UTR. 
It is a 1.3 kb region of five highly structured RNA elements. The elements are: the S-
fragment, the poly-C tract, two to four pseudoknot structures, the cis-acting 
replicative element (cre), and the internal ribosome entry site (IRES). 
1.2.3.1.1 The S-fragment 
FMDV has a much larger 5ʹ UTR that other picornaviruses containing approximately 
1,300 bases (Forss et al., 1984; Grubman et al., 1984; Robertson et al., 1985). The 
5’UTR, upstream of the ORF, can be divided into five structural elements (Fig 1.5). 
The first structural element is the S-fragment, a long, 360 base-pair stem-loop 
structure believed to be involved in maintaining genome stability, and may play a 
role in virus genome replication. The S-fragment is found in all FMDV serotypes, some 
sequence conservation has been observed by digestion with RNase H in the presence 
of oligo (dG), and use of sequencing gels within this region of the FMDV genome 
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(Rowlands et al., 1978; Harris, 1979; Harris, 1980; Newton et al., 1985; Belsham et 
al., 1990; Bunch et al., 1994; Mason et al., 2002; Belsham, 2005; Carrillo et al., 2005; 
Jamal et al., 2013). Some S-fragment truncations have been reported in the wild 
within SAT isolates (personal communication Lidia Lasecka, Pirbright Institute; Joseph 
Ward, Leeds; Valdazo-González et al., 2013) 
1.2.3.1.2 The Poly-C tract 
Following the highly structured S-fragment is a poly-C tract of variable length (100-
200 bp) (Brown et al., 1974; Newton et al., 1985; Black et al., 1979; Costa Giomi et 
al., 1984) (Fig 1.5). The function of the poly-C tract is currently unknown, however, it 
has been suggested that it could be associated with virulence, or in regulating the 
switch from translation to genome replication through a proposed interaction with 
the cellular poly(rC) binding protein (PCBP). Other studies have suggested that the 
removal of the poly-C tract had no effect on viral replicon in vitro (personal 
communication, Joseph Ward (Leeds)), or on virus infectivity (Harris et al., 1977; 
Rowlands et al., 1978; Sangar et al., 1980; Kühn et al., 1990; Rieder et al., 1993; 
Gamarnik et al., 1997).  
1.2.3.1.3 The Pseudoknots and the cis-acting replicative element 
At the 3ʹ end of the poly-C tract are a series of two to four RNA pseudoknots of 
unknown function (Clarke et al., 1987; Rieder et al., 1993; Le et al., 1993; Escarmís et 
al., 1995; Carrillo et al., 2005), followed by a cis-acting replicative element (cre) (Fig 
1.5). The cre is a short (55 nucleotide) stem-loop structure with a conserved motif 
around the bulge of the loop (AAACA) which is essential for the initiation of RNA 
genome replication. The cre acts as the template for the uridylylation of replication 
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primer(s) 3B (or VPg) (which then becomes linked to the 5ʹ end of the genome 
upstream of the S-fragment). In other picornaviruses, for example, in PV, the cre is 
located within the protein-coding region, however, in FMDV this structure is localised 
to the 5ʹ UTR (Paul et al., 2000; Mason et al., 2002; Mason et al., 2003; Grubman et 
al., 2004; Belsham, 2005). 
1.2.3.1.4 The Internal Ribosome Entry Site 
As with all picornaviruses, FMDV does not contain a 5ʹ 7-methylguanosine cap to 
initiate translation, instead it contains a 450-nucleotide internal ribosome entry site 
(IRES) structure. The FMDV IRES immediately precedes the AUG translation initiation 
codons of the genome (Fig 1.5). It is at this site that the ribosome and translation 
initiation factors bind and drive translation of the viral RNA. (Belsham et al., 1990; 
Kühn et al., 1990; Pilipenko et al., 1992; Mason et al., 2002; Grubman et al., 2004; 
García-Nuñez et al., 2014).  
The FMDV IRES is classified as a type II IRES structure, shared with cardioviruses such 
as encephalomyocarditis virus (EMCV). Other types of IRESs include type I (found in 
enteroviruses and rhinoviruses), type III found in hepatitis A virus, and finally a HCV-
like ‘type IV’ IRES (Beales et al., 2003; Martínez-Salas et al., 2015). As with other IRES, 
the FMDV type II IRES it is a cis-acting highly-structured RNA sequence located at the 
5ʹ region of the genome. Despite the lack of conserved sequence and RNA structure, 
the function of the IRESs of different viruses remains the same. The key differences 
between the different IRES types are primarily in the number and secondary RNA 
structure of the domains, and the combination of cellular interacting and binding 
partners (Beales et al., 2003; Kieft, 2008; Martínez-Salas et al., 2015). 
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Eukaryotic cells have also been shown to be able mediate translation of up to 85 
mRNAs in a cap-independent manner. The first of such IRES-containing cellular 
mRNAs that was defined encodes for BiP, the immunoglobulin heavy chain binding 
protein (Sarnow, 1989; Macejak et al., 1991; Hellen et al., 2001; Baird, 2006). 
1.2.3.2 The 3ʹ UTR 
Figure 1.6 Schematic depicting the location and organisation of the FMDV 3ʹ UTR. 
The region is composed of two stem-loop structures preceding a poly-A tail. 
The 3’ UTR located downstream of the ORF termination codon contains a sequence 
of ≈90 nucleotides that forms two stem-loop structures, followed by a poly-A tail 
(Porter et al., 1978; Belsham, 2005; Serrano et al., 2006) (Fig 1.6). The 3’ UTR has 
been shown by multiple studies to be important in PV and FMDV genome replication 
and infectivity through the circularisation of the genome mediated by the poly-A 
binding protein (PABP) and the S-fragment in the 5ʹ UTR (Barton et al., 2001; Herold 
et al., 2001; López de Quinto et al., 2002; Serrano et al., 2006). The terminal A 
residues of the poly-A tail also permit for the generation of a negative strand 
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replication intermediate through the binding of the uridylylated VPg during genome 
replication (Herold et al., 2001; Barton et al., 2001; Mason et al., 2003). As mentioned 
previously, the two stem-loops at the 3ʹ UTR have been shown to be involved in the 
replication ability of the RNA. Exchanging the 3ʹ UTR with the equivalent region of 
swine vesicular disease virus, or deleting the 3’ UTR region abrogated virus 
replication (Sáiz et al., 2001). Additionally, the deletion of one of the stem-loop 
structures in 3’ UTR has been shown to affect the replication efficiency in virus 
infected, and in replicon transfected cells (Sáiz et al., 2001; Gao et al., 2016; Fiona 
Tulloch (Edinburgh), personal communication). 
1.2.3.3 The Leader proteinase 
The first product of the genome ORF is the leader (Lpro) protein, a proteinase unique 
to Aphthoviruses, which contains two in-frame initiation codons (AUG). Two forms of 
the L-proteinase are generated: Labpro and Lbpro. Site-directed mutagenesis studies 
have shown that Lbpro alone was sufficient and necessary for the production of live, 
infectious virus (Fig 1.7). Deletion of the first AUG (Labpro) abolished replication of 
viral RNA, whereas deleting the second AUG (Lbpro) had no effect on replication 
(Carroll et al., 1984; Sangar et al., 1987; X Cao et al., 1995; Belsham, 2013). Deletion 
of the Lpro from the genome without the spacer function of the leader sequence, 
rendering it ‘leaderless’, whilst maintaining the second AUG, affected the virulence 
of FMDV, but was not necessary for viral replication (Piccone et al., 1995; Grubman 
et al., 2004). Studies of viruses recovered from infectious clones where the L-
proteinase was deleted showed remarkable attenuation in cattle, caused no clinical 
symptoms, and were unable to spread to other animals despite being able to 
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replicate at slightly reduced efficiency in cell culture (X Cao et al., 1995; Brown et al., 
1996; Chinsangaram et al., 1998).  
L-proteinase has been shown to play a role in promoting translation of the virus RNA 
as it inhibits host-cell cap-dependent mRNA translation and protein synthesis. The L-
proteinase cleaves the host-cell translation initiation factor eIF4G (Piccone et al., 
1995; Mason et al., 1997). Cleavage of eIF4G effectively shuts off the host-cell 
translation mechanism and allows for the various translation initiation factors 
including eIF4A to bind to the virus IRES and interact with the ribosome to drive viral 
RNA translation but eliminates the ability of eIF4G to bind eIF4E, the cap binding 
protein (Devaney et al., 1988; Kirchweger et al., 1994; López de Quinto et al., 2000; 
Saleh et al., 2001). 
Figure 1.7 Schematic of the FMDV genome showing the proposed ORFs of each of 
the viral proteins. The 5’ untranslated region (UTR) is located upstream of the 
polyprotein. The leader protease (Lpro) is shown containing both transcription start 
codons; (LbPro) is sufficient for transcription and translation. The structural proteins 
are transcribed from segment P1 (1A-1D) and are co-and post-translationally 
processed to make mature capsid proteins (VP1-4). Segments P2 and P3 encode for 
the non-structural proteins necessary for replication of the genome (2A-3D). 
Likewise, both these segments are co- and post-translationally modified into the 
mature proteins. A poly-A tract at the 3’ UTR signifies the end of the genome ORF. 
Adapted from Forrest et al., 2014. 
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1.2.3.4 Structural proteins 1A-1D/2A  
As highlighted in figure 1.4, the structural proteins of FMDV that form the virus capsid 
are encoded by the P1 region of the genome. 1A, 1B, 1C and 1D encode for VP2, VP4, 
VP3 and VP1, respectively (Bachrach, 1968) (Fig 1.7). The capsid is composed of 60 
copies of each of the four proteins but is initially assembled into asymmetric 
protomers consisting of VP1, VP3 and VP0 (precursor to VP2 and VP4). Five 
protomers associate into a pentamer, and 12 pentamers form into a pseudo-
icosahedral capsid containing the ssRNA genome. VP0 is autocatalytically cleaved 
into the mature structural proteins VP2 and VP4 upon genome encapsidation 
(reviewed in Sobrino et al., 2001) It is important to highlight that the protomers never 
exist ‘alone’; the smallest stable capsid component is the pentamer. 
The three-dimensional arrangement of the structural proteins provides the main 
antigenic sites used for antibody binding that elicit responses to vaccination or to 
infection, as well as to mediate receptor binding of the virus to the host cell (Mason 
et al., 2003). Unlike enteroviruses and cardioviruses, FMDV lacks receptor binding 
sites formed within surface pockets, or canyons. Instead, FMDV has a protruding loop 
in the VP1 protein that may comprise of a major neutralisation and receptor-binding 
site (Hogle et al., 1985; Rossmann, 1989; Acharya et al., 1989).  
The FMDV capsid contains a hydrophobic channel located at the 5-fold axis which 
allows for the penetration of small molecules such as intercalating dyes and caesium 
ions which results in the inactivation of the virus and capsid instability at pH < 6. It is 
because of this that FMDV also has a high buoyant density compared to other 
picornaviruses (Acharya et al., 1989). 
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1.2.3.5 Non-structural proteins 2A-3Dpol 
1.2.3.5.1 Proteins 2A, 2B and 2C 
The P2 region of the FMDV polyprotein encodes for three mature protein: 2A, 2B and 
2C (Rueckert et al., 1984) (Fig 1.7). 2A in FMDV is smaller than its PV analogue, at only 
18 amino acids in length (Robertson et al., 1985; Ryan et al., 1997). During the 
primary polyprotein processing events, the 2A protein remains associated with the 
P1 region mediating cleavage between the P1 and P2 regions through 
autoproteolysis, despite a lack of any characteristic protease motifs (Ryan et al., 
1994; Ryan et al., 2001). 2A is removed from the P1 region to allow for maturation of 
the structural proteins by cleavage with another FMDV protease, 3C (Vakharia et al., 
1987; Ryan et al., 1989; Ryan et al., 1991). The autoproteolytic property of 2A has 
been shown to function and mediate cleavage in an artificial system, however for this 
to occur the 2A-2B boundary needed to remain intact (Ryan et al., 1994; Ryan et al., 
1997; Donnelly et al., 2001). This cleavage function of 2A yielded a much higher ratio 
of proteins upstream to the 2A insertion site, which led to the hypothesis that FMDV 
2A was not a traditional protease but was mediating a modification of the translation 
machinery termed ‘ribosome skipping’ which allowed for the ribosome to release at 
2A but then continue to translate the proteins downstream (Ryan et al., 2001; 
Donnelly et al., 2001).  
Proteins 2B and 2C have been shown to function synergistically as a precursor, 2BC, 
as well as having distinct functions as individual proteins. One of the functions 
attributed to the 2BC precursor protein, as defined by immunofluorescence and co-
localisation studies, is the blocking of host protein ER-to-Golgi transport which results 
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in eventual generalised cytopathic events within FMDV infected cells (Mason et al., 
2003; Moffat et al., 2005). A similar function is attributed to PV 3A. 
2B is thought to function as a viroporin. The 54 amino acid peptide contains two 
putative transmembrane domains typical of viroporins (Nieva et al., 2012; Ao et al., 
2014; Ao et al., 2015). 2B in related picornaviruses including PV and Coxsackievirus 
has been shown to localise to the ER membrane, thought to be the site of viral 
replication, but has also been shown to be able to induce damage to the cell 
membrane resulting in a dysregulation of the calcium ion concentration within the 
cell and activating autophagy (Bienz et al., 1987; Doedens et al., 1995; van Kuppeveld, 
Melchers, et al., 1997; van Kuppeveld, Hoenderop, et al., 1997; Suhy et al., 2000; Ao 
et al., 2015). However, knowledge on the exact function of the protein is limited and 
much remains to be confirmed for FMDV. 
FMDV 2C is a 318 amino acid protein shown to co-localise with membrane-bound 
replication complexes within infected cells concentrating at the cell membrane and 
the ER (Tesar et al., 1989; Klein et al., 2000; Teterina et al., 2006; J. Wang et al., 2012; 
Gao et al., 2016). It is the largest membrane-binding protein of the FMDV genome 
and is proposed to have a number of functions primarily in the role of membrane 
rearrangements and the regulation of the cellular immune response, similar to those 
seen in other picornaviruses such as hepatitis A virus and PV (Troxler et al., 1992; 
Bolten et al., 1998; Jecht et al., 1998; Gosert et al., 2000; O’Donnell et al., 2011; 
Gladue et al., 2012).  
Studies on FMDV, PV, and on enterovirus 71 2C have shown that it may function as a 
helicase, unwinding RNA in an ATP-dependent manner, due to the presence of a well 
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conserved ATPase domain placing 2C within the superfamily III helicases. 
(Gorbalenya et al., 1990; Mirzayan et al., 1994; Sweeney et al., 2010; Xia et al., 2015). 
Through inhibition studies on PV and FMDV with guanidine hydrochloride, it has been 
observed that 2C is essential for virus replication (Saunders et al., 1982; Saunders et 
al., 1985; Barton et al., 1997; Pfister et al., 1999; Klein et al., 2000). Studies on PV 2C 
have also identified the necessity for 2C in the initiation of negative strand RNA 
synthesis, and, as the protein is highly conserved across all picornaviruses, it is 
believed that FMDV 2C could also share the same function (Barton et al., 1997). 
Interestingly, the presence of 2C has only been observed within virus replication 
complexes and not in clarified virus stocks used in vaccine preparation, providing an 
attractive candidate as a differentiator between ‘carrier’ livestock (that had been 
previously infected and had cleared the infection), and vaccinated livestock (Lubroth 
et al., 1995; Lubroth et al., 1996; Meyer et al., 1997; Lu et al., 2010). 
1.2.3.5.2 Proteins 3A and 3B 
The 3A protein encoded by FMDV is the largest picornaviral 3A protein (at 153 amino 
acids in length) compared to the 87 amino acid PV protein (Mason et al., 2003). Using 
in situ protein fluorescent ligation assays and structural data from nuclear magnetic 
resonance studies, it has been determined that FMDV 3A homodimerizes through 
interactions between two intermolecular hydrophobic α-helix domains (González-
Magaldi et al., 2012; González-Magaldi et al., 2015). Interference of the hydrophobic 
interface interaction results in a reduction in virus yield in virus-infected cells 
(González-Magaldi et al., 2015).  
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The N-terminal domain of 3A  is highly conserved amongst the FMDV serotypes and 
contains a hydrophobic, membrane-associated domain that co-localises to ER and 
Golgi-derived membranes (O’Donnell et al., 2001; Moffat et al., 2005; García-Briones 
et al., 2006). In contrast to PV 3A, the C-terminal domain of FMDV 3A is structurally 
flexible and is prone to a number of deletions and mutations as identified from 
sequencing data. There were two natural deletion mutants reported in the C-
terminal domain, both of which resulted in a change in virulence and host range of 
the virus (Beard et al., 2000; Pacheco et al., 2013). These deletions in 3A were 
associated with an increased virulence in swine infected with FMDV, but showed a 
reduced ability for these viruses to cause disease in cattle, or in bovine-derived cells 
(Giraudo et al., 1987; Beard et al., 2000; Knowles et al., 2001). 
FMDV encodes for three non-identical tandem repeats of 3B (3B1, 3B2, 3B3) and is the 
only picornavirus to do so. Each copy of 3B is 23-24 amino acids in length and encodes 
the VPg protein. Therefore viral RNA includes VPg covalently linked through the 
conserved tyrosine residue at position 3 (Tyr3) at the 5ʹ end (Forss et al., 1982; Mason 
et al., 2003; Pacheco et al., 2003). In order for replication to occur, the VPg is 
uridylylated into VPg-pU(pU) by the viral polymerase 3Dpol (Paul, 2002). Most 
naturally circulating FMDV strains contain three copies of 3B , suggesting a strong 
selective advantage (Pacheco et al., 2003; Carrillo et al., 2007), however, studies have 
observed that, although the presence of all three 3B copies are required for efficient 
replication, there appears to be a preference for 3B3 (Falk et al., 1992; Pacheco et al., 
2003; Nayak et al., 2005; Arias et al., 2010; Herod et al., 2017). These studies show 
that deleting 3B3 resulted in the production of a non-infectious RNA transcript. 
Studies have shown that the VPg is removed from the genome during translation 
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(Sangar, Rowlands, et al., 1977; Sangar et al., 1980), but is present at the 5ʹ ends of 
transcripts. 
1.2.3.5.3 Protein 3C 
The major protease encoded by FMDV is 3C (Klump et al., 1984). 3C is one of the 
more well-defined proteins of the species and is responsible for the majority of the 
processing of the viral polyprotein during replication of the genome. 3C is responsible 
for the processing of 7 cleavage sites between the non-structural proteins with the 
exception of the autocatalytic cleavage events occurring between Lpro and P1, P1-2A 
and 2BC, and the maturation cleavage of VP0 into VP2 and VP4 (Vakharia et al., 1987; 
Clarke et al., 1988; Palmenberg, 1990; Bablanian et al., 1993). FMDV 3C shows 
greater heterogeneity amongst its cleavage sites being able to cleave between Gln-
Gly, Glu-Gly, Gln-Leu and Glu-Ser dipeptides, in comparison to the singular Gln-Gly 
cleavage site for PV 3C (Robertson et al., 1985; Palmenberg, 1990; Birtley et al., 
2005). 
Similar to the protease activity seen in Lpro, FMDV 3C is able to cleave host-cell 
proteins as well, primarily cleaving the translation initiation factor eIF4A (Belsham et 
al., 2000) and the histone protein H3 (Grigera et al., 1984; Falk et al., 1990; Tesar et 
al., 1990). This function of 3C is thought to be a unique mechanism of FMVD to 
subvert host-cell translation in favour of viral replication. More recently, 3C has also 
been implicated in immune evasion by reducing the RIG-I/MDA-5 signalling through 
the cleavage of the nuclear transcription factor kappa B (NF-kB) essential modulator 
(NEMO) (Wang et al., 2012). 
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3C and its precursor 3CD may also have non-catalytic roles during the FMDV life-
cycle, particularly during the initiation of replication and the mediating of VPg 
uridylylation (Murray et al., 2003; Nayak et al., 2005; Nayak et al., 2006; Steil et al., 
2009) 
1.2.3.5.4 3Dpol 
The RNA-dependent RNA polymerase (RdRp) from FMDV, 3Dpol, is a 54 kDa enzyme. 
The main function that has been described for 3Dpol is in the synthesis of positive- 
and negative-strand RNA during viral genome replication. The first description of 
3Dpol was detailed in a study by Polatnick and Arlinghaus, 1967 where the 3Dpol was 
originally described as the foot-and-mouth disease virus infection-associated antigen 
(FMD-VIAA) as antibodies against it could be detected in the sera of infected cattle 
(Cowan et al., 1966) but was unable to antigenically recognise FMDV structural 
proteins (Morgan et al., 1978). As such, it was subsequently shown to be the viral 
polymerase (Lowe et al., 1981). 
The sequence and structure of 3Dpol is highly conserved among the different FMDV 
serotypes (Villaverde et al., 1988; George et al., 2001). Crystal structure analyses also 
show a similar structure between all other picornavirus RdRps. The structure 
resembles a standard ‘right-hand’, that consists of ‘palm’, ‘fingers’ and a ‘thumb’ 
domains (Ferrer-Orta et al., 2004). The catalytic domain of these RdRps is located in 
the ‘palm’ region. This region has the most conserved structure amongst 
polymerases and consists of a three-stranded antiparallel β-sheet flanked by three 
α-helices. This core domain is integral in maintaining correct structure of the enzyme 
catalytic site (a highly conserved YGDD sequence) and is necessary for the 
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recognition, binding, and priming of nucleotides for downstream binding to the 
phosphoryl transferase and subsequent formation of nascent RNA strands (Hansen 
et al., 1997; O’Reilly et al., 1998; Ferrer-Orta, Arias, Escarmís, et al., 2006). 3Dpol is a 
non-proof-reading polymerase resulting in a high level of mutation and 
recombination occurring during replication, lending FMDV a quasispecies nature, 
common across all picornaviruses. 
Most of the understanding of the structure and function of the FMDV 3Dpol has 
occurred as a result of studies on PV 3Dpol and from recent crystallographic studies. 
FMDV 3Dpol structures have been solved as unliganded or as proteins in complex with 
RNA. Structures have also been solved showing the interaction of 3Dpol along with 
the VPg (Ferrer-Orta et al., 2004; Ferrer-Orta, Arias, Agudo, et al., 2006; Ferrer-Orta, 
Arias, Escarmís, et al., 2006; Ferrer-Orta et al., 2009). Additionally, PV 3Dpol was 
shown to function as a higher-order oligomeric structure and form complex fibrils 
that have been shown by cryo-EM to contain RNA within the active sites (Pata et al., 
1995; Beckman et al., 1998; Lyle, Bullitt, et al., 2002). The formation of fibrils within 
FMDV has also been investigated. These studies have shown that FMDV 3Dpol is able 
to form higher-order fibrils, however, their function is still being investigated 
(Bentham et al., 2012).  
The elongation of nascent RNA chains and replication of the genome catalysed by PV 
3Dpol has been shown to occur within membrane associated replication complexes 
(Flanegan et al., 1977; Bienz et al., 1983; Bienz et al., 1987; Bienz et al., 1992). 
Structures resembling PV replication complexes containing 3Dpol and RNA have also 
been described in FMDV-infected cells (Polatnick and S.H. Wool, 1983; Polatnick and 
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S. Wool, 1983). However, more recent evidence from the literature shows that the 
reorganisation of cellular membranes during FMDV infection is different to that seen 
during infection with other picornaviruses. FMDV infection results in a dramatic 
condensation and relocalisation of intracellular organelles to one side of the 
cytoplasm in the perinuclear region (Monaghan et al., 2004) as opposed to the 
association to specific intracellular membranes. 
The highly-conserved structure and function of the FMDV 3Dpol make it an attractive 
target for antiviral therapeutics. Studies using nucleoside analogue 5-fluorouracil 
have shown it to be mutagenic for a number of viruses including FMDV. A well-
defined antiviral, Ribavirin, has also been shown to be able to eliminate FMDV from 
persistently infected cells due to its ability to enhance mutagenesis (Sierra et al., 
2000; Graci et al., 2002; Airaksinen et al., 2003). 
1.2.4 FMDV genome replication  
FMDV enters cells by binding the αV subgroup of the integrin family of receptors via 
a highly-conserved arginine-glycine-aspartic acid (RGD) motif located on the VP1 
capsid protein (Berinstein et al., 1995; Neff et al., 1998; Jackson et al., 2000; Jackson 
et al., 2002; Duque et al., 2003; Jackson et al., 2004; O’Donnell et al., 2005). Upon 
binding to the cellular receptor, the virus is internalised by clathrin-mediated 
endocytosis (Fox et al., 1989; Mason et al., 1994; Leippert et al., 1997; Berryman et 
al., 2005; O’Donnell et al., 2005; Martín-Acebes et al., 2007). The capsid is 
subsequently broken down into pentamers within the low pH environment of the 
endosomes, and the viral RNA is released into the cytoplasm where replication can 
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occur (Cavanagh et al., 1978; Baxt, 1987; O’Donnell et al., 2005; O’Donnell et al., 
2008). 
FMDV RNA first undergoes initial translation mediated by host-cell translation factors 
once within the cytoplasm. Two of the first host-cell interacting partners that were 
discovered to be involved in the translation of the FMDV genome were a 57 kDa 
protein known as the polypyrimidine tract-binding protein (PTBP), and a 45 kDa IRES-
specific trans-acting factor (ITAF45) protein (Luz et al., 1991; Stewart et al., 1997; 
Pilipenko et al., 2000). Both of these proteins have been shown to interact with the 
FMDV IRES and are essential for the formation of the ribosomal translation initiation 
complex. 
Figure 1.8 Schematic of the relationship of host-cell translation initiation factors 
and the FMDV 5 ʹUTR. The recruitment of these translation initiation factors allows 
for the cap-independent translation of the FMDV viral genome. Adapted from (Jamal 
et al., 2013). 
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Host-cell translation initiation factors eIF4G and recruited subunits eIF4A, eIF3a and 
eIF4B, and the 40s-ribosomal subunit, along with cellular co-factors PTBP, ITAF45, the 
poly-A binding protein (PABP) and the PCBP bind to the IRES element located in the 
5ʹ UTR. The binding of the cellular co-factors to the RNA initiate internal translation 
of the viral RNA genome in a cap-independent manner typical of a number of 
positive-sense RNA viruses such as pestiviruses, hepaciviruses, aphthoviruses and 
enteroviruses (Pelletier et al., 1988; Jang et al., 1988; Belsham et al., 1990; Sizova et 
al., 1998; Niepmann, 2009) (Fig. 1.8). The viral genome is thus translated into a single 
polyprotein from which the structural and non-structural protein precursors are co- 
and post-translationally processed into the mature, functional proteins (detailed in 
section 1.2.3.5) (Blyn et al., 1997; López de Quinto et al., 2002; Rodríguez Pulido et 
al., 2007; Martínez-Salas, 2008; Yu et al., 2011). The processing of the non-structural 
proteins is mediated by the action of 3C, and various defined intermediate precursors 
are formed, as highlighted in figure 1.7, in a defined order (Semler et al., 1981; 
Pallansch et al., 1984; Lawson et al., 1992; Oh et al., 2009; Cameron et al., 2010; 
Herod et al., 2017) 
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Figure 1.9 Schematic of the process of FMDV replication. Positive strand RNA is used 
as the template for replication and the synthesis of a negative strand intermediate. 
This negative strand intermediate is used as the template to form nascent positive 
strand RNA which can either be packaged into newly synthesised virions or be further 
used for replication. 
Following translation of the genome, replication is initiated. Initiation of both 
replication and translation has been shown to involve the circularisation of the 
genome through discrete RNA-RNA and RNA-protein interactions between the 3ʹ 
UTR, the 5ʹ UTR, cellular host factors, and virus-encoded proteins such as 3Dpol, 3A 
and 2BC. Examples of interactions that have been proposed are the PCBP with the 5ʹ 
UTR, the PABP with the 3ʹ UTR and the PCBP and the PABP with the S-fragment 
(Herold et al., 2001; López de Quinto et al., 2002; Serrano et al., 2006). This 
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mechanism is thought to be widespread amongst positive-strand RNA viruses (Pogue 
et al., 1994; Gamarnik et al., 1998; Villordo et al., 2010; Park et al., 2013). 
Replication of FMDV RNA begins with 3Dpol, in the presence of 3CD, mediating the 
uridylylation the Tyr3 residue of VPg. The template for VPg uridylylation has been 
shown to be the cre, however in PV, the poly-A tail at the 3ʹ end of the genome is 
also responsible for VPg uridylylation (Paul et al., 1998; Murray et al., 2003). In FMDV, 
a copy of uridylylated VPg (VPg-pUpU) binds to the 3’ end of the template RNA and 
acts as a primer to initiate replication. It is thus covalently linked to the 5ʹ end of the 
daughter strand for both positive and negative strand synthesis (Fig. 1.9) (Goodfellow 
et al., 2003; Murray et al., 2003; Nayak et al., 2005; Nayak et al., 2006; Steil et al., 
2009).  
The process of replication involves 3Dpol binding to the poly-A tail and replicating the 
RNA template to form a negative strand intermediate from which positive strands 
can be made and used as templates for translation and to be packaged into nascent 
virions (Fig 1.9). Translation of the input RNA occurs in a 5’ to 3’ direction beginning 
at the IRES located in the 5ʹ UTR, whereas replication occurs in the opposite direction. 
Therefore, these two functions cannot occur concurrently on the same RNA strand, 
and it is proposed that a switch must occur for replication to begin, or the two 
processes of replication and translation occur within different compartments (Harris 
et al., 1994; Gamarnik et al., 1998; Barton et al., 2001; Paul, 2002; Nayak et al., 2005). 
In PV, the switch from translation to replication on the genomic RNA is mediated by 
the binding of the cellular protein PCBP to the cloverleaf. This binding enhances viral 
translation, while the binding of the viral protein 3CD represses translation and 
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facilitates negative-strand synthesis (Gamarnik et al., 1998; Serrano et al., 2006). It is 
possible that in FMDV the S-fragment (section 1.2.3.1) performs the same function 




1.3 Replication Complex  
Replication of viral RNA is thought to occur within intracellular membrane-associated 
compartments known as replication complexes. Evidence of such compartments 
have been shown for a number of positive-strand RNA viruses such as PV, HCV and 
dengue virus (Troxler et al., 1992; Schlegel et al., 1996; Westaway et al., 1999; Gosert 
et al., 2003; Novoa et al., 2005; den Boon et al., 2010; den Boon et al., 2010). 
Replication is thought to occur within these compartments as a way for the virus to 
concentrate the structural and non-structural components into a small area to 
facilitate replication, as well as to be able to protect the virus components from host-
cell pathogen recognition and innate immune responses.  
Studies on FMDV have shown that the virus dysregulates Golgi and ER-derived 
membranes like PV and has been found to concentrate on small membranous 
vacuoles within the cell (Polatnick and S. Wool, 1983; Schlegel et al., 1996; O’Donnell 
et al., 2001; Monaghan et al., 2004; Knox et al., 2005). However, no distinct 
membrane-bound replication complex comprised of viral RNA, structural and non-
structural proteins, and host-cell proteins have yet to be identified for FMDV. 
1.3.1 FMDV Fibrils 
Investigations on the formation of a discrete replication complex during FMDV 
replication are ongoing. Studies have shown that, like PV, FMDV 3Dpol is able to form 
higher-order fibrils in vitro, but only when combined with an RNA template-primer 
and free nucleotides, suggesting that these structures could be associated with 
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replication of the viral genome (Pata et al., 1995; Lyle, Bullitt, et al., 2002; Bentham 
et al., 2012; Wang et al., 2013). 
The function of the fibrils in FMDV replication is still to be elucidated, however, it is 
speculated that these structures may play a role in concentrating the viral replication 
complex to increase the efficiency of replication, or that these structures may be 
involved in preventing the formation of double-stranded RNA which could trigger an 
innate immune response against the virus. 
1.3.2 Cellular Interacting Partners in Replication Complex Formation 
Viruses have been shown to hijack ER, Golgi and trans-Golgi network (TGN) 
membranes in order to form these factories. Although of particular interest is the 
composition of the membranes that are formed, the membranes are rich in 
phosphatidylinositol-4-phosphate (PI4P) lipids, shown to be required for the 
replication of multiple members of the family Picornaviridae and Flaviviridae. These 
viruses enrich the factory membranes with PI4P lipids by up-regulating and 
selectively recruiting components of the phosphatidylinositol-4-kinase (PI4K) enzyme 
pathway that phosphorylate phosphatidylinositol lipids into their functional form 
(discussed in more detail in chapter 5).  
There are two types of well-defined families of PI4Ks expressed in mammalian cells, 
type II and type III. Type III PI4Ks are the larger of the two and are made up of two 
enzymes PI4KIIIα and PI4KIIIβ, which function in ER and Golgi, respectively (Balla et 
al., 2006; Konan et al., 2014). Previous studies on PV and Coxsackievirus B3 (CVB3) 
have identified PI4KIIIβ as the host enzyme upregulated in viral replication factories 
(Belov et al., 2007; Hsu et al., 2010; Arita et al., 2011; Altan-Bonnet et al., 2012; Boura 
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et al., 2015). Depletion of PI4KIIIβ activity within infected cells by RNA silencing or 
the use of specific kinase inhibitors, such as PIK93, a selective small molecule 
inhibitor against PI4KIIIβ, (Belov et al., 2007; Altan-Bonnet et al., 2012) appeared to 
block poliovirus RNA synthesis (Hsu et al., 2010; Arita et al., 2011; Greninger et al., 
2012). It is thought that the PV 3Dpol is able to bind to PI4P lipids and is then either 
anchored to the viral replication complex, or is stimulated to perform its enzymatic 
activity (Hsu et al., 2010). A related family of PI-kinases, is the PI3K family of enzymes. 
These have been documented to be involved in hepacivirus replication in a similar 
manner to the PI4Ks (Altan-Bonnet et al., 2012).  
Other lipids have also been shown to interact with related picornavirus replication. 
Cholesterol is known to be recruited into the enterovirus replication complex by 
oxysterol-binding protein (OSBP) (Balla et al., 2006; Arita, 2014; Wang et al., 2014). 
OSBP plays a central role in cholesterol transport and shuttles cholesterol between 
different cellular organelles in exchange for PI4P (Mesmin et al., 2013). Enteroviruses 
have been shown to subvert OSBP in order to exchange PI4P for cholesterol at the 
replication complex (Ilnytska et al., 2013; van der Schaar et al., 2013; Arita et al., 
2013; Roulin et al., 2014; Dorobantu, Albulescu, et al., 2015; Albulescu et al., 2015). 
Similar to the studies on PI4K, the chemical inhibition of OSBP disrupts virus 
replication factory formation, and subsequent RNA synthesis. In PV cholesterol has 
also been shown to be involved in the processing of the 3CD precursor into mature 
3C and 3Dpol, however in other enteroviruses (namely human rhinovirus) cholesterol 
biosynthesis has been shown to have little active role in replication, but to be crucial 
to support replication, and is enriched in the replication sites (Ilnytska et al., 2013; 
Roulin et al., 2014; Berryman et al., 2016). 
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The involvement of the PI4KIIIβ family of enzymes, or OSBP and cholesterol, on FMDV 
replication and translation has yet to be clearly defined, however previous studies on 
other Picornaviridae, and the identification of 3Dpol fibril formation, suggest that 
FMDV may use these mechanisms.  
40 
 
1.4 Aims of the Project 
The principal aim of this project was to dissect the role of the FMDV 3Dpol in viral 
replication and to further investigate the formation of 3Dpol fibrils in vitro in an 
attempt to understand the relationship between structure and function of these 
higher-order structures. 
In order to investigate this, a number of FMDV 3Dpol mutations were made that 
abrogated function. Structure was investigated using cryo-electron microscopy and 
x-ray crystallography. 
Additionally, it was pertinent to investigate the role of membrane-associated kinases, 
such as PI4K, as a number of related viruses utilise these cellular factors to form an 
optimal environment within which viral replication can occur.  
Ultimately, by improving our understanding of the formation of the FMDV replication 
complex, either through the abrogation of intracellular membranes and the 
pathways necessary for this function to occur, or by investigating the role of the 3Dpol 
fibrils, we will be able to develop better treatments or antiviral therapeutics. 
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Chapter 2  
Materials and Methods 
2.1 General Buffers, Media and Solutions 
Media/Buffer/Reagent Recipe 
Luria-Bertani (LB) medium and agar 1 % (w/v) Tryptone 
0.5 % (w/v) NaCl 
0.5 % (w/v) Yeast Extract 
(Add 1.5 % (w/v) Agar for LB Agar) 
1 x TBE buffer (Tris-borate-EDTA) 10 % 10 x TBE buffer (Thistle Scientific) 
90 % ml dH2O 
1 x Tris-glycine SDS-PAGE running buffer 25 mM Tris 
192 mM Glycine 
0.1 % sodium dodecyl sulphate (SDS)  
1 x Transfer buffer 25 mM Tris 
192 mM Glycine 
0.1 % SDS  
15 % (v/v) Methanol 
10 x TBS (Tris-buffered saline) 250 mM Tris 
1.37 M NaCl 
pH 7.5 
1 x TBS-T (Tris-buffered saline-Tween-20®) 10 % 10 x TBS 
0.1 % ml Tween-20® 
Diethylpyrocarbonate (DEPC)-treated 
dH2O 
0.1 % (v/v) DEPC in dH2O 
1 x 3-(N-morpholino)propanesulphonic 
acid (MOPS) buffer 
10 % 10 x MOPS buffer (VWR) 
90 % DEPC-treated dH2O 
Buffer A (wash) 50 mM Tris 
500 mM NaCl 
25 mM Imidazole 




Buffer B (elution) 50 mM Tris 
500 mM NaCl 
500 mM Imidazole 
pH to 8 with HCl 
Dialysis buffers (pH 8) 50 mM Tris 
500 mM NaCl 
Buffer 1) 250 mM Imidazole 
Buffer 2) 100 mM Imidazole 
Buffer 3) 25 mM Imidazole 
Buffer 4) 0 mM Imidazole 
10 x Elongation assay buffer 300 mM MOPS (pH 7) 
250 mM NaCl 
50 mM MgCl2 
600 µM ZnCl2 
RNA binding buffer 20 mM Tris-HCl (pH 8) 
100 mM NaCl 
0.01 % Triton X-100 
RIPA buffer 25 mM Tris (HCl) pH 7.6 
150 mM NaCl 
1 % (v/v) nonidet-P40 (NP-40) 
1 % (v/v) sodium deoxycholate 
0.1 % (v/v) SDS from 10 % (w/v) stock. 
1 mM EDTA 
1 x protease inhibitor 
4 % paraformaldehyde (100 ml) 4 g paraformaldehyde powder 
10 µl 10M NaOH 
10 ml 10 x PBS 
90 ml ddH2O 
pH 7 
Saponin buffer (100 ml) 10 ml FCS (Foetal calf serum) 
100 mg saponin 




MOPS-formaldehyde gel 0.32 g Agarose 
29.5 ml DEPC-treated dH2O 
3.5 ml 10 x 3-(N-
morpholino)propanesulphonic acid 
(MOPS) buffer (VWR) 
2 ml 37 % formaldehyde 
5 ml 5 % SDS-PAGE Stacking gel 
(Cold Spring Harbor Laboratory, 2015) 
3.44 ml dH2O 
0.63 ml 1 M Tris-HCl (pH 6.8) 
0.05 ml 10 % (w/v) SDS 
0.83 ml 30 % Acrylamide/bis-acrylamide 
0.05 ml 10 % (w/v) ammonium persulfate 
(APS) 
0.005 ml TEMED 
10 ml 10 % SDS-PAGE Running gel 
(Cold Spring Harbor Laboratory, 2015) 
4.0 ml dH2O 
2.5 ml 1.5 M Tris-HCl (pH 8.8) 
0.1 ml 10 % (w/v) SDS 
3.3 ml 30 % Acrylamide/bis-acrylamide 
0.1 ml 10 % (w/v) APS 
0.01 ml TEMED 
Full MEM MEM 
0.1 % (v/v) NEAA 
1 % (v/v) L-glutamine 
10 % (v/v) FBS 
100 units/ml penicillin  
100 units/ml streptomycin 
Transfection Minimum Essential Media 
(MEM) 
MEM (Life Technologies) 
0.1 % (v/v) NEAA 
1 % (v/v) L-glutamine 
DNA Transfection mix for 6-well plate 2 µg DNA 
10 µl Polytheylenimine (PEI) 
700 µl Transfection MEM 
44 
 
2.2 Cell Lines 




BHK-21 Hamster kidney Fibroblast ATCC 
Huh 7.5 Human hepatocarcinoma Epithelial ATCC 
HeLa Human cervical adenocarcinoma Epithelial ATCC 
MDBK Bovine kidney Epithelial ATCC (via St. Andrews) 








PIK93 5 mM 1 μM- 5 μM Sigma 
Compound 3 40 mM 0.5 μM – 20 μM AstraZeneca 
Compound 7 40 mM 0.5 μM – 20 μM AstraZeneca 
Wortmannin 2 mM 0.5 μM – 2 μM 





Antibody Species Dilution Source Target 
Anti-3A (2C2) Rabbit 1:2000 Gift from Francisco Sobrino 
(Madrid) 
Primary 
Anti-3B (IF8) Mouse 1:1000 Gift from Francisco Sobrino 
(Madrid) 
Primary 
Anti-3C (2D2) Mouse 1:2000 Gift from Francisco Sobrino 
(Madrid) 
Primary 
Anti-3D (397) Rabbit 1:5000 Gift from Francisco Sobrino 
(Madrid) 
Primary 
Anti-His (HRP) Mouse 1:5000 Sigma-Aldrich Primary 
Anti-FLAG Rabbit 1:5000 Sigma-Aldrich Primary 
Anti-HA Mouse 1:5000 Sigma-Aldrich Primary 
Anti-Biotin Mouse 1:5000 Sigma-Aldrich Primary 
Anti-GAPDH Mouse 1:5000 Sigma-Aldrich Primary 
Anti-PI4P Mouse 1:50 Echelon Primary 
Anti-NS5A Sheep 1:5000 Gift from Mark Harris (Leeds) Primary 
Anti-Mouse (HRP) Goat 1:2000 Sigma-Aldrich Secondary 
Anti-Rabbit (HRP) Goat 1:5000 Sigma-Aldrich Secondary 
Anti-Rabbit Alexa 
Fluor 568 




Donkey 1:5000 Life Technologies Fluorescent 
secondary 
2.5 Nucleic acid manipulation 
2.5.1 Plasmids and Replicons 
Several plasmids have been designed and DNA or RNA from those plasmids were 
used in both replication and translation assays. The plasmids can be classed into four 
types; those based on GFP-pac, ptGFP and mCherry, luciferase, and bicistronic. The 
bicistronic plasmids contained sequences of FMDV, encephalomyocarditis virus 
(EMCV), hepatitis C virus (HCV) and human rhinovirus (HRV) IRES. 
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2.5.1.1 FMDV Replicon Constructs 
GFP-pac based plasmid constructs include the FMDV replicon insert replacing the 
structural proteins 1A-1D with a green fluorescent protein (GFP) reporter gene and a 
puromycin acetyltransferase resistance gene (pac). ptGFP replicons are the second 
generation GFP-pac plasmids designed by Fiona Tulloch (St. Andrews) replacing the 
GFP-pac reporter with a GFP derived from Ptilosarcus gurneyi (ptGFP), a 
bioluminescent sea pen, which is brighter than the Aequorea GFP (extracted from 
the Aequorea victoria jellyfish) used in GFP-pac. mCherry constructs have replaced 
the structural proteins 1A-1D with the mCherry fluorescent report gene (Fiona 
Tulloch, St. Andrews). Plasmids have also been designed to contain various point 
mutations or synonymous scrambled DNA sequences to act as experimental controls. 
These replicons are shown schematically in Table 2.1 and 2.2. 
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Replicon Name Designed by Plasmid backbone 
GFP-pac-WT F. Tulloch (St. Andrews) pBR3222 
 
GFP-pac-LL F. Tulloch (St. Andrews) pBR3222 
 
GFP-pac-Δ3D F. Tulloch (St. Andrews) pBR3222 
 
GFP-pac-GNN F. Tulloch (St. Andrews)/M. Herod (Leeds) pBR322 
 
ptGFP-WT F. Tulloch (St. Andrews)/M. Herod (Leeds) pCDNA 
 
Table 2.1: Summary of GFP-containing replicon constructs. All GFP-pac replicon constructs 
have been designed with the structural proteins encoded for by 1A-1D have been replaced 
by GFP-pac reporter cassette. The final ptGFP replicon shows the change from GFP-pac with 
a simple exchange of the structural proteins 1A-1D to the new ptGFP reporter gene. 
 
 
Table 2.2: Summary of mCherry-containing replicon constructs. The mCherry 
replicon constructs share a similar structure to the GFP-pac constructs; replacing 
the 1A-1D structural proteins with an mCherry red fluorescent protein. 
Replicon Name Designed by Plasmid Backbone 




2.5.1.2 Bicistronic Replicon Constructs 
The bicistronic luciferase constructs contain a Renilla luciferase reporter gene under 
the control of a 7-methylguanosine cap, followed by a firefly luciferase reporter gene 
under the control of an IRES from FMDV, EMCV, HCV, and HRV. These constructs 
were designed in the Hirasawa laboratory (Memorial University of Newfoundland, 
Canada). These replicons are shown schematically in Table 2.3. 
Replicon Name Designed by  






Licursi et al., 2012  
 
Table 2.3: Summary of bi-cistronic reporter constructs. The constructs described are dual 
luciferase bi-cistronic constructs. Two different luciferase reporter genes are under the 
expression of two alternative methods of translation: cap- and IRES-dependent. 
Luminescence of luciferase depends on the method of translation being utilised.  
2.1.1.3 CVB3 Replicon Constructs 
The CVB3 plasmids (kind gift from Frank van Kuppeveld, University of Utrecht) 
encode an ORF for a CVB3 replicon. The structural proteins have been replaced with 
a luciferase reporter gene. Two plasmids were provided, one encoding a WT CVB3 
49 
 
replicon, and one with a mutation in non-structural protein 3A rendering the replicon 
replication-defective. The replicons are shown schematically in Table 2.4. 
Replicon Name Designed by  
Rib-Fluc-CB3/T7 or CB3/T7-3A H.Tongren-van der Schaar (Utrecht)  
 
Table 2.4: Summary of CVB3 replicons constructs. The CVB3 replicon constructs, Rib-Fluc-
CB3/T7 contain a firefly luciferase reporter gene in place of the structural proteins 1A-1D. A 
mutant construct was also provided (Rib-Fluc-CB3/T7-3A) which replaced amino acids at 
positions 6-11 in non-structural protein 3A with 5 alanine residues. 
2.5.1.4 HCV Replicon Constructs 
The HCV sub-genomic replicon RNA (kind gift from Mark Harris, University of Leeds) 
termed HCV SGR-Luc-GFP-JFH1, is encoded by a plasmid containing the non-
structural proteins of HCV genotype 2a, JFH-1. The structural proteins E1, E2, core 
and P7 have been replaced with a luciferase reporter gene and a neomycin resistance 
gene used for stable selection in cell culture. The luciferase reporter gene is under 
the control of the HCV IRES, and the non-structural proteins NS3-5B are under the 
control of the EMCV IRES. The replicon is shown schematically in Table 2.5. 
Replicon Name Designed by  
SGR-Luc-GFP-JFH1 Jones et al., 2007; Saeed et al., 2012  
 
Table 2.5: Summary of HCV replicon construct. The HCV replicon construct, SGR-Luc-
GFP-JFH1 contains a firefly luciferase reporter gene and a neomycin resistance gene 
in place of the structural proteins E1, E2, core and p7.  
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2.5.2 Replicon DNA Preparation 
2.5.2.1 Transformation 
Plasmids were transformed into and DH5α competent E. coli bacterial cells by adding 
250 ng DNA to 50 µl thawed DH5α competent cells and incubated on ice for 30 mins. 
Subsequently, the bacteria and DNA were subjected to a heat shock at 42°C for one 
minute, followed by rapid cooling on ice for two minutes. 500 µl LB media was added 
and the transformed bacteria were recovered at 37°C for one hour prior to lawn 
spreading on LB agar plates containing 100 μg/ml ampicillin. The plates were 
incubated for 16 hours at 32°C. 
2.5.2.2 Preparation of plasmid DNA 
A single colony from the LB agar plates was picked and grown for 16 hours (overnight) 
in a 32°C shaking incubator in 10 ml LB containing 100 μg/ml ampicillin. Following the 
overnight culture growth of the colony in the media, 300 μl of the culture was 
transferred to an Eppendorf tube and mixed with 600 μl 30 % (v/v) glycerol. The 
glycerol stock of the culture was stored at -80°C for long term storage. 
The overnight cultures were subjected to either Miniprep or Maxiprep protocols per 
manufacturer’s instructions (Qiagen), depending on the volume of the culture. 
Distilled water was used to elute the DNA. The concentration of the eluted plasmid 
DNA was measured using a nanodrop spectrophotometer and recorded. 
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2.5.2.3 DNA linearisation 
GFP-pac plasmid DNA was linearised with restriction enzyme HpaI (New England 
Biolabs - NEB). ptGFP and mCherry plasmid DNA was linearised with AscI (NEB). CVB3 
Rib-Fluc-CB3/T7(-3A) was linearised with MluI (NEB). HCV SGR plasmid was linearised 
with XbaI (NEB). Linearisation occurred by incubating 1 µl enzyme with 500 ng DNA 
in a 10 µl reaction. Linearisation was confirmed by resolving DNA by 1 % agarose (1 
% (w/v) agarose in 1 x TBE buffer) gel electrophoresis. 
2.5.2.3 DNA Purification 
Linearised plasmid DNA (500 ng) was phenol-chloroform extracted and ethanol-
precipitated by mixing equal volumes of phenol-chloroform with linearised plasmid 
DNA and centrifuging the sample at approximately 16,000 x g (or 13,300 RPM) for 10 
minutes at 16°C. The upper aqueous phase was carefully withdrawn and dispensed 
into a fresh nuclease-free Eppendorf tube. The aqueous phase was then mixed with 
an equal volume of chloroform and centrifuged at 16,000 x g (or 13,300 RPM) for a 
further 10 minutes at 16°C. The upper aqueous phase was once again removed and 
dispensed into a fresh nuclease-free Eppendorf tube. The aqueous phase was 
subjected to ethanol precipitation by mixing in 1/10 volume 3M sodium acetate and 
2.5 x volume 100 % ethanol. The mixture was gentle agitated and placed at -20°C for 
20 mins. After precipitation, the mixture was centrifuged at 16,000 x g (or 13,300 
RPM) for 30 mins at 16°C. The supernatant was removed and discarded. Equal 
volume of the supernatant was replaced with fresh nuclease-free 70 % ethanol. The 
DNA pellet was gently resuspended and the mixture was centrifuged once more at 
16,000 x g (or 13,300 RPM) for 30 minutes at 16°C. The supernatant was removed 
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and discarded and the pellet of purified DNA is resuspended in 18 µl nuclease-free 
dH2O. The concentration of the purified DNA was measured using a nanodrop 
spectrophotometer. 
2.5.3 RNA Preparation 
2.5.3.1 T7 In vitro Transcription 
The purified DNA containing the FMDV insert was used as a template for in vitro 
transcription in a T7 in vitro transcription reaction. 2.5 μl 10 x T7 transcription buffer, 
0.5 μl bovine serum albumin (BSA) (10 mg/ml) and 1.25 μl 20 x RNA Secure were 
added to the purified DNA and incubated at 60°C for 10 minutes, followed by cooling 
on ice. Subsequently, 0.75 μl RNase inhibitor, 2 μl ribonucleoside tri-phosphates 
(RNTPs) from 100 mM stock and 1 μl T7 RNA polymerase was added prior to 
incubation at 32°C for four hours. Reactions were treated with 1.25 μl RQ1 RNase-
free DNase for 30 minutes at 37°C. The RNA was recovered and purified using RNA 
Clean and ConcentratorTM-25 (Zymo Research) according to manufacturer’s 
instructions and eluted twice in 25 μl nuclease-free water. The RNA concentration 
was measured by nanodrop spectrophotometry and stored at -80°C. 
Ethanol-precipitated, purified HCV SGR DNA was in vitro transcribed using a 
RiboMAX™ T7 in vitro transcription kit (Promega) according to the manufacturer’s 
instructions. The integrity and concentration of the RNA was tested by 
electrophoresis on a 1 % MOPS-formaldehyde gel (see section 2.1). 500 ng RNA was 
heated to 85°C for 10 minutes and added to the gel. The gel was subjected to 80 V 
for 45 minutes.  
53 
 
2.6 Cell Culture 
2.6.1 Cell Culture Maintenance 
The cell lines used during the project (BHK-21, Huh 7.5 and HeLa) were maintained 
in DMEM in T75 or T175 flasks (Corning). Cells were passaged every 48-72 hours, or 
when they were 80-90 % confluent by removing the media and washing the cells in 
1 x PBS and detaching the cells using 1 x trypsin-EDTA. Cells were re-suspended in 
DMEM supplemented with 10 % (v/v) Foetal Bovine Serum (FBS), 100 units/ml 
penicillin and 0.1 units/ml streptomycin, and passaged at 1:12 dilution. Cells were 
grown at 37°C in a humidified incubator with 5 % carbon dioxide.  
2.6.2 Preparing Cells for IncuCyte Analyses 
IncuCyte analyses to measure levels of fluorescence in replicon-transfected cells 
were undertaken in cells seeded out into 24-well plates at a density of 1x105 cells per 
well and maintained in 500 µl DMEM for 24 hours.  
2.6.3 Transfection of RNA 
Cells prepared in 24-well plates were used for transfection with a total of 1 µg RNA 
using Lipofectin® transfection reagent (Life Technologies) as previously described 
(Tulloch et al., 2014; Herod et al., 2015). For complementation studies, 0.5 µg of both 
ptGFP and mCherry replicon RNAs were simultaneously co-transfected using 
Lipofectin® (Life Technologies) as previously described. Evidence of replication as a 




2.6.4 Preparing Cells for Dual Luciferase Assays 
Dual luciferase assays were undertaken in BHK-21 cells seeded at a density of 2x105 
per well in 6-well plates. These cells were maintained in DMEM for 24 hours until 
they reach 40-60 % confluency at the time of transfection.  
2.6.5 Transfection of DNA 
Cells were prepared as described in section 2.6.4. The transfection mix (section 2.1) 
was optimised as previously described in Licursi et al., 2011; the cells were 
supplemented in 1300 µl full MEM and placed at 37°C. After 5-8 hours post-
transfection, the media was changed to 2 ml full MEM for a further 48 hours. The 
cells were lysed in 1 x passive lysis buffer (Promega) and placed at -20°C for at least 
2 hours. The cell lysates were collected in Eppendorf tubes, vortexed briefly and 
centrifuged at approximately 1,000 x g (or 4,000 RPM) for 5 minutes to pellet the cell 
debris. Following pelleting, 30 μl of an undiluted lysate sample and a lysate sample 
diluted to 1/100 in 1 x PBS, and were placed in a white opaque 96-well plate and 
placed in the luminometer. The Dual-Luciferase® Reporter Assay System kit 
(Promega) was used.  The luciferase luminescence in luciferase forming units (LFU) 
in the neat, undiluted lysate samples and lysate samples diluted 1/100 was 
measured.  
2.6.6 Preparing cells for electroporation 
Huh 7.5 cells in a T175 flask (Corning) were washed with 1 x PBS and trypsinised to 
remove the adherent cells from the flask. The cells were collected and washed three 
times in diethyl pyrocarbonate (DEPC)-treated 1 x PBS by centrifuging the cells at 
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approximately 1,000 x g (or 4,000 RPM) for 5 mins at 4°C. Cells were resuspended in 
DEPC-treated 1 x PBS at a density of 2x106 cells. 
2.6.7 Electroporation of RNA 
5 µg RNA transcripts were transfected into 2x106 cells in DEPC-treated 1 x PBS by 
electroporation using a square-wave protocol at 260 V for 25 ms. Electroporated cells 
were resuspended in DMEM to 2x105 cells/ml and seeded on cover slips in 24-well 
plates at a density of 1x105 cells per well. 
2.6.8 Compound treatments 
PIK93, Compound 3 and Compound 7, and wortmannin were added to cell cultures 
either 2 hours prior to transfection, or at the same time as transfection or 
electroporation at the concentrations described in section 2.3. If the compounds 
were added 2 hours prior to transfection, the compound was refreshed when the 
transfection components were added to the cells. 
2.6.9 Cytotoxicity (MTT) assay 
An MTT cytotoxicity assay of the compounds described in section 2.3 was 
undertaken prior to experimental use. Cells were plated out into a 96-well plate at a 
density of 1x104 cells per well. Cells were allowed to recover and settle for 24 hours 
in 100µl DMEM. The compounds were added to the cells at increasing 
concentrations (ranging from 0 µM up to 20 µM) and allowed to incubate for 24-48 
hours. Following the appropriate incubation times, MTT substrate MW414 (Sigma) 
was dissolve to a concentration of 1 mg/ml in filter-sterilised serum-free medium. 
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The DMEM and compound were removed from the cells and they were washed in 1 
x PBS. 100 µl of MTT solution was added to each well and incubated in the dark at 
37°C in a humidified incubator with 5 % carbon dioxide for 30 minutes. Following 
incubation, the MTT solution was removed from the cells and replaced with 100 µl 
DMSO. The plate was agitated for 5 minutes at 60 rpm to allow for the purple 
precipitant to re-dissolve. Any bubbles were removed and the plate was analysed 
by measuring absorbance at 570 nm using a fluorescent plate reader. 
2.7 Immunofluorescence 
2.7.1 Preparation of Cells for Immunofluorescence 
BHK-21 and Huh 7.5 cells were seeded on to glass coverslips in 24-well plates and 
transfected with FMDV replicon RNA as described in section 2.6.2 and section 2.6.3, 
or after electroporation with HCV SGR as described in section 2.6.6 and 2.6.7. 
Transfected cells were incubated for a range of times (2-8 hours). Following 
incubation, the media was removed and the cells were gently washed once with 1 x 
PBS and fixed using 4 % paraformaldehyde for 10 minutes at room temperature. 
Once fixed, the cells were stored in 1 x PBS at room temperature. 
2.7.2 Permeabilisation and Antibody Probing 
Cells were permeabilised either in 0.2 % triton X-100 in PBS or in saponin buffer for 
2 hours at room temperature on a rocking platform. Permeabilised cells were 
subsequently washed 3 times in 1 x PBS and probed with the appropriate primary 
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antibody diluted in 1 x PBS for 2 hours at room temperature, or for 16 hours at 4°C. 
Cells treated with the appropriate primary antibody (as listed in section 2.4).  
Following primary antibody incubation, coverslips were washed 3 times in 1 x PBS 
and probed with the appropriate secondary fluorescent antibodies (as listed in 
section 2.4). The antibodies were diluted in 1 x PBS. Cells were incubated with 
secondary fluorescent antibodies for 2 hours at room temperature on a rocking 
platform. Incubation of coverslips with secondary antibody was undertaken in the 
dark.  
Coverslips were washed 3 times in 1 x PBS and mounted on microscope slides after 
blotting dry with 5 µl ProLong Gold antifade mountant with DAPI (Life Technologies). 
Mounted coverslips were sealed before visualising by confocal microscope. 
2.8 Immunoblotting 
2.8.1 Harvesting Cell Lysates 
BHK-21 cells were transfected with RNA as outlined previously. Every hour after 
transfection for 10 hours the cells were lysed by adding 100 μl RIPA buffer and 
scraped from the well into an Eppendorf tube, vortexed and centrifuge at 
approximately 16,000 x g (or 13,300 RPM) for 15 minutes to pellet the lysates. The 
lysates could be stored in -20°C. Lysate samples were subjected to SDS-PAGE 
electrophoresis on 10 or 15 % resolving gels, with 5 % stacking gel (Cold Spring Harbor 




2.8.2 SDS-PAGE Gel Electrophoresis 
SDS-PAGE gels were prepared for electrophoresis of samples (Cold Spring Harbor 
Laboratory, 2015) . An equal volume of cell lysate sample and 2 x Laemelli loading 
dye was heated at 95°C for five minutes. The samples were loaded on to the gels. The 
gels were subjected to 200 V for one hour in 1 x Tris-glycine SDS-PAGE running buffer. 
2.8.3 Western Blotting  
After electrophoresis, the protein on the gel was transferred onto Immobilon®-P 
polyvinylidene difluoride (PVDF) membrane (Merck) (activated in 100% methanol 
prior to transfer) on XCell SureLock Mini-Cell wet transfer apparatus (Life 
Technologies) in 1 x transfer buffer for one hour 30 minutes at 25 mA. The membrane 
was subsequently washed in 1 x TBS-T and blocked in 10 % blocking buffer (10 % 
(w/v) skimmed milk powder in 1 x TBS-T) for one hour at room temperature on a 
rocking platform.  
2.8.4 Antibody Incubation 
The membranes were incubated for 16 hours at 4°C on a rocking platform with the 
primary antibodies (section 2.4), diluted to the appropriate concentration in in 5 % 
milk (5 % (w/v) milk powder in 1 x TBS-T). Following incubation, the membranes were 
washed 3 times in 1 x TBS-T and incubated for 2 hours at room temperature on a 
rocking platform with the appropriate secondary antibody (section 2.4) diluted to the 




2.8.5 Developing SDS-PAGE membranes 
The membranes were washed and incubated in combined ECL I and II enhanced 
chemiluminescence reagents (Pierce) and are exposed on film. The film was 
automatically developed using the Xograph Compact X4 Automatic Processor to 
develop the film. 
2.9 Expression and purification of His-tagged 3Dpol 
WT his-tagged 3Dpol (kind gift from Esteban Domingo) and mutants constructed by 
PCR mutagenesis were expressed in Codon plus (+) RiPL competent E. coli. For protein 
production, a 12 ml LB medium containing kanamycin (100 µg/ml) and 
chloramphenicol (34 µg/ml in 100% ethanol) was grown for 16 hours at 37°C was 
used as a starter culture. 10 ml of starter culture was used to inoculate 1 L LB broth 
with 100 µg/ml kanamycin. The cultures were grown at 37°C in a shaking incubator 
until optical density at 600 nm (OD600) was in the range of 0.6-0.8. Cultures were then 
induced with 1 mM IPTG and grown for a further 3 hours at 37°C. The cultures were 
centrifuged at approximately 6,000 x g (or 5,000 RPM) for 10 minutes and the 
supernatant was discarded. The bacterial pellet was resuspended in 1 ml storage 
buffer (20 mM Tris-HCl, pH 8) and stored at -80°C. 
Pellets were lysed with the addition of 30 ml lysis buffer (20 mM Tris-HCl, 500 mM 
NaCl, pH 8), 200 µl 100 mg/ml lysozyme (Sigma), 15 µl 100 mg/ml DNaseI (Life 
Technologies), and 1 cOmplete EDTA-free protease inhibitor cocktail tablet (Roche) 
and placed on a roller at 4°C for 30 minutes. The lysed pellets were subsequently 
sonicated alternating 10 seconds on and 40 seconds off for 6 minutes. The sonicated 
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lysate was centrifuged at approximately 27,000 x g (or 15,000 RPM) for 20 minutes 
and the supernatant filtered through 0.22 µm filter. 
The filtered supernatant (load) was subjected to nickel affinity chromatography using 
1 ml HisTrap HP columns (GE Healthcare) attached to a peristaltic pump. HisTrap 
columns were prepared by washing with five column volumes (CV) dH2O, and 
equilibrating with five CV buffer A (wash). The load was added and collected as 
flowthrough. The column was washed three times in 3 CV buffer A (wash). Each wash 
was collected separately. The column was then washed with 5 CV buffer B (elution). 
The flowthrough was collected in eight 250 µl fractions and the final three ml was 
collected in fraction 9. 
The load flowthrough, washes and eluted fractions (1-9) are analysed by SDS-PAGE 
and Coomassie (brilliant blue) stain. The typical approximate concentrations, as 
determined by Bradford assay, of the purified His-3Dpol WT, DD388/9NN, DD240/5NN 
and GC216/7AA mutant proteins were 185 µM, 300 µM, 92 µM and 130 µM, 
respectively. 
2.10 His-tagged 3Dpol in vitro assays 
2.10.1 3Dpol Activity Assay 
A 100 µl master-mix of 10 µl 10x elongation buffer, 20 µl 500ng/µl poly-A template 
RNA (GE Healthcare), 2.4 µg oligo-d(T)15 (Promega), 4 mM UTP (Thermo Fisher), and 
1 µl [α-32P]-UTP (250 µCi) (Perkin Elmer) was made alongside 20 µl master-mix for 
controls which include one without any RNA components, one without poly-A 
template RNA, one without oligo-d(T) primer DNA, and one without any UTP. 10 µl 
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of each master mix was aliquoted into an RNAse-free Eppendorf tubes (one for each 
timepoint and for the controls). Immediately before use, a final concentration of 
18.52 µM of his-3Dpol was added to each reaction tube except for the control tube 
(that contained no protein). All reactions were controlled for salt concentrations as 
dilution of individual components (solutes) of the assay were made using the same 
solvent/buffer. 
Reaction tubes were incubated at 30°C for increasing lengths of time (1-120 minutes). 
Reactions were stopped by the addition of 1.5 µl 500 mM EDTA. 2 µl of each reaction 
was blotted onto filter paper (Whatmann) and allowed to dry. The dried filter paper 
was washed by gentle rocking for 2.5 minutes in activity assay wash buffer (200 mM 
di-sodium hydrogen phosphate, 75.2 mM sodium pyrophosphate) 5 times, followed 
by once in in dH2O for 1 minute and, once in 100 % ethanol for 1 minute. The filter 
paper was allowed to dry and was then exposed on to film for 16 hours at -80°C. The 
film was developed automatically using Xograph Compact X4 Automatic Processor. 
The individual dots on the filter paper could then be excised and scintillated with the 
addition of 3 ml scintillation fluid (Perkin Elmer) and the radioactive counts were 
measured by 32P scintillation counts per minute. 
2.10.2 3Dpol Crosslinking Assay 
Individual RNase-free Eppendorf tubes were prepared containing 7.5 µl 1 x 
elongation buffer and 15 µL 10 mM glutaraldehyde, alongside 80 µl activity assay 
master-mix consisting of 8 µl 10 x elongation buffer, 16 µl 500ng/µl poly-A template 
RNA (GE Healthcare), 2.4 µg oligo-d(T)15 (Promega) and 4 mM UTP (Thermo Fisher). 
Immediately before use, a final concentration of 18.52 µM of his-3Dpol was added to 
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the master-mix. Controls were also included that substituted each RNA component, 
protein, or the addition of glutaraldehyde with nuclease-free dH2O. 
7.5 µL of master-mix was added to each individual assay Eppendorf tube before the 
samples were incubated at 30oC for increasing lengths of time (1-120 minutes). 
The reaction was stopped by the addition of 30 µL 2x Laemmli buffer. The samples 
were then heated for 5 minutes at 95oC. Samples were analysed by gradient SDS-
PAGE (12 %, 10 %, 8 %, 6 %, 4 % resolving gels, and 4 % stacking gel (Cold Spring 
Harbor Laboratory, 2015)), Coomassie (brilliant blue) stain and Western blot probing 
with primary anti-His or anti-3D antibodies as detailed in section 2.4.  
2.10.3 3Dpol RNA-binding fluorescent polarisation anisotropy 
Using a black opaque 384-well plate (Perkin Elmer), 20 µl of RNA binding buffer (20 
mM Tris-HCl (pH 8), 100 mM NaCl, 0.01 % Triton X-100) was added to each well 
followed by 40 µl of protein to the first well and mixed by pipetting. A serial dilution 
of the protein was completed across each well by transferring 40 µl of the RNA 
binding buffer and protein to the next adjoining well and finally discarding 40 µl from 
the last well resulting in each well containing equal volumes of 20 µl. 
Next, 20 µl of 20 nM FITC-labelled 13mer poly-A (from 1 µM stock) was overlaid into 
each well containing buffer and protein. A control row that contained no fluorescent 
RNA to establish background polarisation was included. The plate was incubated at 
room temperature for 1 hour in the dark. 
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Polarisation was measured using the Tecan plate reader (Darren Tomlinson, 
University of Leeds) with an excitation filter at 480 nm and S and P channel emission 
filters at 530 nm. 
2.10.4 Transmission electron microscopy (TEM) negative staining 
Carbon-coated copper grids were prepared by glow discharge at 25 mA for 30 
seconds. 
The activity assay master mix was prepared as described for the crosslinking assay in 
section 2.10.2. Samples were incubated for 30 minutes at 30°C. Reactions were 
stopped by loading 10 µl onto carbon-coated copper EM grids for 1 minute. The 
sample was blotted off and the grids washed twice with 10 µl dH2O for 5 seconds 
each. The grids were loaded with 10 µl 2 % uranyl acetate for 1 minute and blotted 
off with filter paper.  
TEM was analysed on the Jeol 1400 (Jeol USA Inc.) at 30, 000 x magnification. 
2.10.5 Cryo-electron microscopy (Cryo-EM) 
Activity assay master-mix was prepared as described in section 2.10.2 and incubated 
at 30°C for 30 minutes. 10 µl of the master-mix was loaded on a C-flat (protochips) 
CF1.2/1.3-4C grid (1.2 µm holes) that had been glow discharged at 25 mA for 1 
minute. The grids were blotted for 6 seconds at blot force 10, using an FEI Vitrobot 
Mark IV in chamber conditions at 4˚C and 95 % relative humidity. 
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Initial analysis of the grids took place at the University of Glasgow. 129 micrographs 
were analysed, yielding 23,700 filament sections by autopicking in Relion 2.0.3. After 
2 rounds on 2D classification, 12,521 sections were used in the 3D classifications. 
Further cryo-EM analysis involved data collection on the Krios 1 microscope 
(University of Leeds), using the Falcon III detector in integrating mode. Data was 
collected at nominal 75,000 x magnification, giving a sampling of 1.05 Å/pixel. The 
dose rate is 60 e¯/pixel/second, giving a dose of 54 e¯/Å2/second. The length of 
exposure was 2 seconds, with 79 frames in total, giving 1.4 electrons/frame. 




Investigating mutations in foot-and-mouth 
disease virus 3D polymerase in viral replication 
3.1 Introduction 
The RNA-dependent RNA polymerase from FMDV, 3Dpol, is a 54 kDa enzyme. The 
main function that has been described for 3Dpol is in viral RNA synthesis. 3Dpol is a 
non-proof-reading polymerase resulting in both mutations and recombination 
occurring during replication, lending FMDV a quasispecies nature, common across all 
picornaviruses (reviewed in Domingo et al., 2012).  
The process of FMDV infection from entry through to egress is extremely quick, 
completing a single lifecycle in cell culture in 6 hours. In livestock, transmission can 
result in disease signs being identified as early as 2-3 days post infection (reviewed 
in Grubman and Baxt, 2004). 
Upon entry into the host-cell cytoplasm, the viral RNA genome undergoes initial 
translation. Host-cell translation initiation factors and ribosomes bind to an IRES 
element located in the 5ʹ UTR and initiate internal translation of the viral RNA 
genome in a cap-independent manner typical of a number of positive-sense RNA 
viruses such as pestiviruses, hepaciviruses, aphthoviruses and enteroviruses (Jang et 
al., 1988; Pelletier et al., 1988; Belsham et al., 1990; Sizova et al., 1998; Niepmann, 
2009). The process of translation is mediated by the binding of translation initiation 
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factor eIF4G to the IRES. This subunit recruits eIF4A, eIF3a and eIF4B, and the 40s-
ribosomal subunit, along with an ever-growing list of cellular co-factors (IRES trans-
acting factors – ITAFs) including the poly-pyrimidine tract binding protein (PTB), the 
poly-A binding protein (PABP) and the poly-C binding proteins 1 and 2 (PCBP1, PCBP2) 
(Martínez-Salas, 2008; Yu et al., 2011; Blyn et al., 1997; Rodríguez Pulido et al., 2007; 
López de Quinto et al., 2002).  
Figure 3.1 Schematic of the FMDV genome showing the proposed ORFs of each of 
the viral proteins. The 5’ untranslated region (UTR) is located upstream of the 
polyprotein. The structural proteins are transcribed from segment P1 (1A-1D) and 
are co-and post-translationally processed to make mature capsid proteins (VP1-4). 
Segments P2 and P3 encode for the non-structural proteins necessary for replication 
of the genome (2A-3D). Likewise, both these segments are co- and post-
translationally modified into the mature proteins. Adapted from Forrest et al., 2014. 
The genome is translated into a polyprotein from a single ORF from which the 
structural and non-structural precursors are co- and post-translationally processed 
into the active mature proteins (Fig. 3.1). The polyprotein is initially processed into 
four primary products: Lpro, P1-2A, 2BC and P3 (Laporte, 1969; Sangar, Black, et al., 
1977; Rueckert et al., 1984). Intermediate polyprotein precursors 2BC and P3 are 
cleaved into the functional, ‘mature’ proteins by the virus-encoded protease, 3C via 
several further intermediates (Doel et al., 1978), including 3AB1-3, and 3CD (Flint et 
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al., 1997). Further processing releases the 3A transmembrane protein (Moffat et al., 
2005; González-Magaldi et al., 2014), three non-identical tandem repeats of primer 
3B (3B1-3) (Forss et al., 1982), 3C (Birtley et al., 2005) and 3Dpol (Ferrer-Orta et al., 
2004). 
The process of replication involves the viral polymerase scanning and replicating the 
RNA template from 5’ to 3’ direction to form a negative strand intermediate from 
which positive strands can be made and used as a template for translation and/or to 
be packaged into virions. Translation of the input RNA occurs in a 5’ to 3’ direction 
beginning at the IRES located in the 5ʹ UTR, however, this cannot occur concurrently 
with replication on the same RNA strand, and it is proposed that a switch occurs for 
replication to begin (Gamarnik et al., 1998; Paul, 2002; Nayak et al., 2005). However, 
it is possible that replication and translation can occur concurrently within different 
cellular compartments. 
Initiation of both replication and translation has been shown to involve the 
circularisation of the genome through discrete RNA-RNA and RNA-protein 
interactions between the 3ʹ UTR, the 5ʹ UTR, cellular host factors, and virus-encoded 
proteins  (Herold and Andino, 2001; López de Quinto et al., 2002; Serrano et al., 
2006). This mechanism is thought to be widespread amongst positive-strand RNA 
viruses (Pogue et al., 1994; Gamarnik et al., 1998; Kim et al., 2003; Villordo et al., 
2010). 
Replication of viral RNA commonly occurs within intracellular membrane-associated 
compartments known as replication complexes. Evidence of such compartments 
have been shown in HCV, dengue virus, and in other picornaviruses such as PV  (Bienz 
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et al., 1992; Schlegel et al., 1996; Westaway et al., 1999; Gosert et al., 2003; Novoa 
et al., 2005; den Boon et al., 2010). Replication of viral RNA occurs within these 
intracellular compartments as a way for the virus to concentrate the structural and 
non-structural components into a small area to facilitate replication as well as to be 
able to protect the virus components from host-cell pathogen recognition and innate 
immune responses. Using immunofluorescent confocal and electron microscopy, 
FMDV has been shown to dysregulate Golgi and ER-derived membranes in a similar 
way to PV (Schlegel et al., 1996; O’Donnell et al., 2001; Monaghan et al., 2004; Knox 
et al., 2005), but no distinct membrane-bound replication complex comprised of viral 
RNA, structural and non-structural proteins, and host-cell proteins have yet to be 
identified for FMDV. 
Much like PV, where replication is mediated by the binding of 3Dpol to the VPg in the 
presence of 3CD binding to the cloverleaf structure (Harris et al., 1994), replication 
of FMDV RNA begins with 3Dpol, in the presence of 3CD, mediating the uridylylation 
of the third tyrosine of VPg. VPg is encoded for by non-structural proteins 3B1, 3B2, 
and 3B3. The template for VPg uridylylation is the cis-acting replicative element (cre) 
located in the 5ʹ UTR. A copy of uridylylated VPg (VPg-pUpU) hybridises to the 3’ end 
of the template RNA and acts as a primer to initiate replication. It is thus covalently 
linked to the 5ʹ end of the daughter strand and is used as a primer for both positive 
and negative strand synthesis (Murray et al., 2003; Nayak et al., 2005; Steil et al., 
2009).  
In addition to functioning as the major catalytic protein necessary for viral genome 
replication, PV 3Dpol has been shown, biochemically and by microscopy, to have 
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another role in creating a support scaffold within which replication can occur. Studies 
on PV have shown that individual molecules of 3Dpol are able to interact with one 
another and multimerise to form higher-order fibril-like structures (Pata et al., 1995; 
Lyle, Bullitt, et al., 2002; Spagnolo et al., 2010; Tellez et al., 2011; Wang et al., 2013). 
Previous work on FMDV has shown, biochemically and by transmission electron 
microscopy, that 3Dpol is also able to form higher-order fibril-like structures, similar 
to those formed by PV 3Dpol (Bentham et al., 2012). This chapter investigates the role 
of FMDV 3Dpol in RNA replication by studying the formation of higher-order 





3.2 Mutations of 3Dpol 
The structure of FMDV 3Dpol has been well characterised and there are high-
resolution crystal structures of wildtype and several mutant polymerases have been 
identified (Ferrer-Orta et al., 2004; Agudo et al., 2010; Ferrer-Orta, Ferrero, et al., 
2015; Ferrer-Orta, de la Higuera, et al., 2015). These structures have also aided in our 
understanding of the catalytic domains and the key RNA binding domains, and 
identified the minimum requirement for nucleotide binding in the polymerase RNA 
binding site (6 nucleotides).  
The model of FMDV serotype C WT 3Dpol, as shown in Fig 3.2, has the different motifs 
outlined. FMDV 3Dpol has the standard ‘right-hand’ structure similar to other 
template-dependent nucleic acid polymerases (Steitz, 1998). The catalytic domain of 
the polymerase is located in conserved motif C in the ‘palm’ region of the structure 
highlighted in green in Fig. 3.2. The main catalytic residues are two aspartic acid 
residues located at amino acid positions 388 and 389. These residues have been well 
characterised as the primary catalytic site in several RNA viruses and is conserved 
amongst all serotypes of FMDV (Jablonski et al., 1991; Hansen et al., 1997; George et 
al., 2001; Carrillo et al., 2005). Changing either one or both aspartic acid residues 





Figure 3.2 Three-dimensional model structure of FMDV 3Dpol produced in PyMol 
based on the structure of recombinant serotype C protein (PDB: 1WNE). The 
structure shows the protein in the standard right-hand orientation with the location 
of the palm, thumb and fingers highlighted. The seven conserved motifs are 
highlighted. Motif A (Orange), Motif B (Yellow), Motif C (Green), Motif D (Purple), 
Motif E (Pink) and Motif F (Red).  
To identify other mutations that affected the function of 3Dpol, work by Herod et al. 
identified areas in the genome that could tolerate insertions by random transposon-
mediated mutagenesis using an FMDV replicon (Herod et al., 2015). The FMDV 
replicons that were developed and used have substituted the structural proteins in 
the P1 region with fluorescent reporter cassettes to monitor replication. These 
replicons are unable to form infectious virus but can still replicate once transfected 
into cell culture. The use of transposon-mediated mutagenesis using the FMDV 
replicon system has been a useful tool to identify key functional regions within viral 
proteins. By identifying permissive insertion sites, these regions can be further 
manipulated to include epitope tags for improved downstream studies such as 
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immunofluorescence (McMahon et al., 1998; Brune et al., 1999; Teterina et al., 2011; 
Remenyi et al., 2014).  
The method of transposon-mediated mutagenesis was used to identify regions in 
FMDV serotype O 3Dpol that could primarily tolerate small genetic insertions but also 
resulted in the identification of non-permissive insertion sites within the replicon. 
These non-permissive sites led to the production of replication-defective replicon 
phenotypes by rendering the polymerase inactive (Herod et al., 2015; Herod et al., 
2016). Out of nine mutations in the 3Dpol region that were identified, three were 
chosen to take forward into further studies: catalytic mutations DD388/9NN and 
DD240/5NN, and non-catalytic mutation GC216/7AA. These mutations were chosen 
to take forward in the studies as it was expected that the catalytic mutations would 
affect the ability for the polymerase to function as an enzyme. The phenotype of the 
non-catalytic mutation was as yet unknown. 
Mutant DD240/5NN corresponds to a substitution of the aspartic acid residues 240 
and 245 for asparagine, GC216/7AA corresponds to a substitution of glycine and 
cysteine residues in positions 216 and 217 for alanine and finally DD388/9NN 
corresponds to a substitution of the two aspartic acid residues in positions 388 and 
389 for asparagine. These mutations are represented schematically in Fig. 3.3a. The 
location of the mutated residues in the polymerase protein in Fig.3.3b is highlighted 
by differently coloured spheres.  
It is important to note that the protein sequences of serotype O and serotype C FMDV 
3Dpol are almost identical (99 % sequence identity) as highlighted in the sequence 
alignment in Table 3.1 below. There are four amino acid changes that differentiate 
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serotypes O and C, the first is located at position 68 from glutamic acid to glycine, the 
second at position 158 from valine to alanine, the third is at position 170 from leucine 
to methionine, and the fourth is located at position 294 from glycine to glutamic acid. 
The amino acids that have been mutated in serotype O (as a result of the transposon 
mutagenesis studies) are the same as those found in serotype C. 




           ************************************************************ 
Serotype-O KGDTKMSEEDKALFRRCAADYASRLHSVLGTANAPLSIYEAIKGVDGLDAMEPDTAPGLP 
Serotype-C KGDTKMSAEDKALFRRCAADYASRLHSVLGTANAPLSIYEAIKGVDGLDAMEPDTAPGLP 
           ******* **************************************************** 
Serotype-O WALQGKRRGALIDFENGTVGPEVEAALKLMEKREYKFVCQTFLKDEIRPLEKVRAGKTRI 
Serotype-C WALQGKRRGALIDFENGTVGPEVEAALKLMEKREYKFACQTFLKDEIRPMEKVRAGKTRI 
           *************************************.***********:********** 
Serotype-O VDVLPVEHILYTRMMIGRFCAQMHSNNGPQIGSAVGCNPDVDWQRFGTHFAQYRNVWDVD 
Serotype-C VDVLPVEHILYTRMMIGRFCAQMHSNNGPQIGSAVGCNPDVDWQRFGTHFAQYRNVWDVD 
           ************************************************************ 
Serotype-O YSAFDANHCSDAMNIMFEEVFRTEFGFHPNAEWILKTLVNTEHAYENKRITVGGGMPSGC 
Serotype-C YSAFDANHCSDAMNIMFEEVFRTEFGFHPNAEWILKTLVNTEHAYENKRITVEGGMPSGC 
           **************************************************** ******* 
Serotype-O SATSIINTILNNIYVLYALRRHYEGVELDTYTMISYGDDIVVASDYDLDFEALKPHFKSL 
Serotype-C SATSIINTILNNIYVLYALRRHYEGVELDTYTMISYGDDIVVASDYDLDFEALKPHFKSL 
           ************************************************************ 
Serotype-O GQTITPADKSDKGFVLGHSITDVTFLKRHFHMDYGTGFYKPVMASKTLEAILSFARRGTI 
Serotype-C GQTITPADKSDKGFVLGHSITDVTFLKRHFHMDYGTGFYKPVMASKTLEAILSFARRGTI 
           ************************************************************ 
Serotype-O QEKLISVAGLAVHSGPDEYRRLFEPFQGLFEIPSYRSLYLRWVNAVCGDA---------- 
Serotype-C QEKLISVAGLAVHSGPDEYRRLFEPFQGLFEIPSYRSLYLRWVNAVCGDAAAALEHHHHH 




Table 3.1 Comparison of the protein sequence alignment of FMDV 3Dpol serotypes 
O and C. Nucleotides that were mutated are highlighted in blue, yellow and green. 
(Carrillo et al., 2005; Ferrer-Orta, Arias, Escarmís, et al., 2006)  
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Figure 3.3 Schematic outlining the location of the mutations identified in 3Dpol. A) 
Schematic of the location of the 3Dpol mutations, in context of the replicon in which 
the mutations were initially introduced by transposon mutagenesis. Non-catalytic 
mutation GC216/7AA is shown in blue, and catalytic mutations DD240/5NN in orange 
and DD388/9NN in green. B) Shows the locations of the three mutations in context 
of the recombinant serotype C WT his-3Dpol model based on protein sequence with 
the individual residues highlighted in coloured spheres (produced in PyMol, PDB: 
1WNE). 
The mutations are located in three different regions of the polymerase molecule. 
DD240/5NN, in motif A, is categorised as a catalytic mutation as the residues that 
have been changed are located in the region that interacts with the magnesium ion 
necessary and integral for enzymatic function of 3Dpol during replication (Jablonski et 
al., 1991; Ferrer-Orta, Ferrero, et al., 2015; Herod et al., 2016).  
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The DD388/9NN mutation located in the enzymatic active site in motif C, was used 
as a standard negative control as the phenotypic profile of this type of mutation in 
these key catalytic residues has been previously defined both in FMDV and in many 
different viruses such as HCV, PV, EMCV and HIV (Jablonski et al., 1991; Hansen et al., 
1997; Krieger et al., 2001; Carrillo et al., 2005; Ferrer-Orta, Ferrero, et al., 2015). In 
the literature this mutation is commonly termed GNN, or GND when only one 
aspartic acid residue is substituted for asparagine. 
The location of the non-catalytic GC216/7AA mutation is at the double-stranded RNA 
exit site (Ferrer-Orta et al., 2004; Ferrer-Orta et al., 2007; Ferrer-Orta, Ferrero, et al., 




3.3 Purification and validation of mutant 3Dpol 
These mutations (DD388/9NN, GC216/7AA, and DD240/5NN) were introduced into 
recombinant serotype C his-tagged 3Dpol constructs (kind gift from Esteban Domingo, 
Madrid). The protein was purified by affinity chromatography alongside WT his-3Dpol 
as described in section 2.9. Mutants DD240/5NN and GC216/7AA expressed well (Fig. 
3.4a). Purity was assessed by SDS-PAGE followed by Coomassie staining and Western 
blot (Fig 3.4) using antibodies specific to 3Dpol or the his-tag as described in section 
2.4. All of the proteins migrated as single species, around the expected molecular 
mass of the WT protein (54 kDa). There was, however, a clear difference in migration 
of one of the mutant proteins; DD388/9NN migrated quicker than WT.  
To investigate this further, samples of each protein were subjected to analysis by 
denaturing mass spectroscopy. Samples were dialysed into Tris-NaCl buffer 4 (pH 8) 
at 50 µM (section 2.1) by spin column buffer exchange. The LC-MS analysis was 
performed by James Ault (University of Leeds) and allows comparison of theoretical 
and measured masses of each protein (Fig. 3.5a-d). 
 It can be seen that all four mutants have very similar masses within the 54 kDa range, 
which is close to the expected mass derived from protein sequence, suggesting that 
there are no additional mutations (Table 3.2). The error range present as part of the 
measured mass (Table 3.2) was due to the method of mass calculation from the data 
produced from the spectra.  It is possible that there are changes in the local 
environment of the mutation as a result of two adjacent amino acid changes that 
result in the slower migration of DD388/9NN by SDS-PAGE.  
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Figure 3.4 Purification of serotype C his-3Dpol recombinant proteins. A) Coomassie 
staining of denaturing SDS-PAGE of uninduced bacterial cell pellet and supernatant 
during protein expression after 3 hours of incubation at 37°C. B) Coomassie staining 
of denaturing SDS-PAGE of bacterial cell pellet and supernatant induced with 1 mM 
IPTG for 4 hours at 37°C during protein expression. C) Coomassie staining of 
denaturing SDS-PAGE of his-trap affinity chromatography purified hexahistidine-
tagged 3Dpol recombinant proteins. D) Western blot of purified his-3Dpol probed with 
polyclonal anti-3D (397) primary antibody. E) Western blot of purified his-3Dpol 




One explanation for proteins migrating differently than expected can be due to 
charge differences. However, in this case, both of the 3Dpol mutant proteins included 
DD to NN mutations (DD388/9NN and DD240/5NN) and only the latter migrated the 
same as WT.  
Table 3.2 Comparison of theoretical and measured masses of his-3Dpol recombinant 
WT and mutant proteins. 
 
Mutant Theoretical Mass (Da) Measured Mass (Da) 
WT 54036 54037.5 ± 0.67 
DD388/9NN 54034 54036.8 ± 1.01 
GC216/7AA 54018 54022.0 ± 7.98 






Figure 3.5 Mass spectroscopy analysis of his-3Dpol recombinant protein. A) WT his-
3Dpol LC-MS spectrum. B) his-3Dpol DD388/9NN mutant LC-MS spectrum. C) his-3Dpol 





3.4 Assessing activity of mutant 3Dpol 
3.4.1 Incorporation of radiolabelled UTP 
The phenotypes of the different polymerase mutants were verified using an 
established polymerase activity (elongation) assay following a protocol originally 
defined in Bentham et al., 2012, and detailed in section 2.10. The activity of 3Dpol was 
assessed by the ability of the enzyme to incorporate [α-32P] UTP into a growing strand 
of RNA, or as part of a larger protein-RNA complex.  
The assay utilised 3Dpol combined with a poly-A template and an oligo-d(T) primer. 
This was supplemented with a 5:1 ratio of UTP to [α-32P] UTP and incubated at 30°C 
as detailed in section 2.10.1. Polymerase activity was measured by dot-blot and 
subsequent scintillation counts per minute (CPM) (Fig.3.6a, b). Increased intensity of 
the signal developed from the dot-blot correspond with higher scintillation counts. 
Incorporation of radiolabelled [α-32P] UTP by the polymerase was unable to occur if 
one or more of the RNA constituents was missing, as shown through the use of 
controls that had either the template, the primer, or the UTP removed (Fig. 3.6a). 
These controls had similar intensities on the dot-blot to the control containing no 
protein (-3Dpol), with the exception of the control containing no UTP which showed 
no dot-blot intensity. Catalytic mutations DD240/245NN and DD388/9NN also 
showed similar reduced levels of intensity as those of the controls (Fig. 3.6a). It is 
interesting to note that the intensity of [α-32P] UTP incorporation of GC216/7AA 
appears to be greater than that of WT at both 10 and 30 minutes incubation, however 
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due to the level of ‘bleed’, it was difficult to determine the difference in intensity and 
in scintillation CPM accurately (Fig. 3.6a, b). 
Normalised scintillation counts quantifying the dot-blot samples incubated for 30 
minutes (Fig. 3.6b) show a greater than 10-fold decrease in CPM of the catalytic 
mutants when compared to the wildtype (96.7 ± 0.6 % and 97.8 ± 1.1 % respectively 
for DD388/9NN and DD240/5NN). The non-catalytic mutation GC216/7AA is able to 
incorporate [α-32P] UTP to increased levels of efficiency to wildtype (106.6 ± 57.7 %) 
(Fig. 3.6a, c). However, the difference in scintillation CPM between WT and 
GC216/7AA are not statistically significant. Once again, it is difficult to accurately 
determine this difference due to the level of ‘bleed’.  
In order to ascertain the difference in [α-32P] UTP intensity by dot-blot, a time course 
of WT and the three different mutants was undertaken (Fig. 3.6c). The time course 
confirmed the initial study (Fig. 3.6a) that the catalytic mutants DD240/5NN and 
DD388/9NN did not appear to be able to incorporate [α-32P] UTP, as expected. 
Mutant GC216/7AA was able to incorporate [α-32P] UTP to a comparable level to WT 
3Dpol. The rate of incorporation was also determined by extrapolating the scintillation 
CPM (Fig. 3.6d). The difference in the rate of total incorporation by WT 3Dpol and 
GC216/7AA is statistically non-significant (Fig 3.6d, e), however, there is a statistically 
significant (p = 0.0014) increase in initial rate of incorporation of radiolabelled 
nucleotides for mutant GC216/7AA compared to WT (Fig. 3.6f). This suggests that the 





Figure 3.6 Polymerase activity assays used to determine activity of the 3Dpol 
recombinant proteins. A) Dot-blot result of an RNA incorporation assay over time 
including controls showing that incorporation and polymerase activity is only 
possible when all RNA components are available. B) Quantification of levels of 
incorporated radiolabelled nucleotides after 30 minutes incubation by scintillation 
counts per minute normalised to WT. (n=3, ± SEM, analysed by two-tailed unpaired 
t-test). C) [α-32P] UTP incorporation by different 3Dpol mutants over time (minutes) 
as detected by dot-blot. D) Linear representation of rate of incorporation of 
radiolabelled nucleotides by 3Dpol over time. E) Graph of the mean slope of the rate 
of incorporation (n=1 ± SEM). F) mean slope of the initial rate of incorporation (1-10 
minutes) (n=1 ± SEM). Statistical analysis performed using two-tailed unpaired t-test; 




All the data presented in Fig 3.6 show that WT and non-catalytic mutant GC216/7AA 
are able to incorporate [α-32P] UTP. The polymerases with the mutations located in 
the catalytic domains (DD240/5NN and DD388/9NN) were, as expected, unable to 
function in this way.  
The intensity of the dot-blots for the two catalytic mutants DD338/9NN and 
DD240/5NN are similar to the controls consisting of samples without either template, 
primer, or 3Dpol (Fig. 3.6a-c). Therefore, the catalytic mutants DD388/9NN and 
DD240/5NN do not appear to be able to form either protein-RNA complexes, or 
incorporate [α-32P] UTP, as expected.  
The RNA-protein complex could involve the formation of higher-order oligomers of 
3Dpol, or aggregates. However, it was not possible to accurately determine the size of 
the protein-RNA complex that was being retained on the dot-blot filter paper. 
3.4.2 Determining the structure of non-catalytic mutant GC216/7AA 
The non-catalytic mutation GC216/7AA is located in the double-stranded RNA exit 
site region of the polymerase. A sample (5 mg/ml) of purified his-tagged 3Dpol 
GC216/7AA was prepared for x-ray crystallography. The crystal structure of 
GC216/7AA, was solved by Cristina Ferrer-Orta (Molecular Biology Institute of 
Barcelona) to a resolution of 2.8 Å (Herod et al., 2016) (Fig. 3.7a). The resulting crystal 
structure, co-crystallised with a 10-nucleotide RNA template-primer duplex 
(GCAUGGGCCC) in the RNA binding channel, showed that there is a minor change in 
the structure of the protein located in the loop region opposing the region of the 
introduced mutation (Fig. 3.6a).  
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Figure 3.7 Crystal structure of mutant polymerase. A) Crystal structure of 
GC216/7AA non-catalytic mutant (from Herod et al., 2016) co-crystallised with 10-
nucleotide RNA primer-template molecule. The mutated residues are highlighted in 
grey spheres. B) Centre: Superimposition of WT 3Dpol (orange) (PDB: 1WNE) and 
GC216/7AA 3Dpol (grey) (PDB: 5JXS) shows the minor structural changes caused as a 
result of the residue changes in the non-catalytic RNA exit site. Left inset: detail of 
mutated region at residues 216 and 217 shows no difference in structure between 
WT and mutant. Right inset, top: Orientation of M16-R17 region of RNA entry 
channel in WT 3Dpol. Right inset, bottom: Orientation of M16-R17 region of RNA entry 
channel in GC216/7AA 3Dpol. (Note: error in right inset, top: CG216/7AA should read 





The structural data shown in Fig 3.7b shows the superimposition of wildtype (orange) 
(PDB 1WNE) and the mutant (grey) (PDB 5JXS) polymerase structures. The structures 
of the mutant and WT proteins are virtually identical with a slight difference in the 
loop region containing residues M16 and R17 opposing the region containing the 
non-catalytic mutations (Fig. 3.7b top right inset) and minor changes in the region 
containing the GC216/7AA mutations (Fig. 3.7b left inset) (Herod et al., 2016).  
The structural changes did not alter the interactions of the RNA with the polymerase 
at the dsRNA exit site. There was, however, a larger structural change as a result of 
the mutation at GC216/7AA located at the opposing RNA template entry channel (Fig. 
3.7b top/bottom right inset). The segment that is altered the most is the M16-R17 
region highlighted in Fig. 3.7b top right inset.  
In all known WT polymerase complexes, the R17 basic side chain has been shown to 
interact with the template nucleotide t+2 (Ferrer-Orta et al., 2007; Ferrer-Orta et al., 
2009; Ferrer-Orta, Ferrero, et al., 2015). In these complexes the t+2 nucleotide is 
orientated towards the active site of the polymerase with the t+1 nucleotide located 
at the entry of the cavity (Fig. 3.7b bottom right inset). In the GC216/7AA mutant, 
the M16-R17 region is orientated differently, with the basic side chain of R17 pointed 
towards the interior of the polymerase molecule instead of towards the polymerase 
active site. This reorientation has been identified before in three different mutants 
(3D-K20E, 3D-K18E and 3D-SSI) that affect the affinity of the polymerase with the 
incoming RNA template molecule and subsequent nucleotide incorporation (Agudo 
et al., 2010; Ferrer-Orta, de la Higuera, et al., 2015). 
87 
 
It was hypothesised that this mutation in the GC216/7AA that resulted in an 
alteration in the template RNA entry channel would decrease the ability for the 
polymerase to transiently bind to RNA (Herod et al., 2016). However, the data shown 
here supports that the mutant polymerase incorporates the radiolabelled 
nucleotides with increased efficiency when compared to WT. The affinity of the 
polymerase-RNA interaction was thus investigated. 
3.4.3 Investigation into RNA binding 
To address this question of protein-RNA binding affinities, a fluorescent polarisation 
anisotropy (FPA) assay was used. FPA measures the tumbling rate of a fluorescently 
labelled molecule, fluorescein- (FITC) labelled RNA (used here). The principle of FPA 
results in the excitation of a fluorescent molecule by polarised light. The excited 
fluorophore emits light whereby the degree of polarisation of the emitted light is 
inversely proportional to the tumbling rate of the fluorescent molecule in solution. 
The smaller the molecule, the higher the tumbling rate resulting in the depolarisation 
of the emitted light as the fluorophore reorients in solution during the lifetime of the 
excitation. Conversely a larger molecule, in this case where fluorescent RNA is bound 
to the polymerase, the tumbling rate will be slower, and thus less depolarisation of 
the emitted light will be detected.  
The FPA assay here used FITC-labelled 13mer poly-A RNA together with the 
polymerases as detailed in section 2.10.3 (Fig. 3.8a, b). The Kd values of WT and 
GC216/7AA were 5.83 ± 0.33 and 6.75 ± 0.52 μM, respectively. The slight decrease in 
binding affinity seen for mutant GC216/7AA was not significant (p > 0.063). In 
contrast, the Kd values of the catalytic mutants DD240/5NN and DD388/9NN were 
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1.92 ± 0.17 and 3.50 ± 0.27 μM respectively. The differences in Kd value when 
compared to WT were highly significant (p > 0.001). The lower Kd values for the 
catalytic mutants would suggest that they bind the 13-mer poly-A RNA with a higher 
affinity.  
The FPA data support the hypothesis that the mutation in the RNA exit site 
(GC216/7AA) results in a slight deficiency in the polymerase binding affinity. 
However, based on the results gleaned from the polymerase activity assay, the 
structural changes due to the RNA exit site mutation do not appear to affect the 




Figure 3.8 Fluorescence polarisation anisotropy assay. A) Graph showing the binding 
affinity of FITC-labelled 13mer poly-A RNA to each of the recombinant 3Dpol mutants. 
B) Graph showing the mean Kd values for RNA binding affinity compared to WT (n=3, 
± SEM, two-tailed unpaired t-test). C) Table summarising the Kd values for each of 
the mutant polymerases (n=3 ± SEM). Statistical analysis performed using two-tailed 




3.5 Investigation into formation of higher-order 
complexes 
Extensive studies on PV polymerase, and previous work on FMDV polymerase, 
outlined in Bentham et al., 2012, showed that catalytically active polymerase 
molecules were able to form higher-order lattice or helical structures (Arnold et al., 
1999; Lyle et al., 2002; Spagnolo et al., 2010; Tellez et al., 2011; Wang et al., 2013). 
In the case of PV, these higher-order structures could form de novo without the 
addition of RNA primer-templates (Arnold et al., 1999). In contrast, studies on the 
oligomerisation of FMDV 3Dpol have shown that higher-order structures could only 
form in the presence of RNA primer-template (Bentham et al., 2012).  
The concept of oligomerization of the polymerase molecules and the binding of the 
RNA to the protein has been shown biochemically to be highly co-operative; multiple 
molecules interact to facilitate the efficient replication of the viral RNA. 
Oligomerisation of replication-associated proteins, such as the polymerase, could 
feature as a functional control by providing stability and protecting the RNA from 
degradation and denaturation (Ferrer-Orta, Ferrero, et al., 2015). Dimers and higher-
order oligomers of polymerase molecules have been reported in a number of 
positive-strand RNA viruses (Hansen et al., 1997; Luo et al., 2000; Lyle et al., 2002; 
Hogbom et al., 2009; Chinnaswamy et al., 2010; Spagnolo et al., 2010). In PV in 
particular, the ability for the polymerase molecules to oligomerise into a planar 
lattice provides an attractive model for the formation of membrane-associated 
replication complexes especially when such models suggest the interaction of PV 
3Dpol with membrane-associated viral precursor protein 3AB and host-cell factors 
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including phosphoinositides such as phosphatidylinositol-4-phosphate (Lama et al., 
1994; Lyle, Clewell, et al., 2002; Lyle, Bullitt, et al., 2002; Hsu et al., 2010). These 
studies have also shown that PV 3Dpol planar lattices are able to fold into helical 
arrays, termed fibrils (Lyle, Bullitt, et al., 2002; Wang et al., 2013). 
Previous work on FMDV polymerase struggled to consistently identify fibril formation 
by transmission electron microscopy (TEM). It was believed that this was the case 
due to the transient nature of the fibril formation during the assay. In order to form 
a more stable and permanent protein-RNA fibril complex, glutaraldehyde, a potent 
crosslinking agent was added to the assay described here (see also section 2.10.2). 
Additionally, the inclusion of a crosslinking reagent could allow for the confirmation 
and resolution of higher-order structure formation by SDS-PAGE. 
Purified his-tagged 3Dpol (WT and mutants) were incubated at 30°C for up to 2 hours 
with glutaraldehyde and the RNA template-primer used for the aforementioned 
activity assay (section 3.4.1). Initially, to characterise 3Dpol oligomerisation, non-
radiolabelled UTP nucleotide was used. Samples were taken at increasing timepoints, 
from 1 to 120 minutes, and the reactions were stopped by adding SDS-PAGE 2x 
Laemmeli buffer loading dye as outlined in Chapter 2 (section 2.10.2). The samples 
were resolved by gradient SDS-PAGE and analysed by Western blot using antibodies 
either against the hexa-histidine tag or against 3Dpol (Fig. 3.9). 
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Figure 3.9 Glutaraldehyde crosslinking assay showing the formation of higher-order 
oligomers by Western blot on denaturing SDS-PAGE gels from a polymerase activity 
assay (section 2.10.2). A) WT polymerase, B) DD388/9NN, C) GC216/7AA and D) 
DD240/5NN. Controls include no protein (-P), no RNA (-R) and no glutaraldehyde (-
G) all incubated for 30 minutes at room temperature. Arrows denote hypothesised 
higher-order species. The Western blot was probed with anti-his antibody at the 




The SDS-PAGE and subsequent Western blot analysis of the crosslinked protein-RNA 
complexes showed the gradual increase in oligomer formation over time for WT 3Dpol 
(Fig. 3.9a) before appearing to form oligomers too large to migrate through the gel. 
Figures 3.9b-d show the resolved crosslinked protein-RNA complexes of the mutant 
polymerases. It is clear to see that the development of oligomers over time differs 
slightly to that seen in WT 3Dpol. While WT shows a gradual increase over time, the 
mutants all appear to show oligomer formation during the early timepoints (1-20 
minutes) before the complexes became too large to migrate through the gel. 
However, it is important to note that the rate of UTP incorporation and subsequent 
oligomer formation was not different between mutants as shown in figures 3.6c and 
3.6d. Reactions containing no RNA (template, primer, or nucleotides), no 3Dpol and 
no glutaraldehyde were included as controls. It is interesting to note that WT 3Dpol 
that was incubated without any RNA also appeared to form oligomers after 30 
minutes of incubation. 
To confirm that the bands of increasing size seen in each polymerase corresponded 
to the formation of higher-order fibril structures, samples were taken at 30 minutes 
and the reactions stopped by the addition of 2 % uranyl acetate when the samples 
were loaded onto carbon-coated copper TEM grids. The grids were analysed under 
standard TEM by negative stain (Fig. 3.10).  
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Figure 3.10 Negative stain TEM of crosslinked polymerase activity assay after 30-
minute incubation. A) WT 3Dpol forms visible fibril formations when incubated with 
RNA template-primer, B) DD388/9NN, C) DD240/5NN and D) GC216/7AA mutant 
polymerases do not show any distinct fibril structure formation but protein 




Negative stain analysis by TEM showed that WT 3Dpol was able to form higher-order 
fibrillar structures when RNA primer-template and free nucleotides were present (Fig 
3.10a). These structures were similar to previous FMDV 3Dpol fibrils (produced in the 
absence of glutaraldehyde) (Bentham et al., 2012). The mutant polymerases were 
therefore investigated in a similar assay (Fig. 3.10b-d). After 30 minutes of 
incubation, no evidence of regular higher-order fibrillar were evident, although 
aggregated protein was visible.  
WT 3Dpol glutaraldehyde crosslinked assay without any RNA (-RNA) appeared to form 
oligomers at 30 minutes (Fig. 3.9a). This sample was also analysed by TEM and 
showed that some fibrils were able to form, however, there was a marked difference 
in morphology, particularly in the diameter of the fibrils, and in abundance to those 
formed by WT 3Dpol in the presence of RNA (Fig. 3.10e). Early incubation timepoints 
were also analysed (Fig. 3.11) and revealed that WT 3Dpol was able to form fibrils 
from as early as 2 minutes.  
Figure 3.11 Negative stain TEM of crosslinked polymerase activity assay after 2-




3.6 Structural determination of FMDV 3Dpol fibrils 
It has been hypothesised through work on other RNA viruses such as PV and HCV 
(Hansen et al., 1997; Luo et al., 2000; Lyle, Clewell, et al., 2002; Hogbom et al., 2009; 
Chinnaswamy et al., 2010; Spagnolo et al., 2010) that these fibrils could reflect part 
of a ‘replication complex’. Therefore, studies focussed on the determination of a 
higher resolution fibril structure. 
WT 3Dpol fibrils were produced as detailed in section 2.10.2 and samples were 
prepared for cryo-EM. Samples were loaded on to carbon-coated C-flat grids and 
plunge-frozen in liquid ethane, after blotting for 6 seconds, using a Vitrobot (FEI). The 
preliminary data collection for a medium-resolution structure was undertaken at the 
Centre for Virus Research at the University of Glasgow with the assistance of Dr David 
Bhella. Using a T12 cryo-EM, 129 micrographs were taken from a single grid, from 
those 129, 23,700 fibril sections were used for computational helical reconstruction. 
Figure 3.12 2D class averaging of fibrils detected by cryo-EM. From this class 
averaging of over 200 micrographs and 25,000 fibril segments. The averaging 




 The helical reconstruction identified two different species of fibrils of different 
diameters as identified by class averaging (Fig. 3.12). The narrower fibril species was 
calculated to have a diameter of 21.6 nm with a maximal distance between peak to 
peak of 10 nm, the larger fibril species had a diameter of 23.2 nm and a maximal 
peak-to-peak distance of 12 nm. Both fibril species had a 2-start helical assembly with 
D2 symmetry. From the class averages a medium-resolution (11 Å) model was 
determined (Fig. 3.13).  
Figure 3.13 Intermediate resolution three-dimensional model fibril structure of WT 
fibril with docked WT 3Dpol crystal structure (PDB: 9EC0). The model is based on 
helical reconstruction of the narrow fibril species. 
The 11 Å resolution model of the narrow FMDV fibrils appears to show a lattice of 
repeating WT 3Dpol dimers (Fig. 3.13). The dimers appear to be oriented in an anti-
parallel formation. Using the standard right-hand orientation, the major 
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intermolecular interfaces appear to lie between the fingers and the thumb, and the 
palm in adjacent molecules and between fingers only between opposing molecules 
(head to tail). 
Figure 3.14 Cartoon schematic depicting the proposed arrangement of polymerase 
molecules. A) Arrangement of FMDV 3Dpol molecules forming the fibrils. B) 
Arrangement of PV 3Dpol molecules forming the fibrils (Tellez et al., 2011; Wang et 
al., 2013). Fingers (F) and Thumb (T) locations are detailed and the arrows () depict 
the direction the individual molecules face highlighting the antiparallel arrangement. 
Dotted cross placed at interacting interfaces to highlight the differences in 
orientation of individual molecules between FMDV and PV. 
Initial analysis of hypothesised interacting residues between molecules in the fibril 
show that they are comparable with the PV fibril counterpart (between fingers and 
thumb in the antiparallel conformation, and fingers and palm between adjacent 
molecules) especially as both helical fibril structures appear to be formed of anti-
parallel interacting molecules, however where FMDV 3Dpol molecules appear to be 
mirror images, PV head-to tail dimers are oriented at 90° to each other (Fig. 3.14), 
99 
 
and translated 44 Å relative to the adjacent molecule as a result of the difference in 
size and flexibility of the helix (Hansen et al., 1997; Wang et al., 2013). PV helical 
polymerase lattices form a much larger (50 nm) fibril body with a 6-start helix. In PV, 
a model has been described whereby the RNA molecule travels through the active 
site which is conveniently located at the head-to-tail interface to fit with the dimer 
orientation, however, the orientation of the FMDV dimers suggest that the RNA 
template would need to weave through adjacent molecules.  
In order to determine the interacting residues more definitively, and to resolve 
nucleic acid density, the grids that were prepared in Glasgow were transferred to 
Leeds, in the Astbury Biostructure Laboratory, to be analysed by the Krios I 
microscope with the Falcon III detector in integrating mode. Data collection was 
automated and collected at nominal 75K magnification, giving a sampling of 
1.05Å/pixel. The calculated dose rate was 60e¯/pixel/second resulting in a dose of 
54e¯/Å2/second. The exposure time was 2 seconds with 79 frames in total giving a 
final 1.4e¯/frame. Data collection occurred at a defocus range of -1.5 to 2.8 nm. 
During 36 hours of automated data collection, 3100 micrographs were taken. The 
data was transferred back to the University of Glasgow for analysis by Dr James 
Streetley. Analysis is currently ongoing using the same helical reconstruction 
parameters developed for the medium-resolution model. After further analysis, a 
higher resolution structure was determined at 9 Å (Fig. 3.15).  
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Figure 3.15 Intermediate resolution cryo-EM structure of FMDV 3Dpol fibrils with 
crystal structure of WT 3Dpol (PDB: 9EC0) docked into the density. 
Despite this, further analysis needs to be undertaken to discern nucleic acid density, 
as even at higher resolution no RNA can be identified. A reason for this could lie in 
the level of occupancy of the RNA within the individual polymerase molecules. If only 
a fraction of the molecules contained RNA, their density may not be easily 
discernible. The current helical reconstruction data is based on the narrow fibril 




3.7 The importance of RNA in the formation of fibrils 
RNA appears to be necessary for the efficient formation of regular fibrils, however, 
the location of RNA within fibrils is under investigation. In order to determine 
whether higher-order complexes contained RNA, samples from a glutaraldehyde 
crosslinked polymerase activity assay with [α-32P] UTP were resolved by SDS-PAGE 
(Fig. 3.9). The gels were subsequently dried and autoradiographed to identify if the 
input RNA used in the activity assay was included within the observed higher-order 
oligomers forming as a result of the assay (Fig. 3.16). 
Figure 3.16 Autoradiograph of glutaraldehyde crosslinking assay showing the 
presence of primer-template RNA and [α-32P] UTP within the formation of higher-
order oligomers on denaturing SDS-PAGE gels over time. A) WT, B) DD388/9NN, C) 
GC216/7AA, D) DD240/5NN. Controls include no RNA (-R), no glutaraldehyde (-G) and 
no protein (-P).  
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The autoradiograph detecting the radiolabelled incorporated nucleotides show 
bands of increasing size appearing from as early as one minute after commencing 
incubation for both WT 3Dpol and GC216/7AA 3Dpol. The pronounced bands appear 
at approximately 54 kDa, 150 kDa, and at greater than 245 kDa (Fig. 3.16a, c). Three 
pronounced bands of similar sizes appear in the crosslinked WT 3Dpol oligomeric 
species bands seen in the Western blot of the activity assay (Fig. 3.9a). From this data, 
we can infer that the higher-order species of WT and GC216/7AA identified by 
Western blot are likely to contain RNA.  
There was no evidence of RNA in the 3Dpol oligomers for the catalytic mutants 
DD388/9NN and DD240/5NN (Fig. 3.16b, d). This is consistent with these proteins 
being unable to incorporate [α-32P] UTP as seen in figures 3.6a and 3.6e, and in 
figures 3.9b and 3.9d. 
With the evidence that RNA may be included in the oligomers, or aggregates, we 
sought to investigate whether the RNA is protected within the fibril helix. It is 
hypothesised that because PV fibrils and FMDV fibrils appear to be oriented 
differently in the model and structure, it may also be hypothesised that instead of 
the RNA running through the groove made by interactions between the different 
3Dpol molecules as seen in PV, the RNA may be weaving in and out of neighbouring 
molecules in this FMDV structure. As such, the RNA may be protected by the protein 
as well as providing a scaffold for the polymerase to multimerise around.  
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Figure 3.17 Glutaraldehyde crosslinking activity assay showing the higher-order 
oligomers treated with DNase I, RNase A and proteinase K. Higher-order oligomer 
formation of WT his-3Dpol analysed by Western blot on a denaturing SDS-PAGE gel. 
Controls include no protein (-P), no RNA (-R) and no glutaraldehyde (-G). The 
crosslinked samples were also treated with RNase A, proteinase K and DNase I after 
30 minutes of incubation at 30°C. Arrow denote hypothesised higher-order species. 
The products of a crosslinked activity assay were treated with either DNase I, RNAse 
A, or proteinase K after incubating the assay for 30 minutes (Fig. 3.17). The data 
showed that there may be a minor effect on oligomer formation (by Western blot) 
when treated with RNase A suggesting that the RNA may not be completely 
protected. When treated with RNase A, the apparent quantity of higher-order 
species is reduced, particularly those species at very high molecular weights 
(highlighted by the arrow). However, these results may not be definitive as the 
reduction in higher-order species may also be due to an error in initial loading of the 
sample. When the assay containing WT 3Dpol and primer-template RNA components 
was treated with DNase I a reduction in higher-order oligomerisation was seen, 
suggesting that there may have been some RNase contamination of the DNase I. 
When treated with proteinase K, no evidence of oligomers remained, as expected.  
104 
 
Figure 3.18 Negative stain TEM of A) his-3Dpol fibrils when products of a 
glutaraldehyde crosslinking assay were treated with B) RNase A, C) proteinase K and 
D) DNase I after 30 minutes of incubation. Scale bar 100 nm. 
Samples of the treated crosslinked activity assay were visualised by TEM in order to 
directly observe the differences in fibril formation when the samples were treated 
with RNase A. The micrographs (Fig. 3.18) show that when treated with RNase A, no 
evidence of higher-order oligomers can be detected by TEM. This is consistent with 
previous results (in the absence of glutaraldehyde) (Bentham et al., 2012). 
Interestingly, treatment of the samples with DNase I appears to have a slight effect 
on fibrils consistent with the data in figure 3.17. Endoribonuclease RNase A was 
chosen as it preferentially cleaves the 3ʹ end of unpaired C and U (pyrimidine) 
residues in RNA (Cuchillo et al., 2011), and can also cleave dsRNA or RNA/DNA 
hybrids at low salt concentrations (Myers et al., 1985). This makes it an appropriate 
choice for endoribonuclease as the nucleotide incorporation due to polymerase 
activity is of UTP. 
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3.8 Is 3CD a catalytically functional precursor? 
3CD is a precursor of 3Dpol and has several documented roles in the lifecycle of FMDV. 
Previous data shows that 3CD contains a potential nuclear localisation signal (García-
Briones et al., 2006; Sanchez-Aparicio et al., 2013). Other roles of 3CD include 
functioning as a potential initiator of viral replication in formation of a complex for 
uridylylation (Murray et al., 2003; Nayak et al., 2005; Nayak et al., 2006; Steil et al., 
2009). Here, the oligomerisation of 3CD was investigated.  
3C is the FMDV major protease involved in the processing of the viral polyprotein 
during replication of the genome (Klump et al., 1984). 3C has also been shown to be 
able to cleave host-cell proteins such as the translation initiation factor eIF4A and 
histone protein H3, as well being involved in immune evasion (Grigera et al., 1984; 
Belsham et al., 2000; Wang et al., 2012). 3C was used as a control in the investigation 
of 3CD oligomerisation alongside 3Dpol. 
To determine these potential functions, samples of recombinant his-tagged 3C and 
3CD were purified (plasmids were kind gifts from Stephen Curry, Imperial College, 
London and Esteban Domingo, Madrid) as described in chapter 2. The optimisation 
of the purification of his-3CD was undertaken by Sue Matthews, University of Leeds. 
Optimisation of his-3C purification was performed by myself and experimental 
results were obtained by an undergraduate project student (Kate Loveday) under my 
supervision (Fig. 3.19). Production of purified recombinant his-3C was undertaken in 
order to assess whether the function of 3CD could be recapitulated by incubating 3C 




Figure 3.19 Purification of his-tagged recombinant 3CD protein. A) Coomassie stain 
of purified 3CD. Initial eluates were pooled and dialysed prior to resolving by SDS-
PAGE. B) Western blot analysis of purified his-tagged 3C and 3CD probed with a 
monoclonal anti-3C antibody. 
Purification of the his-3C protein was more complicated than expected due to its 
propensity to aggregate and precipitate out of solution at high concentration. The 
recombinant protein contained three mutations from the catalytically active cysteine 
residues in order to inhibit protease activity and improve protein solubility (C95K, 
C142L, and C163A). It should be noted that such mutations may have a downstream 
effect on the ability for the protein to function in the proposed assays.  
His-3CD, however, did not have any mutations that affected the solubility of the 
protein, but the active site of the protease was mutated to disable its function as a 
protease. Once again, this may play a role in the downstream functional assays. It is 
interesting to note that although Coomassie staining of purified 3CD (Fig. 3.19a) 
shows a band at 75 kDa (the expected size of 3CD), the subsequent Western blot (Fig. 
3.19b) shows a number of smaller protein products possibly representing aberrant 
cleavage products, most likely as a result of bacterial proteases during protein 
expression, or the presence of 3D* at approximately 35 kDa. 3D* is thought to be a 
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fragment of incorrectly processed 3CD. Studies on PV have observed a similar 
aberrant processing event (Lawson et al., 1992; Parsley et al., 1999). 
As his-3CD is a precursor to 3C and 3Dpol, it was hypothesised that the recombinant 
precursor protein would still be able to interact with RNA, or at least be able to bind 
nucleotides, particularly as it is believed to be involved with VPg uridylylation. A dot-
blot activity assay was used to determine the ability for 3CD to bind to, or incorporate 
[α-32P] UTP. An RNA primer-template and [α-32P] UTP, as described for his-3Dpol 
activity assays (section 2.10) was used, and the complex was incubated at 30°C for 
increasing lengths of time from 0 to 10 minutes. The samples were blotted on to filter 
paper. Samples incubated for longer than 10 minutes resulted in the formation of 
aggregate too large to be resolved by SDS-PAGE, therefore it was decided to limit the 
length of the reaction times to match the trends observed in 3Dpol crosslinking assays. 




Figure 3.20 Dot-blot of 3CD activity assay. A) Incorporation activity dot-blot assay 
with purified recombinant his-3CD protein over time (minutes). B) Dot-blot of his-
3Dpol activity assay from figure 3.5 with the controls (No template, no primer, no UTP) 
for comparison. The his-3Dpol and his-3CD assays were undertaken on the same day 
with identical controls. 
3CD was subjected to the same glutaraldehyde crosslinking assay as was used for 
3Dpol in an attempt to capture the formation of potential higher-order structures, or 
fibrils. The crosslinked assay was resolved by gradient SDS-PAGE (as described in 
section 2.10.2) and analysed by Western blot using anti-His, polyclonal anti-3D 397, 
and anti-3C 2D2 antibodies as outlined in section 2.4. 
Similarly to the his-3Dpol recombinant proteins mutants, 3CD appears to form some 
higher-order oligomeric structures by Western blot, despite being unable to 
incorporate [α-32P] UTP (Fig. 3.21). However, TEM of these early timepoint oligomers 
show aggregate formation instead of any distinct higher-order structure formation 
(Fig. 3.21d) similar to the results of the 3Dpol mutants (Fig. 3.10 b-d). 
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Figure 3.21 Glutaraldehyde crosslinking assay on recombinant 3CD incubated with 
RNA over time. A) Western blot of crosslinking assay probed with monoclonal anti-
3C antibody. Control lanes with  no RNA (-R), no protein (-P), no glutaraldehyde (-G), 
and purified 3CD not subjected to the crosslinking assay (3CD) were also included 
(n=2). B) Repeat of the glutaraldehyde crosslinking assay with 3CD probed with 
monoclonal anti-3C antibody, C) Repeat of the glutaraldehyde crosslinking assay with 
3CD probed with polyclonal anti-3D antibody (n=1). D) Negative stain TEM of 3CD 
with RNA primer-template incubated for 10 minutes. 3CD does not show any distinct 





3.9 Chapter discussion 
The RNA-dependent RNA polymerase, 3Dpol, was one of the first proteins to be 
characterised both in PV (Baltimore et al., 1962) and in FMDV (Polatnick et al., 1967). 
In both viruses one of the initial findings showed that the polymerase was not 
sensitive to actinomycin D (Baltimore et al., 1962; Black et al., 1969), but was able to 
incorporate nucleoside triphosphates into virus RNA. Both PV and FMDV 
polymerases were also shown to mediate replication of the virus genomes by binding 
to VPg (Paul et al., 1998; Nayak et al., 2005). Recent biochemical, microscopic, and 
structural studies on PV and FMDV 3Dpol have also shown that they are both able to 
form higher-order structures in vitro in the form of fibrils (Pata et al., 1995; Lyle, 
Bullitt, et al., 2002; Tellez et al., 2011; Bentham et al., 2012; Wang et al., 2013). 
Here, we have confirmed previous data, showing that FMDV fibrils can only form if 
the polymerase is catalytically active and replication-competent. Mutations located 
in the catalytic active sites and in the non-catalytic dsRNA exit site of the protein 
abrogated protein function in vitro and in context of the RNA replicon. All three 
mutations that were tested: DD388/9NN, DD240/5NN, and GC216/7AA, were unable 
to form fibrils, even in the presence of primer-template RNA, as was shown for WT 
(Bentham et al., 2012). The non-catalytic mutant GC216/7AA was able to bind RNA 
with a similar affinity to WT, despite incorporating RNA nucleotides at a faster rate 
than WT. However, GC216/7AA was unable to form fibrils. The catalytic mutations 
DD388/9NN and DD240/5NN bound RNA with low affinity and were unable to 
incorporate RNA nucleotides or form fibrils. This is in contrast to data for PV (Arnold 
et al., 1999), where fibrils form spontaneously. These data would suggest that the 
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formation of the fibrils in FMDV replication is functional in addition to providing 
support and protection, contrary to the function suggested for PV fibrils (Tellez et al., 
2011; Wang et al., 2013). 
All three FMDV 3Dpol mutations were able to form oligomers as detected by Western 
blot, however mutant DD240/5NN appeared to aggregate more readily instead of 
forming distinct higher-order structures unlike DD388/9NN. This would suggest an 
aberrant protein-protein interaction occurring. For non-catalytic mutant GC216/7AA 
and WT, the ability to incorporate [α-32P] UTP would also suggest that, in addition to 
there being a protein-protein interaction, protein-RNA interactions are involved, 
however they only lead to the formation of fibrils for WT. In PV, a number of different 
polymerase mutations that affected catalytic function were analysed and it was 
suggested that some, despite resulting in a non-functional, non-catalytically active 
protein, were still able to provide structural support to the planar lattice and result 
in helical fibril formation (Spagnolo et al., 2010; Tellez et al., 2011).  
The crystal structure of non-catalytic mutant GC216/7AA showed that the mutation 
in the double-stranded RNA exit site had minor effects on the structure of the 
polymerase when compared to WT (Herod et al., 2016). The differences in the 
structure of the molecule are predicted to have a minor effect on the incoming 
nucleotides which lends to the non-replicative phenotype of the mutant. From the 
cryo-EM structure, the residue changes do not have any effect on the regions on the 
molecule that could be involved in inter-molecular interactions with neighbouring 
polymerases. The structural changes in the DD240/5NN and DD388/9NN mutants are 
also predicted to have no effect on the inter-molecular interactions. These structural 
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predictions suggest that the formation of fibrils is linked to the enzymatic function of 
FMDV 3Dpol. Work is currently ongoing to dock the crystal structure of the 
GC216/7AA mutant into the fibril cryo-EM model to verify that the mutation does 
not affect the protein to form intra-molecular interactions necessary to form fibrils. 
Further work to establish the interacting residues between polymerase molecules is 
necessary to establish additional regions of the FMDV polymerase that are essential 
for fibril formation. Identifying these residues could help elucidate the function of 
the fibrils in vitro and in vivo. It is predicted that similar residues are involved as those 
found in PV fibril intra-molecular interactions. These regions are found 
predominantly in the finger regions of the molecules (Lyle, Bullitt, et al., 2002; Wang 
et al., 2013) and those regions that are located towards the N-terminus of the 
molecule (Lyle, Bullitt, et al., 2002). 
The importance of the enzymatic ability for 3Dpol to form fibrils can also been seen in 
the assays with 3CD. Here, a mutant 3CD was used in which the 3C active site within 
his-3CD was abrogated and thus the protease was unable to function and cleave 
correctly to release 3Dpol. 3CD is unable to form higher-order structures. This 
supports the model that 3CD has an independent, non-catalytic function in 
replication. However, more work needs to be undertaken to identify the exact role 
of 3CD and interactions with components of the replication complex. Additionally, it 
would be prudent to identify the reason for the aberrant cleavage events occurring 
post-purification in 3CD as seen in the Western blot in figure 3.19b. These cleavage 
products equate to sizes larger than 3C but smaller than 3Dpol suggesting that 
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cleavage is occurring in a location within 3Dpol. However, it appears that this 
truncated 3Dpol cannot form fibrils. 
The formation of a classical intracellular, membrane-associated replication complex 
for FMDV has yet to been identified within infected cells. Studies have shown, that 
like a number of related positive-strand RNA viruses, FMDV is capable of 
dysregulating cellular membranous organelles such as the Golgi and the ER, but no 
distinct complexes composed of viral structural, non-structural and host-cell proteins 
have been identified unlike PV (Schlegel et al., 1996; O’Donnell et al., 2001; 
Monaghan et al., 2004; Knox et al., 2005).  
The formation of 3Dpol fibrils provides a plausible model for a replication complex in 
FMDV. However, the lack of RNA in the current fibril structure was unexpected. The 
model proposed here is based upon the ability for FMDV 3Dpol to be involved in 
protein-protein interactions mediated by RNA binding. The ability to form fibrils 
could be as a result of a conformational change mediated by the binding of 3Dpol to 
RNA. The conformational change would then allow for the binding of further 
polymerase molecules in a regular pattern to form a fibril-like structure. The catalytic 
mutants were unable to bind or incorporate RNA and therefore may not be able to 
change confirmation. They would therefore be unable to form structured fibrils and 
aggregation could result instead. The non-catalytic mutant GC216/7AA, although 
able to bind and incorporate [α-32P] UTP was still unable to form fibrils suggesting 
that the mutation may be unable to adapt the correct conformation or to form the 
correct interactions necessary for fibril formation. 
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The precursor 3AB has been found to associate with PV 3Dpol fibrils (Spagnolo et al., 
2010). Further work needs to be undertaken to establish if other non-structural 
proteins, such as 3CD, 3A and 3B1,2,3, are also able to interact with the FMDV 3Dpol 
fibrils. Apart from providing an enclosed, protective environment within which 
replication can occur, one could speculate, in the context of a cellular replicon 
complex, that the polymerase molecules could coat newly synthesised negative-
sense intermediate and prevent the formation of double-stranded RNA, a potent 
innate immune response trigger. By avoiding the double-stranded RNA formation it 
would also allow for a more energetically favourable replication process.  
Finally, it would be important to identify if fibrils are able to form when FMDV 
template RNA is used instead of poly-A, particularly to determine if RNA secondary 
structure hinders the ability for 3Dpol to form fibrils. The use of FMDV genomic RNA 
would also allow for the development of a more physiological environment to assess 
any other hypothesised protein-protein interactions that could occur, such as with 




Investigating the role of foot-and-mouth 
disease virus 3D polymerase mutants on 
replicon replication 
4.1 Introduction 
Upon entry of the FMDV into the host-cell cytoplasm, the viral RNA genome 
undergoes initial translation by host-cell translation initiation factors and the 40s 
ribosomal subunit by binding to the IRES element in the 5ʹ UTR. (Belsham et al., 1990; 
López de Quinto et al., 2002; Rodríguez Pulido et al., 2007).  
FMDV has a much larger 5ʹ UTR than other picornaviruses, containing approximately 
1,300 bases (Forss et al., 1984; Grubman et al., 1984; Robertson et al., 1985). It can 
be divided into five functional elements comprising of a 360-base stem-loop 
structure called the S-fragment, followed by a poly-C tract of variable length, 
between two and four RNA pseudoknot structures, the cre, and a type II IRES 
(Newton et al., 1985; Belsham et al., 1990; Rieder et al., 1993; Bunch et al., 1994; 
Escarmís et al., 1995; López de Quinto et al., 2002; Mason et al., 2002; Carrillo et al., 
2005). The functions of the S-fragment, poly-C tract, and the pseudoknots have yet 
to be elucidated.  
The genome is translated into a polyprotein from which the structural and non-
structural precursors are co- and post-translationally cleaved into the active proteins. 
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Lpro autocatalytically cleaves itself from the polyprotein.  Intermediate polyprotein 
precursors 1A-2A and 2BC separate themselves from the P3 intermediate through a 
process known as ribosomal skipping due to the sequence of 2A (Ryan et al., 1994). 
Both 2BC and P3 are further cleaved into the mature proteins by the virus-encoded 
protease, 3C, via several intermediate precursors: 2B, 2C, 3AB1-3, and 3CD (Flint et 
al., 1997). The P3 region (3A-3D) undergoes further processing to produce mature 
3A, 3B1-3, 3C and 3Dpol (Forss et al., 1982; Flint et al., 1997; Ferrer-Orta et al., 2004; 
Birtley et al., 2005; Moffat et al., 2005; González-Magaldi et al., 2014). 
Replication of FMDV RNA begins with 3Dpol binding to a copy of uridylylated VPg (VPg-
pUpU) that is covalently linked to the 5ʹ end of the negative strand intermediate 
genome and acts as primer for both positive and negative strand synthesis (Murray 
et al., 2003; Nayak et al., 2005; Steil et al., 2009). 3Dpol replicates the genome in a 5ʹ 
to 3ʹ direction via a negative sense intermediate which acts as a template for the 






The development of FMDV replicon systems based on the genome of FMDV serotype 
O (O1/Kaufbeuren/FRG/66) have provided the opportunity to study the replication 
of a high-containment pathogen under low-containment (McInerney et al., 2000; 
Tulloch et al., 2014; Forss et al., 1984) and have allowed for the study of separate 
stages of the virus life cycle such as replication and packaging. The replicon systems 
that have been developed have substituted the structural proteins in the P1 region 
with chloramphenicol acetyltransferase (1st generation replicons) or with green 
fluorescent reporter gene and antibiotic resistance fusion protein, puromycin-N-
acetyltransfease (GFP-PAC) (2nd generation replicons) (McInerney et al., 2000; 
Tulloch et al., 2014; Herod et al., 2015). These FMDV replicons are unable to form 
infectious viruses, but are still able to replicate within a host cell when transfected as 
RNA. The inclusion of a fluorescent protein (in the second generation GFP-PAC 
replicons) (Fig. 4.1) has allowed the monitoring of viral RNA replication in real-time 
(Forrest et al., 2014).  
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Figure 4.1 Schematic diagrams of second-generation FMDV replicons. A) Schematic 
of infectious viral genome containing structural proteins 1A-1D in the P1 region. B) 
Schematic of WT replicon showing the substitution of structural proteins 1A-1D with 
GFP-PAC reporter cassette (GFP-pac-WT). C) Schematic of replicon showing the 
substitution of structural proteins in P1 with GFP-PAC reporter cassette. This replicon 
contains a large deletion in the polymerase protein encoding region (3Dpol) and is 
termed GFP-pac-Δ3D. D) Schematic of replicon showing the substitution of structural 
proteins in P1 with GFP-PAC reporter cassette. This replicon contains two point 
mutations (GNN) in 3Dpol that renders the polymerase enzymatically inactive (GFP-
pac-GNN). 
Here we have investigated the effect of the catalytic and non-catalytic mutations 
within 3Dpol previously described in Chapter 3, in context of an FMDV replicon, and 
the ability to recover the function of the mutated polymerases within cells by co-
transfection with WT functional helper replicons. The process of co-transfection and 
the ability to recover replication-deficient replicons in trans has been well 
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established in PV as well as in HCV (Ryan et al., 1994; Xuemei Cao et al., 1995; 
Teterina et al., 1995; Towner et al., 1998; Lyons et al., 2001; Tiley et al., 2003; Appel 
et al., 2005; Jones et al., 2009; Herod et al., 2014). 
4.2.1 Replication 
In order to determine the replicative ability of the GFP-expressing FMDV replicons, 
GFP-pac-WT, GFP-pac-Δ3D, and GFP-pac-GNN RNA was transfected into BHK-21 cells. 
The number of GFP-positive cells, which correlated with the efficiency of GFP-
expression, following transfection reflected the replicative ability of the replicon 
construct (Fig. 4.1). It is important to note that the replicons containing the mutation 
termed GNN are the same as the active site catalytic mutation DD388/9NN used in 
the activity assays in Chapter 3; the mutation is referred to as GNN here for simplicity. 
To establish the correct conditions for the transfection reactions, experimental 
conditions were optimised. Reassuringly, the optimum conditions were identical to 
those previously identified (Forrest et al., 2014). The conditions that produced the 
best GFP expression in all three of the GFP-pac RNAs were found to be: 0.5 µg RNA 
with 2.5 µl Escort transfection reagent in 250 µl total volume of MEM per well in a 
24-well plate reaction (section 2.6.3).  
Transfected cells were imaged at regular intervals over 16 hours post-transfection in 
an IncuCyte FLR Zoom kinetic imaging system (Essen Bioscience); a fluorescence 
microscope, housed inside an incubator at 37°C/5 % CO2. The images were analysed 
by measuring the number of GFP-positive cells per well, indicating translation and 
subsequent replication of the GFP-containing replicons, using the IncuCyte imaging 
processing software.  
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Figure 4.2 Representative data of transfected BHK-21 cells. A) graph showing the 
mean number of GFP-expressing BHK-21 cells over time (hours) after transfection 
with GFP-pac replicons (WT, GNN and Δ3D). n=3, error bars removed for clarity. B) 
IncuCyte image showing representative levels of GFP expression in BHK-21 cells 
transfected with GFP-pac-WT replicon at 10 hours post-transfection. C) IncuCyte 
image showing representative levels of GFP expression in BHK-21 cells transfected 
with GFP-pac-GNN replicon at 10 hours post-transfection. D) IncuCyte image showing 
representative levels of GFP expression in BHK-21 cells transfected with GFP-pac-Δ3D 
replicon at 10 hours post-transfection. 
Data collected on the IncuCyte were analysed using two different methods; by 
enumerating the total number of cells expressing the fluorescent transgene (e.g. 
number of GFP-positive cells per well) and by measuring the total fluorescent 
intensity per well using the integrated software. It is important to note that there 
was no difference observed when the data were analysed either as total cell counts 
of total fluorescent intensity. The data presented here represents the total number 
of fluorescence-positive cells per well unless otherwise stated. 
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The results from the IncuCyte analysis of the optimisation reaction defined the 
optimum levels of GFP expression for each of the replicon RNAs (GFP-pac-WT, -Δ3D 
and -GNN). Figure 4.2a shows the results of a representative assay. The graph 
represents the expression of GFP over time post-transfection. Expression of GFP 
began at 4 hours post-transfection. As expected, GFP-pac- Δ3D and GFP-pac-GNN 
had very low GFP counts per well suggesting that the fluorescence measured 
reflected input RNA translation only, as expected. These replicon constructs can thus 
be used as controls in further replication assays. Expression of GFP from the construct 
GFP-pac-WT peaked at 10-12 hours post-transfection. Representative images of peak 
GFP expression for each replicon are shown in figure 4.2 b-d.  
4.2.2 Evidence of protein expression 
To complement the IncuCyte analysis, a Western blot analysis of BHK-21 cells 
transfected with GFP-pac-WT replicon was undertaken. Cells were lysed with RIPA 
buffer and harvested as described in section 2.8.1. Lysates were subjected to SDS-
PAGE and membranes were probed with antibodies against three FMDV non-
structural proteins: 3A, 3B and 3D (described in section 2.4 and 2.8.4) (Fig. 4.3). 
The results from the Western blot analysis showed the presence of each of the three 
viral proteins with the appropriate antibody. A band at 54 kDa corresponding to the 
expected size of 3Dpol was visible in figure 4.3a when probed with the rabbit anti-3D 
397 polyclonal antibody as specified in section 2.4. The antibody also seemed to 
identify the 3CD precursor at ≈75 kDa and the P3 precursor at ≈110 kDa at later time 
points (Fig. 4.3a). The mouse anti-3A 2C2 monoclonal antibody used to probe cell 
lysates transfected with GFP-pac-WT (fig. 4.3b) that was used was very non-specific 
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which resulted in the detection of non-specific, background bands on the blots. 
However a band at ≈20 kDa visible after 7 hours may indicate the presence of 3A 
expression. Analysis of the blots identified a darker band located at approximately 
26 kDa from the lysates transfected with GFP-pac-WT. It is possible that this band 
may be corresponding to the expected size of a 3A-3B precursor (Fig. 4.3b). Figure 
4.3c shows the presence of at least 5 bands when the cell lysates were probed with 
a mouse anti-3B 1F8 monoclonal antibody. The sizes of individual 3B bands do not 
correspond to the molecular weight of the proteins suggesting that the bands 
represent a variety 3B precursors, however the identities of the precursors have yet 
to be determined.  
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Figure 4.3 Western blot analysis of BHK-21 cells transfected with GFP-pac-WT 
replicon RNA and lysed at incremental time points. A) Blot probed with anti-3D (397) 
antibody showing levels of protein expression corresponding to 3Dpol (54 kDa), 3CD 
(75 kDa) and P3 (110 kDa). B) Blot probed with anti-3A antibody showing levels of 
protein expression corresponding to 3A (20 kDa) and a 3A-B precursor (≈27 kDa). C) 
Blot probed with anti-3B antibody showing levels of protein expression over time 
corresponding to 3B precursors (≈30-50 kDa). 
The Western blot data supports the IncuCyte transfection data shown in figure 4.2. 
However, FMDV non-structural protein expression in the cell lysates occurs at earlier 
time points, i.e. beginning as early as 4 hours and peaking at 7-9 hours for GFP-pac-
WT transfected lysates, instead of peaking at 10-12 hours as seen in figure 4.2. The 
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earlier expression times of the non-structural proteins seen in the cell lysates could 
be due to the different modes of measuring replication. In figure 4.2, replication was 
measured by analysing the number of GFP-positive cells per well, whereas in figure 
4.3, protein expression was measured by probing with the appropriate antibody. The 
difference in expression times could be due to the rate of GFP synthesis and 
degradation within the cell, and may need longer to accumulate enough to induce a 




4.3 Mutations in 3Dpol 
It has been previously discussed in Chapter 3 that work by Herod et al. identified 
areas in the genome that could tolerate insertions by random transposon-mediated 
mutagenesis (Herod et al., 2015). Transposon-mediated mutagenesis identified key 
functional regions within viral proteins, particularly within 3Dpol that were both 
permissive and could be further manipulated to include epitope tags for improved 
downstream studies such as immunofluorescence, and also non-permissive, which 
resulted in the production of replication-defective replicon phenotypes (McMahon 
et al., 1998; Brune et al., 1999; Teterina et al., 2011; Remenyi et al., 2014; Herod et 
al., 2015; Herod et al., 2016).  
Out of nine mutations in the 3Dpol region that were identified, three were chosen to 
take forward into further studies: catalytic metal ion-interacting site DD240/5NN, 
dsRNA exit site GC216/7AA, and classical replication-deficient motif C mutation GNN 
(also known as DD388/9NN) (Jablonski et al., 1991; Hansen et al., 1997; Ferrer-Orta 
et al., 2004; Carrillo et al., 2005; Ferrer-Orta et al., 2007; Ferrer-Orta, Ferrero, et al., 
2015; Herod et al., 2016). These functional 3Dpol mutations (characterised in the 
context of recombinant proteins in Chapter 3) were introduced into FMDV replicons 
here. The schematic in figure 4.4 summarises the location of the mutations in context 
of the replicon. 
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Figure 4.4 Schematic diagram of FMDV replicon highlighting 3Dpol diagrammatically 
showing the location of the three non-replicative mutations in 3Dpol identified by 
transposon mutagenesis. 
4.3.1 Epitope-tagging of replicons 
Recognition of replication-competent insertion sites by transposon-mutagenesis 
allowed for the identification of potential locations for insertion of epitope tags such 
as FLAG (DYKDDDDK) and haemagglutinin (HA; YPYDVPDYA). Herod et al., 2015 
identified two locations in non-structural protein 3A and one in 3Dpol that could 
tolerate insertions by transposon-mutagenesis and demonstrated high levels of 
replication in BHK-21 cells (Herod et al., 2015). As a result of this, FLAG and HA 
epitope tags were cloned into these sites. The 3A epitope tag-containing insertion 
sites replicated to the levels of WT, whereas the epitope-tagged 3Dpol insertion site 
was unable to replicate. 
Due to the inability of the original epitope-tagged 3Dpol insertion to replicate, the 
FLAG and HA epitope tags were cloned into the C-terminus of 3Dpol, in an identical 
location to the his-tag in the recombinant protein described in Chapter 3. It was 
believed that although the C-terminus was not identified by transposon mutagenesis 
as a permissive location, it would not affect the function of the WT protein, thereby 
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not affecting the replication ability of the replicon due to flexible nature of that 
region of the protein. The hypothesis was tested by transfecting GFP-pac-WT 
replicons containing FLAG and HA tags at the C-terminus of 3Dpol into BHK-21 cells as 
described in section 2.6.3 (Fig. 4.5). FLAG- and HA-tagged GFP-pac-WT replicons were 
able to replicate to the level of the unmodified GFP-pac-WT replicon.  
Figure 4.5 Levels of GFP-expression in BHK-21 cells transfected with GFP-pac 
replicon RNA. A) Levels of GFP-expression at 11 hours post-transfection in BHK-21 
cells transfected with GFP-pac-WT, GFP-pac-GNN, GFP-pac-WT-FLAG and GFP-pac-
WT-HA replicon RNA. B) Mean levels of GFP-expression in BHK-21 cells transfected 
with GFP-pac-WT, GFP-pac-GNN, GFP-pac-WT-FLAG and GFP-pac-WT-HA replicon 
RNA over time. n=2, ± SEM. Error bars on the graph have been removed for clarity. 
To ensure that the epitope-tagged replicons had been successfully cloned and were 
not structurally altered, transfected BHK-21 cells were lysed as described in section 
2.8.1, resolved by SDS-PAGE, and then analysed by Western blot (Fig. 4.6). The 
Western blots were probed with rabbit anti-3D 397 polyclonal antibody, anti-FLAG, 
and anti-HA antibodies. As the antibodies were able to detect the protein (3Dpol) and 
the appropriate tags at 54 kDa it can be assumed that the insertion of the epitope 
tags did not alter the native folding of the protein or obscure the antigenic site, 
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providing support that the insertion of the epitope tags did not affect the function of 
the replicon, or polyprotein processing.  
Figure 4.6 Western blot analysis of BHK-21 cells transfected with 3Dpol epitope-
tagged GFP-pac-WT constructs in addition to controls (unmodified GFP-pac-WT and 
unmodified GFP-pac-GNN). Protein lysates were prepared at eight hours post-
transfection and probed by Western blotting for FLAG and HA expression and 3Dpol. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. 
The appearance of extra bands in the samples probed with anti-3D 397 antibody was 
expected due to the polyclonal nature of the antibody. This resulted in the detection 
of additional bands upon Western blot analysis at 75 kDa and a doublet band located 
at approximately 35 kDa. It is thought that the band located at 75 kDa is 3CD, and the 
band at approximately 35 kDa is a non-specific interaction of the antibody with a 
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fragment of incorrectly processed 3CD, termed 3D*. A similar observation has been 
made in studies on PV (Lawson et al., 1992; Parsley et al., 1999). 
4.3.2 Next generation replicons 
A third generation of WT and GNN replicons were also developed replacing the GFP-
pac reporter cassette with either mCherry red fluorescent protein or with a new GFP 
report gene from Ptilosarcus sea pen (ptGFP) (Herod et al., 2015, F. Tulloch, G. Luke, 
J. Nicholson and M. D. Ryan, unpublished data) as shown in figure 4.7.  
Figure 4.7 Schematic diagrams of third-generation FMDV replicon. A) Schematic of 
infectious viral genome containing structural proteins 1A-1D in the P1 region. B) 
Schematic of WT replicon showing the substitution of structural proteins 1A-1D with 
ptGFP (ptGFP-WT). C) Schematic of WT replicon showing the substitution of 
structural proteins 1A-1D with mCherry (mCherry-WT). 
ptGFP is a GFP that has been described as having higher absorption peak (495 nm), 
and an emission peak at 508 nm, than the corresponding enhanced GFP (eGFP) or 
Aequorea GFP used in the GFP-pac replicons (absorption at 395 and 470 nm and 
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emission at 507-510 nm). The emission curve of ptGFP show that the molar 
absorbance of ptGFP is higher, and the excitation and emission peaks are nearly 
symmetrical, unlike those of Aequorea GFP, and is therefore brighter (Bryan et al., 
2001; Environmental Sciences Inc., 2015; Hicks, 2002). Particularly as Aequorea GFP 
has two excitation peaks and current green fluorescence filters are largely 
inadequate for detection of both (Hicks, 2002). Negative control ptGFP-GNN and 
mCherry-GNN replicons were also prepared (mutagenesis performed by Morgan 
Herod, University of Leeds). A representative replication assay (Fig. 4.8) shows the 
expression of both ptGFP and mCherry over time in BHK-21 transfected cells. The 
trend in fluorophore expression is similar to that seen in GFP-pac replicon-
transfected cells (Fig. 4.2), however, the expression of ptGFP appears earlier in 
transfected cells (from 3 hours) and peaks at an earlier timepoint (7-9 hours). 
Expression of ptGFP is not thought to occur at a faster rate, but is detected sooner 
due to the increase brightness when compared to GFP-pac. 
Figure 4.8 Representative data of transfected BHK-21 cells. Graph showing the 
mean number of ptGFP- and mCherry-expressing BHK-21 cells over time (hours) after 




Identical replicons with contrasting fluorescent reporters opened up the possibility 
of being able to use two replicons simultaneously as they could be easily 
distinguishable from each other when co-transfected (Herod et al., 2015). 
4.3.3 Epitope-tagging of replication-deficient replicons 
To improve the signal of GFP, two epitope tags (FLAG and HA), and mutations were 
introduced into the ptGFP third-generation replicon. Replication of the different 
replicons was assayed in BHK-21 cells alongside unmodified controls (Fig. 4.9). There 
is a 100-fold difference in the number of cells expressing GFP between WT ptGFP 
replicons and GNN ptGFP replicons.  
Figure 4.9 Levels of GFP-expression in BHK-21 cells transfected with ptGFP replicon 
RNA. A) Levels of GFP-expression at eight hours post-transfection in BHK-21 cells 
transfected with ptGFP-WT, ptGFP-GNN, ptGFP-WT-FLAG and -HA, ptGFP-GNN-FLAG 
and -HA, ptGFP-D240/5NN-FLAG and -HA, and ptGFP-GC216/7AA-FLAG and -HA 
replicon RNA. Levels of GFP expression of mutants GC216/7AA and DD240/5NN are 




As expected, the replicons that contained the point mutations in 3Dpol (DD240/5NN 
and GC216/7AA) were unable to replicate, resulting in significantly lower levels of 
GFP expression than that the WT control, and to approximately the same level of GFP 
expression as the ptGFP-GNN negative controls. All the mutant replicons had similar 
levels of GFP expression as the GNN control, within error. 
4.3.4 Recovery of replication-deficient replicons 
Co-transfection and use of helper replicons to recover replication-deficient replicons 
in trans is an established method to determine the function of viral proteins, 
particularly their role in viral genome replication. A number of studies on FMDV and 
other picornaviruses have used this method to demonstrate that certain non-
functional, non-structural proteins can be recovered in trans by co-expression with 
replication-competent helper virus or replicon (Xuemei Cao et al., 1995; Teterina et 
al., 1995; Towner et al., 1998; Tiley et al., 2003; Nayak et al., 2005).  
As it can be seen from previous figures (Figs. 4.2, 4.7 and 4.9), the mutant replicon 
3Dpol-GNN is unable to replicate, producing levels of GFP expression synonymous 
with input translation from positive-strand template RNA. Previous work outlined in 
Herod et al., 2015 observed that the replication-deficient ptGFP-GNN replicon was 
able to be recovered by co-transfection of a WT ‘helper’ replicon containing the 
different fluorescent reporter gene, mCherry as outlined in figure 4.10. The use of 
different reporter genes allowed for the discrimination of replication between the 
WT helper replicons and the mutant replication-defective replicons.  
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Figure 4.10 Co-transfection of mCherry-WT helper replicon RNA and control tRNA 
with ptGFP mutant replicon (ptGFP-GNN) or with ptGFP-WT replicon. Levels of GFP 
expression was measured using the IncuCyte FLR as the number of GFP-positive 
cells/well at eight hours post-transfection when GFP expression was maximal. n=6 ± 
SEM. *** = p < 0.001. 
The levels of GFP expression produced by ptGFP-GNN replicon, when co-transfected 
with mCherry-WT replicon, were increased significantly when compared to the 
ptGFP-GNN replicon co-transfected with transfer RNA (tRNA) that is used as a control 
to maintain equal amounts of RNA in the transfections. The replication-deficient 
mutant ptGFP-GNN was unable to be recovered when co-transfected with tRNA 
control, highlighting that it is necessary for a fully-functional WT polymerase to be 
present for the recovery of replication to occur. Levels of GFP expression of ptGFP-
WT replicon when co-transfected with WT mCherry helper replicon or with control 
tRNA were not significantly different, implying that there were no negative effects as 
a result of competition for cellular resources. 
It has been previously mentioned in Chapter 3 that two additional replicons with 
mutations in 3Dpol were chosen to take into further functional studies: DD240/5NN 
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and GC216/7AA (in addition to GNN, or DD388/9NN). In vitro polymerase activity 
assays performed on recombinant his-tagged mutant 3Dpol (detailed in Chapter 3) 
showed that mutant DD240/5NN was unable to incorporate 32P-αUTP when 
incubated with an RNA-primer-template as a result of the point mutations located in 
a catalytic site of the enzyme. Mutant GC216/7AA was, however, able to incorporate 
radiolabelled nucleotides to a similar level as WT his-tagged recombinant 3Dpol 
protein, showing that the mutant was still enzymatically active as a result of the 
mutation not being located in a catalytic domain. 
Here, investigations into whether these mutations could be recovered by co-
transfection with a WT helper replicon as with the ptGFP-GNN replicon were 
undertaken. As expected based on previous transposon mutagenesis data, all three 
replicons containing mutations in 3Dpol were unable to replicate, producing levels of 
GFP expression approximately equivalent to the ptGFP-GNN replicon due to input 
translation only (Herod et al., 2016; Herod et al., 2015) (Fig. 4.11).  
Figure 4.11 Levels of GFP expression at eight hours post-transfection of mutant 
polymerase ptGFP replicons (DD240/5NN, GC216/7AA, and GNN) when co-
transfected with either mCherry-WT or mCherry-GNN helper replicons n=7 ± SEM. * 
=  p < 0.05. 
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Levels of GFP expression in these two replicons were increased significantly when 
compared to the levels of GFP expression in the same replicons co-transfected with 
a replication-deficient helper replicon. When the mutant replicons were co-
transfected with mCherry-GNN helper replicons, none of the mutants were able to 
replicate confirming that a fully functional 3Dpol is necessary for replication to occur 
(Fig. 4.11). Surprisingly, only two of the three mutant replicons (ptGFP-GNN and 
ptGFP-DD240/5NN) could be recovered when co-transfected with an mCherry-WT 
replicon. These two mutant replicons (DD240/5NN and GNN) contained mutations in 
catalytic domains of the polymerase.  
Mutant replicon ptGFP-GC216/7AA, containing a mutation in the non-catalytic 
polymerase dsRNA exit site, was unable to be recovered when co-transfected with a 
WT helper replicon (Fig. 4.11). These results suggest that only catalytic mutations 
GNN and DD240/5NN were able to be recovered in trans, opening the possibility that 
there were certain functions of the polymerase that could only be supplied in cis. It 
is interesting to note that the non-catalytic mutant, GC216/7AA, recombinant 
protein was able to incorporate 32P-αUTP in the in vitro assay (section 2.10, and 
Chapter 3), but was unable to replicate in context of the replicon (Fig. 4.9 and Fig. 
4.11) suggesting that both catalytic and non-catalytic mutations were essential for 
the replication of RNA. 
4.3.5 Cellular localisation of FMDV 3Dpol 
One of the reasons that the WT helper replicon could not recover the non-catalytic 
mutant GC216/7AA could be that the two replicons were localising to different areas 
of the cell and were unable to come into close enough proximity for the functional 
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WT polymerase to be provided to the non-functional replicon in trans. The use of 
epitope-labelled replicons could be analysed successfully by confocal microscopy, 
therefore in order to test this hypothesis of differential localisation BHK-21 cells were 
transfected with mutant C-terminal FLAG-tagged replicons in a ptGFP replicon 
backbone (ptGFP-GNN-FLAG, ptGFP-GC216/7AA-FLAG and ptGFP-DD240/5NN-FLAG) 
and C-terminal HA-tagged WT (ptGFP-WT-HA) helper replicons in a Renilla luciferase 
replicon backbone.  
By removing the fluorescent reporter gene, the replicons would be able to be used 
for confocal microscopy with the ability to probe for more than two targets as there 
would be no interference from the fluorescent gene. It should be noted that by 
removing the fluorescent reporter the same replicons could not be monitored using 
the IncuCyte in real-time. 
The transfected cells were fixed at four hours post-transfection as detailed in section 
2.7 and the epitope tags were detected by indirect immunofluorescence using 
commercially available antibodies (section 2.4). The cells were analysed by confocal 
microscopy using a Zeiss LSM-880 confocal microscope with Airyscan (Fig 4.12a).  
The results of the dual colour immunofluorescence analysis show that there is clear 
co-localisation of both FLAG- and HA-labelled polymerases within cells (Fig 4.12b). 
This is indicative of both mutant and WT polymerases targeting the same intracellular 
compartments. This would suggest that the lack of recovery of the GC216/7AA 








Figure 4.12 (p. 137) Dual immunofluorescence analysis showing co-localisation of 
WT and mutant non-structural proteins (adapted from Herod et al., 2016). A) BHK-
21 cells co-transfected with FLAG-tagged mutant replicon and HA-tagged WT helper 
replicons. Cells were fixed at four hours post-transfection and labelled with anti-FLAG 
(green) and anti-HA (red) antibodies. Cell nuclei were stained with DAPI (blue). 
Zoomed images represent the boxed are outlined in ‘merge’. Scale bar: 20 µM. B) 
Quantification (%) of co-localised 3D-FLAG and 3D-HA by measuring the number of 




4.4 Role of structural RNA elements in 5ʹ UTR in replicon 
recovery 
There is evidence for the interaction of the non-structural proteins with the 5ʹUTR 
particularly involved in the control of translation and replication of the viral genome. 
The non-structural proteins that have been identified to interact with the 5ʹUTR are 
primarily the polymerase 3Dpol and the precursor 3CD. 
3Dpol and 3CD have been shown to mediate replication by binding to various 
structural RNA elements in the 5ʹUTR, such as the cre and the S-fragment (Nayak et 
al., 2005; Nayak et al., 2006; Lawrence et al., 2009). The cre  and poly-A act as the 
template for VPg uridylylation which drives the production of negative strand 
synthesis by acting as a primer for 3Dpol (Paul et al., 1998; Goodfellow et al., 2000; 
Barton et al., 2001; Murray et al., 2003; Nayak et al., 2005; Steil et al., 2009). A current 
model outlined in Herod et al., 2016 suggests that 3CD, or a 3D-containing precursor,  
may also be able to bind to the VPg and prime for genome replication similar to the 
models described for the process of PV replication (Andino, Rieckhof and Baltimore, 
1990; Andino, Rieckhof, Trono, et al., 1990; Andino et al., 1993; Xiang et al., 1995; 
Herold et al., 2001; Serrano et al., 2006; Spear et al., 2015).  
A study detailed in Lawrence and Rieder, 2009 has shown that 3C binds to the S-
fragment and can be co-precipitated with the large RNA structure highlighting the 




4.4.1 Role of mutations the 5ʹ UTR in replicon recovery 
To investigate the relationship of the 5ʹ UTR structural RNA elements with non-
structural proteins in the process of replicon recovery, two regions of the FMDV 5ʹ 
UTR were mutated. It was hypothesised that the structured RNA elements in the 5ʹ 
UTR may sequester 3Dpol, or its precursors, in cis therefore reducing their availability 
to assist in trans in the recovery of replication-deficient replicons (Herod et al., 2016). 
Morgan Herod and Joseph Ward (University of Leeds) undertook mutagenesis of the 
first adenine nucleotide located in the conserved cre stem-loop sequence (AAACA) 
into a guanine (creA1G, hence GAACA) as previously described (Mason et al., 2002), 
and removed the S-fragment in its entirety. Both mutations to the 5ʹ UTR structured 
RNA elements rendered the replicon unable to replicate (Joseph Ward, personal 
communication). These mutations were cloned into the helper replicon constructs 
and were then co-transfected with the replication-deficient polymerase mutant 
replicons ptGFP-GNN, ptGFP-DD340/5NN, and ptGFP-GC216/7AA. 
When the replicons containing the mutations in the polymerase were co-transfected 
with either the tRNA control or with the mCherry-WT helper replicon, the results 
were the same as observed previously (Fig. 4.13). With the tRNA control, no recovery 
of replication was observed, as expected. When co-transfected with mCherry-WT 
replicon, both ptGFP-GNN and ptGFP-DD240/5NN were readily recovered. However, 
when the two catalytic mutant replicons ptGFP-GNN and ptGFP-DD240/5NN were 
co-transfected with a helper replicon mCherry-ΔS-creA1G, containing both mutations 
in the 5ʹ UTR, levels of GFP expression was increased more than 100-fold above the 
tRNA control.  
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Figure 4.13 Levels of GFP expression at eight hours post-transfection of mutant polymerase 
ptGFP replicons (ptGFP-GNN, ptGFP-DD240/5NN and ptGFP-GC216/7AA) when co-
transfected with either control tRNA, mCherry-WT or mCherry-ΔS-creA1G helper replicons.  
n=3 ± SEM. * = p < 0.05, ** = p < 0.01. 
The replicon mutant ptGFP-GC216/7AA was not recovered to the same levels as the 
other mutants when co-transfected with mCherry-WT helper replicon as previously 
observed (Fig. 4.11). However, when the replicon was co-transfected with the 
mCherry-ΔS-creA1G helper replicon, a greater than 100-fold increase in GFP 
expression was observed, similar to that seen with the catalytic mutant replicons 
GNN and DD240/5NN.  
These data would suggest that there is a cis function of 3Dpol which interacts with the 
structured RNA elements in the 5ʹ UTR, distinct from its catalytic polymerisation 
function which is provided in trans. By removing the RNA elements from the 5ʹ UTR 
of the helper replicon that are proposed to interact with 3Dpol or with 3Dpol 
precursors, the WT functional polymerase would be unable to interact with the WT 
genome in cis. Conversely, it would be free to bind to the replication-deficient 




4.4.2 Is 3Dpol sufficient to recover replication? 
With the characterisation of a novel cis function of FMDV 3Dpol (Herod et al., 2016) 
we asked whether the presence of a functional WT 3Dpol was sufficient for the 
recovery of a replication-deficient replicon.  
The FMDV genome encodes for 12 functional proteins, four structural proteins (1A-
1D), followed by a short peptide sequence, 2A that is necessary for processing and 
separation of the structural proteins from the eight non-structural proteins (2B-3D). 
All 12 proteins are expressed as a single polyprotein that is co- and post-
translationally processed during the replication cycle of the virus. During polyprotein 
processing, several precursors are formed (outlined in Fig. 4.14). The function of 
many of the precursors have yet to be elucidated.  
Figure 4.14 Schematic of the FMDV genome outlining the different regions (P1, P2 
and P3), the structural proteins (1A-1D), and non-structural proteins (2B-3D). Arrow 
denotes cleavage of the polyprotein by Lpro. Ribosomal skipping through short 
peptide 2A separates the structural and non-structural proteins denoted by ellipses 
(…). The asterisks (*) denote cleavage by FMDV protease 3C. Schematic of some of 
the possible variations of P3 polyprotein processing are also shown whereby full P3 
can be produced followed by 3A and 3B-3D, 3A-3B, 3A-3C, and 3C-3D before 
production of individual proteins. 
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In order to determine if 3Dpol was sufficient to recover a replication-deficient 
replicon, ptGFP-GNN, ptGFP-DD240/5NN, and ptGFP-GC216/7AA were co-
transfected into BHK-21 cells with truncated replicons, as described previously. 
These truncated replicons (made by Morgan Herod, University of Leeds) contained 
the mutated 5ʹ UTR from mCherry-ΔS-creA1G and no reporter gene. The mutated 5ʹ 
UTR was linked to decreasing lengths of the genome starting from the full-length 
non-structural proteins 2A-3Dpol, successively down to just 3Dpol (Fig. 4.15) 
Figure 4.15 Schematic outlining the FMDV replication-deficient mutant ptGFP 
replicon that was co-transfected with a series of truncated helper replicons 




The replication-deficient ptGFP replicons were co-transfected with each truncated 
helper replicon and control helper replicons (mCherry-ΔS-creA1G-WT and mCherry-
ΔS-creA1G-GNN), and tRNA. Levels of GFP expression were monitored for 24 hours 
using the IncuCyte FLR (Fig. 4.16). The results for the recovery of all mutant replicons 
with the controls were the same as previously observed with the tRNA and mCherry-
ΔS-creA1G helper replicons as shown in figure 4.13. There was a statistically significant 
difference in GFP expression between all mutant replicons co-transfected with 
mCherry-ΔS-creA1G-WT and those transfected with successively truncated replicons 
from 2C-3D (Fig. 4.16). 
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Figure 4.16 Recovery of truncated replicons. Levels of GFP expression at nine hours post-
transfection of mutant polymerase ptGFP replicons co-transfected with control tRNA, 
control mCherry-ΔS-creA1G WT and GNN helper replicons, against truncated P2 and P3-
containing replicons compared to the control mCherry-ΔS-creA1G WT replicon (A) ptGFP-GNN 
n = 6 ± SEM,  B) ptGFP-GC216/7AA n = 4 ± SEM and C) ptGFP-DD240/5NN n = 2 ± SEM. 
Statistical analysis performed using two-tailed unpaired t-test; * = p > 0.05, ** = p > 0.01, *** 
= p > 0.001. 
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Recovery of GFP expression in the mutant replicons ptGFP-GNN, ptGFP-GC216/7AA, 
and ptGFP-DD240/5AA to the levels of mCherry-ΔS-creA1G-WT co-transfected 
replicons was achieved when co-transfected with truncated replicons of increasing 
size from 2B-3D (Fig. 4.16). 
It was interesting to observed that, although 3Dpol alone was not sufficient to recover 
replication in any of the replication-deficient mutant replicons, the full non-structural 
protein region was not necessary. The results across all the mutants show that when 
the size of the helper replicon was at least the size of 2B-3D, the replication-deficient 
replicon could be recovered to produce the same levels of GFP expression as when 
co-transfected with the mCherry-ΔS-creA1G-WT helper replicon. It appears from these 
data that 2B, 2BC, or a P2-P3 precursor may be important for the recovery of 
replication-deficient replicons. Alternatively, the cleavage site between 2B and 2C 
could also be a region of interest in the same vein as the importance of the 3B3-3C 






In this chapter, we have investigated the phenotype of several of the mutations in 
the FMDV polymerase, 3Dpol, that were identified by transposon mutagenesis as 
described in Herod et al., 2015. Two mutations in 3Dpol were located in catalytic sites 
(GNN, also termed DD388/9NN, and DD240/5NN) and one was located in a non-
catalytic region (GC216/7AA). All three mutations resulted in an inability to replicate 
replicon RNA when transfected into cells. However, the mutations did not appear to 
affect the cellular localisation of the polymerase as identified by 
immunofluorescence. 
The ability for picornaviruses to provide non-structural proteins in trans has been 
well documented, particularly the interactions between non-structural proteins 2B, 
3A, and 3D with structural RNA elements such as the cre and the IRES (Giachetti et 
al., 1992; Ryan et al., 1994; Xuemei Cao et al., 1995; Teterina et al., 1995; Towner et 
al., 1998; Lyons et al., 2001; Tiley et al., 2003; Nayak et al., 2005). 
Here, the mutant replicons, ptGFP-GNN, ptGFP-GC216/7AA, and ptGFP-DD240/5NN, 
were co-transfected with replicons containing a WT 3Dpol in an attempt to recover 
their activity. The two polymerase replicons that contained mutations in the catalytic 
domains of 3Dpol were shown to be readily recovered by a functional WT helper 
replicon when the two were co-transfected within cells, however, the non-functional 
mutation located in the dsRNA exit site, GC216/7AA was not able to be recovered 
with a functional WT helper replicon. These data would point to the existence of a 
necessary secondary non-catalytic function of the polymerase that could not be 
provided in trans.  
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It was hypothesised that the polymerase has a secondary cis-preferential function 
that interacted with the structured RNA elements within the 5ʹ UTR. The hypothesis 
led to the removal of these RNA elements (S-fragment and cre) from the WT helper 
replicon. This could increase the “availability” of the WT 3Dpol as it would no longer 
be able to bind in cis to the parental genome and would thus be recruited by the 
replication-deficient replicon. Since the replication-deficient replicon would have a 
fully structured 5ʹ UTR, the WT 3Dpol would be able to bind to those structures and 
provide its necessary cis-function in addition to its catalytic (trans) function. In the 
case of the GC216/7AA mutant, in vitro studies outlined in chapter 3 showed that the 
protein was catalytically active and could bind RNA with similar affinity to WT and 
could also incorporate radiolabelled UTP nucleotides to a similar rate as WT. The 
results would suggest that the trans activity within replicon could be provided by the 
mutant. However, replicon studies show that this mutation rendered the replicon 
non-functional as well as non-recoverable unless the structured 5ʹ UTR elements 
were removed, suggesting that the cis function was vital for replication of the 
replicon RNA. 
The two different function of 3Dpol described here alongside the results discussed in 
chapter 3 that highlight the ability for FMDV WT 3Dpol to form fibrils provide an 
attractive hypothesis that these higher-order structures could act as “sponges” for 
withholding polymerase molecules and maintaining an appropriate equilibrium of 
enzyme to RNA. In order to test this hypothesis proposed experiments include 
performing complementation assays with the different mutants (catalytic and non-
catalytic) and observing their ability to replicate in the context of replicon, as well as 
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in the context of recombinant proteins within activity assays and fibril formation 
assays. 
The non-covalent interaction of viral non-structural proteins and host proteins with 
the 5ʹ and 3ʹ UTRs have been shown to be necessary for the formation of a 
ribonucleoprotein complex that may facilitate the process of replication, 
transcription, and translation of the PV genome (Herold et al., 2000; Barton et al., 
2001; Herold et al., 2001). In FMDV, replication is thought to begin with the binding 
of 3Dpol to the uridylylated VPg in the presence of 3CD. The template for VPg 
uridylylation is the cre located in the 5ʹ UTR. A copy of uridylylated VPg (VPg-pUpU) 
is covalently linked to the 5ʹ end of the daughter strand and acts as a primer for 
positive strand synthesis (Goodfellow et al., 2003; Murray et al., 2003; Nayak et al., 
2005; Steil et al., 2009). Studies have shown that FMDV 3CD is also able to bind to 
the S-fragment, equivalent to PV 3CD binding to its cloverleaf structure (Nayak et al., 
2006; Lawrence et al., 2009). In PV, the switch from translation to replication on the 
genomic RNA is thought to be mediated by the binding of the cellular protein PCBP 
to the cloverleaf. This binding enhances viral translation, while the binding of the viral 
protein 3CD represses translation and facilitates negative-strand synthesis (Gamarnik 
and Andino, 1998; Serrano et al., 2006). However, biochemical studies have shown 
that 3CD has no polymerase activity in PV, suggesting that the processing of 3CD into 
active 3C and 3Dpol is essential for the function of 3Dpol (Flanegan and Baltimore, 
1979; Flanegan and Van Dyke, 1979; Harris et al., 1994). The studies reported in 
Chapter 3 have also demonstrated no polymerase activity for FMDV 3CD. 
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The data presented here, and additional studies outlined in Herod et al., 2016 and 
Herod et al., 2015 are consistent with studies performed on both PV and HCV. A 
recent study in PV  by Spear et al., 2015 proposed a mechanism to characterise the 
role of 3Dpol and its precursors during replication using a cell-free system. The model 
based on their data suggested that 3Dpol entered the replication complex in the form 
of its precursor, P3 (or 3CD), and was cleaved to release the active polymerase 
enzyme. One P3 molecule (or smaller precursor 3CD) binds directly to the 5ʹ UTR, 
while a second precursor molecule provides the functionally active 3Dpol (Spear et al., 
2015). In HCV, similar co-transfection studies outlined in Kazakov et al., 2015 showed 
that the RdRp NS5B could be supplemented in trans, it was also required in cis 
indicating that the polymerase had an essential cis-acting role distinct from its 
enzymatic activity (Kazakov et al., 2015; Gomes et al., 2016). 
The non-recoverable mutant GC216/7AA, which has helped identify an essential cis-
preferential role for FMDV 3Dpol, contains a mutation in the dsRNA 
binding/interacting residues located in the dsRNA exit sites. This mutant polymerase, 
as shown in Chapter 3, was still able to bind RNA as shown by fluorescent anisotropy 
assays, and was able to incorporate [α-32P] UTP. However, in context of the FMDV 
replicon, it resulted in a phenotype unable to replicate.  
The S-fragment, proposed to have a long stem-loop structure (Bunch et al., 1994), is 
inherently highly base-paired. This structure could point to a potential interaction 
between the polymerase and the 5ʹ UTR. By mutating the dsRNA exit site residues, 
the interaction was abrogated. However, it is interesting to note that a study showed 
no interaction between the polymerase and the S-fragment by co-
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immunoprecipitation (Lawrence et al., 2009). This may suggest that the interaction 
is with a polymerase precursor, or by a separate protein. 
Despite both cis and trans functions of 3Dpol being necessary for replication to occur, 
the polymerase, or its precursors, were not sufficient to recover replication of a 
mutant replicon. For recovery to occur it appears that having a minimum size for a 
helper replicon that includes 2B may be important for recovery, however, it is not 
known if 2B alone is sufficient for replicon recovery. The function of FMDV 2B protein 
is still not very well understood. Recent studies have suggested that 2B may be a 
viroporin due to the presence of two putative transmembrane domains that target 
the ER membrane and induces damage to the host-cell membrane integrity (Ao et 
al., 2015; Gao et al., 2016). However, the viroporin activity of 2B in FMDV has still not 
been confirmed.  
Some reports have indicated that 2B may also function synergistically with other non-
structural proteins, particularly with 2C, or as the precursor 2BC. These studies have 
shown that the presence of 2BC or the co-expression of 2B and 2C abolished ER-to-
Golgi transport of cellular proteins during infection (Moffat et al., 2005; Moffat et al., 
2007; Gao et al., 2016).  
There has been no evidence to date of a direct interaction between FMDV 2B and 
3Dpol however, the potential function of 2B, or the precursor 2BC, to dysregulate the 
ER membrane could be necessary for FMDV replication to occur by facilitating the 
recruitment of cellular membranes within which a replication complex can form.  
Work is ongoing to determine whether it is the RNA structure or the protein function 
of 2B that is important in the recovery of mutant replicon RNA. To do this, the 2B 
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RNA sequence has been scrambled to produce synonymous mutations of every 
codon, this ensures that although the native RNA structure is disrupted, the protein 
sequence remains the same and thus protein function should not be disrupted. 
Cloning of the scrambled 2B region into the helper replicon has been undertaken by 




Foot-and-mouth disease virus genome 
replication is unaffected by inhibition of type III 
phosphatidylinositol-4-kinases 
5.1 Introduction 
Due to the highly infectious nature of FMDV, handling is restricted to a small number 
of facilities worldwide. Sub-genomic replicons were developed to allow for the study 
of viral replication in laboratories at lower containment level (Forss et al., 1984; 
McInerney et al., 2000; Tulloch et al., 2014). The FMDV replicon constructs employed 
here (GFP-pac-WT) have the structural proteins replaced by a GFP reporter and a 
puromycin acetyltransferase resistance gene cassette. Replication-deficient 
constructs have a GDD to GNN substitution in the catalytic active site of 3Dpol (GFP-
pac-GNN) as described previously (refer to Chapters 3 and 4, also termed 
DD388/9NN). Levels of GFP expression over time can be measured using an IncuCyte 
Dual Colour ZOOM® FLR (Forrest et al., 2014; Tulloch et al., 2014; Herod et al., 2015). 
Replicons have also been used to study the replication of a number of other viruses. 
Here, we have also used hepatitis C virus (HCV) sub-genomic replicons pSGR-Luc-GFP-
JFH-1 (Jones et al., 2007) and SGR-feo-JFH-1 (Wyles et al., 2009), together with a 
Coxsackievirus B3 (CVB3) sub-genomic replicon, pRib-Fluc-CB3/T7 (Lanke et al., 
2009).  
Replication of a number of positive-sense RNA viruses has been shown to occur at 
cytoplasmic membrane-associated sites (den Boon et al., 2010). The formation of 
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such membrane compartments is thought to allow for the creation of a kinetically-
favourable environment in which viruses can replicate rapidly and effectively, 
concurrently protecting the replication machinery from the hostile environment of 
the host cell. A number of viruses including CVB3, PV, and HCV have been shown to 
subvert and rearrange the membranes of the ER, Golgi, and trans-Golgi network in 
order to form discrete intracellular membranous complexes where viral replication 
can take place in a protected environment within the cytoplasm, as well as 
maintaining a region of high concentration of viral proteins for efficient virus 
assembly. Membranes rich in phosphatidylinositol-4-phosphate (PI4P) lipids, such as 
those found on the Golgi complex, have been specifically implicated in the replication 
of multiple members of the Picornaviridae and Flaviviridae families, including PV, 
enterovirus 71, CVB3, encephalomyocarditis virus (EMCV), and HCV (den Boon et al., 
2010; Altan-Bonnet et al., 2012; Dorobantu, Albulescu, et al., 2015). 
The relationship between PI4P and the role it plays in viral replication has been well-
defined through studies with HCV (Trotard et al., 2009; Reiss et al., 2011; Bishé et al., 
2012; Zhang et al., 2012). HCV, a +ve ssRNA virus in the family Flaviviridae, and the 
causative agent of hepatitis C and related sequealae including hepatocellular 
carcinoma, utilises a number of phosphoinositide (PI) lipids and kinases to build 
cytoplasmic membrane-associated replication complexes. PIs are phosphorylated 
derivatives of phosphatidylinositol. It has been documented that the primary kinase 
used by HCV for viral replication is phosphatidylinositol-4-kinase IIIα (PI4KIIIα) 
(Trotard et al., 2009). HCV has also been shown to utilise another related pathway, 
the phosphatidylinositol-3-kinase (PI3K) pathway, especially during the formation of 
autophagosomes within the cells (Sir et al., 2012; Liu et al., 2012; Mohl et al., 2016). 
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Another well-characterised virus that utilises the PI pathway is CVB3, a +ve ssRNA 
virus and a related picornavirus to FMDV. It is a cardiotropic virus and is primarily 
known for its role as a causative agent of myocarditis (Melnick et al., 1949; 
Garmaroudi et al., 2015). Multiple studies have shown that CVB3 is dependent on 
PI4KIIIα and PI4KIIIβ for replication as it hijacks the function of these kinases, 
including their interacting partners such as oxysterol binding protein and becomes 
able to subvert intracellular membrane formation in favour of viral replication 
(Greninger et al., 2012; van der Schaar et al., 2012; Arita et al., 2013; van der Schaar 
et al., 2013; Dorobantu et al., 2014). As a result, both HCV and CVB3 serve as excellent 





5.2 The role of phosphoinositides in virus RNA 
replication 
Different intracellular membrane-bound organelles contain one of the seven distinct 
PI species (Matteis et al., 2004; Di Paolo et al., 2006; Krauß et al., 2007). For example, 
the plasma membrane contains more free phosphatidylinositol 4,5-bisphosphate 
than PI4P, which is found predominantly on Golgi-derived membranes (Matteis et 
al., 2004; Krauß et al., 2007). The distribution of PIs on the different intracellular 
membranes is largely determined by the enzymatic activity of specific lipid kinases 
and phosphatases.  
Phosphorylation of PI lipids on the 4-carbon of the inositol ring which generates PI4P 
(Fig 5.1) is affected by the up-regulation and selective recruitment of PI4K (Fig 5.2). 
There are two types of well-defined families of PI4Ks: type II (PI4KIIα and PI4KIIβ) and 
type III (PI4KIIIα and PI4KIIIβ). Previous studies on PV and CVB3 have identified 
PI4KIIIβ as the host enzyme upregulated in viral replication factories (Belov et al., 
2007; Lanke et al., 2009; Hsu et al., 2010; Arita et al., 2011). Depletion of PI4KIIIβ 
activity within infected cells by RNA silencing or the use of kinase inhibitors, such as 
PIK93 (Knight et al., 2006), were shown biochemically to be able to block PV and CVB3 
viral RNA synthesis and virus replication. In contrast, HCV replication is generally 
accepted to be dependent on PI4KIIIα activity (Berger et al., 2011; Reiss et al., 2011; 
Bishé et al., 2012), although there is some evidence for a dependence on PI4KIIIβ 
(Borawski et al., 2009; Arita et al., 2011; Zhang et al., 2012).  
The PI4K family represents a possible pan-viral therapeutic target, however, 
involvement in FMDV replication has yet to be clearly defined. Using bi-cistronic 
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reporter constructs and sub-genomic replicons, we have compared the effects of 
type III PI4K and PI3K inhibitors on FMDV with other positive-sense RNA viruses. 
Using this approach, we have separated effects on RNA translation from direct 
effects on genome replication and show that FMDV replication appears not to be 
significantly dependent on either kinase pathway. 
Another class of PIs, phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) and its related 
kinase PI3K, has also been shown to be involved in viral RNA replication, particularly 
during HCV replication (Fig 5.1). PI(3,4)P2 synthesis on endosomal membranes is 
initiated after clathrin-mediated endocytosis by PI3K. There are three classes of PI3Ks 
active in a mammalian cell. Class I PI3Ks (p110α-δ) are involved in engaging the Akt 
pathway (a signal transduction pathway also known as the PI3K-Akt pathway) and 
acting as effectors to further downstream activation of the pathway required for cell 
growth and survival by generating PIP3 (phosphatidylinositol (3,4,5)-triphosphate) 
phospholipids concentrated at the plasma membrane. Classes II and III PI3Ks are 





Figure 5.1 Schematic adapted from Delang et al., 2012 showing the chemical structures 
of the different PI phosphorylation states. PI4K phosphorylates the 4-carbon on the 
inositol ring (highlighted) to form PI4P, the reaction is reversible with the catalytic activity 
of phosphatidylinositol 4-phosphatase (4-pase). PI4P is an intermediate lipid which can be 
further phosphorylated into phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) or 




Figure 5.2 Simplified diagrammatic representation of the localisation of 
phosphatidylinositol (PI) lipids in the cell. Unphosphorylated PI is concentrated on 
the plasma membrane. PI is phosphorylated by either PI4Ks and PI3K into PI4P or 
PI3P, and thus translocate to intracellular membranes where the phosphorylated PIs 
are active. PI4P lipids are concentrated on the Golgi complex, as well as on the plasma 
membrane and are responsible for intracellular transport. PI4KIIIα primarily is active 
on PIs located on the plasma membrane, whereas PI4KIIIβ is functional on Golgi-
associated PIs. Additionally, inhibitors to each kinase is highlighted.  
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5.3 Inhibitors of phosphatidylinositol-4 kinases 
Previous studies have identified the prominent role that the PI4KIIIβ pathway plays 
in the development of intracellular viral replication factories in cells infected with 
other positive-sense RNA viruses (e.g. HCV, PV and CVB3) (Altan-Bonnet et al., 2012). 
CVB3, HCV, and PV infection results in a dramatic remodelling of the host-cell 
secretory membrane pathway. During peak replication times of these viruses 
(approximately 6 hours post infection for enteroviruses) a large pool of viral proteins 
involved in genome replication are found localised within membranous organelles at 
the Golgi and ER membranes (Hsu et al., 2010; Limpens et al., 2011; Reiss et al., 2011; 
Belov et al., 2012). These membrane-bound organelles have been shown by 
immunofluorescence and coimmunoprecipitation to contain high levels of PI4KIIIβ; 
the enzyme responsible for catalysing the production of PI4P lipids in the ER 
membrane. Depletion of PI4KIIIβ from the cells by either siRNA or through the use of 
inhibitors (such as PIK93), results in a marked reduction in PV and CVB3 RNA synthesis 
(Knight et al., 2006; Hsu et al., 2010; Arita et al., 2011; Greninger et al., 2012). 
Similarly HCV infection enhanced the production of PI4P through stimulation of both 
PI4KIIIα and PI4KIIIβ, and depletion of PI4P also inhibited HCV RNA synthesis 
(Borawski et al., 2009; Berger et al., 2011; Zhang et al., 2012). 
In order to elucidate the role of the intracellular lipid PI4P in the formation of FMDV 
replication factories, a number of small-molecule inhibitors of the lipid pathway were 
used to treat replicon-transfected BHK-21 cells. These were the well-characterised 
inhibitors PIK93 and wortmannin, alongside two novel compounds recently 
developed by AstraZeneca. 
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Figure 5.3 Chemical structures of the PI4K inhibitors used. A) Phenylthiazole PIK93 
(adapted from Knight et al., 2006), B) AstraZeneca PI4KIIIβ inhibitor, compound 3 
(adapted from Waring et al., 2014). C) AstraZeneca PI4KIIIα inhibitor, compound 7 
(adapted from Waring et al., 2014). D) Fungal steroid metabolite, wortmannin 
(adapted from NCBI, PubChem Substance Database; SID=24278777). 
5.3.1 PIK93 
PIK93 was originally developed as an inhibitor of a class I PI3K, p110α (IC50: 39 nM) 
as a treatment for diabetes, due to the key role the kinase plays in the downstream 
activity of the insulin receptor.  
PIK93 is a phenylthiazole compound (Fig. 5.3a), a multi-targeted compound designed 
to have several target selectivities within the PI-kinase family. It was shown to have 
a potent effect against members of the PI4K family of enzymes, particularly on 
PI4KIIIβ (IC50 PI4KIIIα: 1.1 µM, PI4KIIIβ: 19 nM) despite being designed as a PI3K 








5.3.2 Compounds 3 and 7 
Recently, the pharmaceutical company AstraZeneca (AZ) produced a number of 
different compounds from a 100,000-compound screen with complementary 
selectivities for PI4KIIIα and PI4KIIIβ (Waring et al., 2014; Raubo et al., 2015). These 
compounds were designed to inhibit the phosphatidylinositol signalling cascade and 
cancer cell proliferation (Waring et al., 2014). Compound 7 (Fig 5.3c) exhibits 
selective inhibition of PI4KIIIα (IC50 PI4KIIIα: 7 nM, PI4KIIIβ: 1.8 µM), whereas 
Compound 3 (Fig 5.3b) exhibits a similar selectivity as PIK93 on PI4KIIIβ (IC50 PI4KIIIα: 
7.3 µM, PI4KIIIβ: 15 nM). These compounds are termed CMPD (7) and CMPD (3), 
respectively, in their literature. 
5.3.3 Wortmannin  
Wortmannin (Fig 5.3d) is a fungal steroid metabolite from Penicillium funiculosum 
and a potent inhibitor of PI3K (Powis et al., 1994; Wymann et al., 1996). Wortmannin 
functions to inhibit PI3K in a non-competitive, irreversible, and non-specific manner; 
as a result it is able to interact with other PI3K-related proteins, including PI4K (Powis 
et al., 1994; Nakanishi et al., 1995; Downing et al., 1996; Meyers et al., 1997). Its 
mode of action is by binding irreversibly to the catalytic domain of the enzyme 
inhibiting its function. It has also been used to inhibit autophagy induced by HCV 




5.4 Effect of PI4K on IRES-mediated translation 
Many positive-sense RNA viruses have been documented to replicate in membrane-
associated complexes (den Boon and Ahlquist, 2010). There have been several 
reports demonstrating the mechanism of inhibitors affecting membrane lipid 
modification, such as PIK93, on viral replication. However, with the use of GFP-
expressing replicons, it has been difficult to separate effects on translation of input 
viral RNA with those effecting genome replication. To elucidate effects of various 
inhibitors including PIK93 on host and viral translation, we exploited the use of bi-
cistronic vectors containing renilla luciferase (Rluc) and firefly luciferase (Fluc) 
reporter genes under the control of either cap- or IRES-dependent translation 
mechanisms, respectively (Licursi et al., 2011) (Fig 5.4). We have employed a similar 
approach previously to demonstrate the absence of any non-specific effects on 
translation with RNA aptamers selected to FMDV 3Dpol (Forrest et al., 2014).  
Figure 5.4 Schematic of bi-cistronic reporter constructs. The control (pRF) contains 
a structured RNA stem-loop element in place of an IRES resulting in minimal Fluc 
expression. The test constructs contain an IRES from different viruses including 
FMDV, HCV, HRV, and EMCV. All constructs have a 7-methylguanosine cap which 




Five different constructs were used; a control (pRF) with no IRES structure, resulting 
in minimal Fluc expression, and constructs in which Fluc translation was controlled 
by the IRES from FMDV, HCV, human rhinovirus (HRV), or EMCV. The HRV IRES is type 
I, EMCV and FMDV are type II, and the HCV IRES is classed as a type III (Tsukiyama-
Kohara et al., 1992; Belsham, 2009; Martínez-Salas et al., 2015).  
Following transfection of the bi-cistronic reporter constructs into BHK-21 cells as 
described in sections 2.6.4 and 2.6.5, translation was assessed by measuring the 
levels of renilla and firefly luciferase luminescence produced as a result of cap-
dependent and IRES-dependent translation respectively, in the presence or absence 
of the inhibitor PIK93 in increasing concentrations (0-5 µM). A preliminary MTT assay 
did not reveal any reduction in cell viability in the presence of PIK93 at any of the 
concentrations used for the translation assay (Fig 5.5). 
Figure 5.5 MTT cytotoxicity assay of a range of PIK93 concentrations (0-5 µM) on 
BHK-21 cells. The assay shows no cytotoxicity of PIK93 on cells at the concentrations 
used (0-5 µM) based on the percentage of viable cells, normalised to the untreated 
control (0 µM). Data showing mean values with SEM (n = 2).  
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For all of the bi-cistronic constructs used, there was a modest but non-significant 
inhibition of cap-mediated translation in the presence of an increasing concentration 
of PIK93 (0–5 µM). However, the effects of PIK93 on IRES-mediated translation (Fig. 
5.6b) were more profound. There was an average decrease in luciferase signal 
ranging from 44.2 ± 13.5 % in constructs treated with 1 µM to 73.3 ± 5.0 % in those 
treated with 5 µM PIK93. Treatment with concentrations higher than 1 µM of PIK93 
significantly reduced FMDV, HCV, and EMCV IRES-driven luciferase expression. 
However, with the HRV IRES, a significant reduction in luciferase expression was only 
observed at 5 µM PIK93.  
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Figure 5.6 BHK-21 cells transfected with the bi-cistronic constructs and treated with 
varying concentrations of PIK93 for 48 hours. The data show levels of luciferase 
expression under the control of (a) Cap-mediated translation, and (b) IRES-mediated 
translation. The control (pRF) contains the Firefly reporter under the control of a non-
IRES structure and the Renilla reporter under the control of cap-mediated 
translation. Data showing mean values with SEM (n = 3). Statistical analysis 
performed using two-tailed unpaired t-test; * = p < 0.05, ** = p < 0.01 *** = p < 0.001, 
**** = p < 0.0001).   
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5.5 Effect of PI4K on RNA replication  
The result of the initial translation assay and treatment with PIK93 brings into 
question whether some of the documented effects of PIK93 on replication could be 
the result of suppression of input viral RNA translation. In order to clarify this, we 
compared the effects of PIK93 on the replication of wildtype (WT) and replication-
deficient FMDV replicons with those of CVB3, previously shown to be dependent on 
PI4K activity (Lanke et al., 2009). Due to the different reporters used, replication was 
monitored by luciferase assay or by GFP expression. 
The development of the FMDV GFP-pac replicon and optimisation of the replication 
assay has been previously described (Forrest et al., 2014). Replication was detected 
by measuring the levels of GFP expression over time using an IncuCyte Dual Colour 
ZOOM® FLR (Tulloch et al., 2014), with maximum fluorescence values being observed 
at 8-10 hours post-transfection. At this time-point up to 80 % of cells transfected with 
the GFP-pac-WT replicon RNA expressed high levels of GFP, and therefore replication 
can be equally assessed by either number of GFP positive cells or total GFP 
fluorescence. Use of the replication-deficient mutant replicon (GFP-pac-GNN) 
resulted in a markedly lower GFP signal (i.e. as a result of input translation only). 
Levels of GFP expression in GFP-pac-GNN replicon-transfected cells were similar to 
those with a second replication-deficient replicon, GFP-pac-Δ3D that contained a 





Figure 5.7 Levels of GFP expression as a measure of replication in BHK-21 cells 
transfected with replicon RNA. BHK-21 cells transfected with GFP-pac-WT (a, b, and 
c) or GFP-pac-GNN (d, e, and f) were either pre-treated for two hours with PIK93 at 
the indicated concentrations, or concurrently with transfection (T=0). Levels of GFP 
expression of pre-treated cells transfected with GFP-pac-WT and GFP-pac-GNN were 
measured over 20 hours (a, b, d, and f). Levels of GFP expression of the treated and 
untreated cells were compared against untreated controls at peak GFP expression 
(11 hours). GFP data were collected by imaging GFP fluorescence hourly in 
transfected cells using an IncuCyte Dual Colour ZOOM® FLR and measuring the 
number of GFP-expressing cells per well. (n = 1).
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Due to the observed lack of cytotoxic effects of PIK93 on the cells at the 
concentrations used for the MTT assay (Fig 5.5), the same concentrations of PIK93 
were applied to the cells at two hours prior to transfection. The effects of the 
addition of PIK93 prior to transfection were investigated to assess if depleting 
intracellular PI4P prior to transfection would further affect the ability for the replicon 
to replicate.  
Results outlined in Fig. 5.7 show that for both GFP-pac-WT and GFP-pac-GNN, two-
hour pre-treatment of cells with PIK93 results in the greatest inhibition of GFP 
expression than in cells treated with PIK93 at the same time as transfection (T=0). In 
WT-transfected cells, pre-treatment with 5 µM PIK93 resulted in a 44.2 % decrease 
in the levels of GFP expression when compared to un-treated cells. Cells that were 
treated with PIK93 concurrently had similar reduction in GFP expression (40.7 %) (Fig 
5.7a). Likewise, GNN-transfected cells showed a 50.3 % reduction in GFP expression 
when pre-treated with PIK93, but no inhibitory effect on GFP expression when cells 
were treated with PIK93 at the time of transfection (14.4 % increase in GFP 
expression) (Fig. 5.7d). It seems possible that PIK93 may be reducing the levels of 
cellular PI4P. 
The addition of PIK93 at two hours pre-transfection was selected as the condition to 
be used for future experiments, this resulted in a dose-dependent reduction in GFP 
expression in cells transfected with GFP-pac-WT or –GNN replicon RNA (Fig. 5.8). 
Reduction of GFP expression in cells transfected with GFP-pac-WT ranged from 30.9 
± 6.7 % to 50.0 ± 3.9 % after treatment with 1 and 5 µM PIK93 respectively, when 
compared to untreated control cells (Fig. 5.8a, b). In GFP-pac-GNN transfected cells 
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there was a 45.5 ± 2.3 % to 69.8 ± 5.2 % reduction (Fig. 5.8c, d). The reduction in GFP 
expression in cells transfected with GFP-pac-GNN in the presence of 5 µM PIK93 (69.8 
± 5.2 %) is similar to the decrease observed on FMDV IRES-mediated translation with 
the same concentration of PIK93 (74.1 ± 5.4 %).  
Figure 5.8 Measuring the effect of replication of FMDV replicon RNA in BHK-21 cells 
treated with PIK93. BHK-21 cells transfected with (a, b) GFP-pac-WT and (c, d) GFP-
pac-GNN replicon RNAs. Transfected cells were pre-treated for two hours with PIK93 
at the indicated concentrations and levels of GFP expression were compared against 
untreated controls. Data were collected by imaging GFP fluorescence hourly in 
transfected cells using an IncuCyte Dual Colour ZOOM® FLR. Levels of GFP expression 
9 hours post-transfection are shown (b) and (d), indicated by dotted line on (a) and 
(c). Mean values with SEM (n = 3) are shown. Statistical analysis performed using two-




The effect of PIK93 was then assayed on WT and replication-deficient CVB3 replicons 
(Fig. 5.9). As expected, and in contrast to the results with FMDV replicons (Fig. 5.8b), 
there was a more pronounced dose-dependent effect of PIK93 on CVB3 replication. 
At 5 µM, PIK93 treatment resulted in a 98.7 ± 0.6 % decrease in luciferase expression 
in cells transfected with WT Rib-Fluc-CB3/T7 RNA, compared to untreated controls 
(Fig. 5.9b). However, cells transfected with replication-deficient Rib-Fluc-CB3/T7-3A 
RNA and treated with 5 µM PIK93 only, exhibited a 38.9 ± 13.7 % decrease in 
luciferase expression (Fig. 5.9c); much less than that seen with FMDV (Fig. 5.8d). It 
should be noted that replication of the FMDV and CVB3 constructs were assayed 
differently; despite this the data were consistent with the hypothesis that FMDV 
genome replication did not require PI4K activity, and that the effect of PIK93 was an 
indirect effect of inhibition of protein translation.
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Figure 5.9 Measuring the effect of PIK93 on CVB3 replicon RNA replication in BHK-
21 cells. a) Schematic diagram of the CVB3 replicon indicating location of the 5' and 
3' untranslated region flanking the genes encoding replication proteins. The firefly 
luciferase reporter gene replaces the structural capsid proteins. Levels of luciferase 
expression in HeLa cells transfected with (b) Rib-Fluc-CB3/T7 or (c) Rib-Fluc-CB3/T7-
3A CVB3 replicon RNAs. Transfected cells were pre-treated for two hours with PIK93 
at the indicated concentrations and levels of luciferase expression were compared 
against an untreated control. Levels of luciferase expression were measured at eight 
hours post-transfection. Data show mean values with SEM (n = 3). Statistical analysis 




5.5.1 FMDV replication does not require PI4KIIIα or β activity. 
Given that some positive strand RNA viruses have been shown to require PI4KIIIα for 
genome replication (e.g. HCV), it was thus formally possible that the lack of effect of 
PIK93 could be explained if FMDV genome replication exhibited a requirement for 
PI4KIIIα but not PI4KIIIβ. 
We therefore proceeded to directly test if the lack of sensitivity to PIK93 could be 
explained by a requirement for PI4KIIIα in FMDV genome replication. As a positive 
control for inhibition of PI4KIIIα we utilised Huh 7.5 cells transiently expressing an 
HCV sub-genomic replicon (SGR-Luc-GFP-JFH1), derived from the JFH-1 infectious 
clone and containing an insertion of GFP into domain III of NS5A (Jones et al., 2007).  
This allowed HCV genome replication to be assayed using the IncuCyte system, as 
described for FMDV above. 
In order to determine if FMDV required PI4KIIIα two novel compounds produced by 
AstraZeneca, compounds (CMPD) 3 and 7 were used. CMPD (7) was designed to have 
selective inhibitory activity against PI4KIIIα, and CMPD (3) against PI4KIIIβ. Prior to 
any experimentation with the compounds it was first necessary to determine 
whether either CMPD (3) or (7) exhibited any cytotoxicity in BHK-21 cells (for FMDV 
experiments), or Huh 7.5 (for HCV) using an MTT assay. As shown in Figs. 5.10a and 
5.10b the compounds were tolerated up to 10 µM by both cell types, although at 20 
µM both exhibited significant cytotoxicity. We therefore tested the effects of CMPD 
(3) and CMPD (7) on both FMDV (Fig. 5.10c) and HCV (Fig. 5.10d) replication at 0.5 
and 10 µM. As shown in Fig. 5.10c, FMDV replication was only modestly reduced (≈20 
%) by the higher concentration of both compounds. Reassuringly, CMPD (7) (selective 
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for PI4KIIIα) inhibited HCV replication even at 0.5 µM (Fig. 5.10d), CMPD (3) (selective 
for PI4KIIIβ) had no effect. We deduce that FMDV genome replication is not 
dependent on either PI4KIIIα or PI4KIIIβ. 
Figure 5.10 The effect of novel PI4KIIIα/β compounds on the replication of FMDV 
and HCV replicon RNA. A) MTT assay of BHK21 cells or (B) Huh 7.5 cells treated with 
either a selective PI4KIIIα inhibitor (compound 7), or PI4KIIIβ inhibitor (compound 3) 
at the indicated concentrations. (C) GFP-pac-WT replicon RNA-transfected BHK21 
cells were treated with inhibitors as indicated and levels of GFP expression were 
compared against an untreated control. Levels of GFP expression was measured at 
eight hours post-transfection. (D) HCV SGR-Luc-GFP-JFH1 replicon RNA-
electroporated Huh 7.5 cells were treated with inhibitors as indicated and levels of 
NS5A-GFP expression were compared against an untreated control. Levels of NS5A-
GFP expression was measured at 48 hours post-electroporation. Data show mean 
values with SEM (n = 3). Statistical analysis performed using two-tailed unpaired t-
test; * = p < 0.05, ** = p < 0.01.  
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5.5.2 FMDV replication does not result in upregulation of PI4P lipids. 
It has previously been described (Reiss et al., 2011; Zhang et al., 2012; Ross-
Thriepland et al., 2015) that HCV utilises the PI4K pathway to assist in the formation 
of membranous intracellular replication factories, termed the ‘membranous web’ 
and consequently the abundance of PI4P lipids is upregulated during HCV RNA 
replication. Due to the lack of evidence that FMDV replication is dependent on PI4K 
activity, it was predicted that cells harbouring FMDV replicons would not exhibit a 
similar upregulation of PI4P lipids. To test this, we compared the levels of PI4P lipids 
in cells harbouring either HCV- or FMDV-derived replicons. As shown in Fig. 5.11a and 
b, Huh 7.5 human hepatoma cells harbouring an HCV replicon showed high levels of 
PI4P lipids as judged by immunofluorescence analysis using antibodies specific for 
PI4P (Ross-Thriepland et al., 2015). This was lost following treatment with PIK93 and 
CMPD (7) (selective for PI4KIIIα), consistent with the replication data shown in Fig. 
5.10d. 
In contrast, BHK-21 cells transfected with FMDV GFP-pac RNA did not exhibit an 
increase in PI4P staining compared to untransfected cells (Fig. 5.11c and d). 
Furthermore, there were no significant differences in the levels of PI4P staining in 
BHK-21 cells after treatment with any of the inhibitors tested. We propose that FMDV 
does not require type III PI4K activity for genome replication and consequently does 










Figure 5.11 (pp. 176-177) Effect of PIK93, CMPD (3), and CMPD (7) on the levels of 
PI4P expression in cells. Fluorescence microscopy of (a) Huh 7.5 cells electroporated 
with HCV SGR-Luc-GFP-JFH1 replicon RNA, and (c) BHK21 cells transfected with GFP-
pac-WT replicon RNA. Transfected cells were treated with 10 µM PI4KIIIα inhibitor 
(AZ13647670), PI4KIIIβ inhibitor (AZ13686489), or 5 µM PIK93. Fixed cells were 
stained with anti-PI4P antibody (mouse).  NS5A was detected by anti-NS5A antibody 
(sheep). Levels of PI4P expression were measured and presented as total PI4P 
intensity measured in arbitrary units in (b) Huh 7.5 cells and (d) BHK21 cells. Scale bar 
= 20 µm. Data show mean values with SEM (n = 10). 
5.5.3 Involvement of PI3K pathway in FMDV replication 
The observed effects of PIK93 on translation of the FMDV replicon (Fig. 5.6), could 
have been as a result of non-specific interactions between the inhibitor and the host-
cell translation mechanism, coupled with the colocalisation immunofluorescence 
studies described in Berryman et al. 2016 supported the hypothesis that FMDV did 
not utilise the PI4K pathway like other Picornaviruses.  
To test if alternative PI pathways were involved in FMDV replication, wortmannin, a 
fungal steroid metabolite that has been shown to inhibit PI3K in a non-competitive, 
irreversible, and non-specific manner was used (Powis et al., 1994; Wymann et al., 
1996; Meyers et al., 1997). The use of wortmannin would discern if FMDV utilised 
PI3K for RNA replication.  
Cells transfected with GFP-pac-WT showed a reduction of GFP expression of up to 
71.6 % in cells treated with 2 µM wortmannin. Similarly, cells transfected with GFP-
pac-GNN also had a decrease of GFP expression of 82.5 %. The results were 
inconclusive in that treatment of cells with wortmannin still resulted in a decrease in 
GFP-positive cells per well in both GFP-pac-WT and GFP-pac-GNN transfected cells, 
179 
 
similar to the effects seen in transfected cells treated with PIK93, even with lower 
concentrations of wortmannin (Fig. 5.12).  
When the wortmannin data were combined with the PIK93 data, the wortmannin 
data suggest that the PI3K as well as the PI4K pathway were either affecting the 
translation mechanisms inside the cells, or both compounds have a non-specific 
effect on transfected cells degrading the replicon RNA. 
Figure 5.12 Effect of wortmannin on replication of FMDV replicon RNA. BHK-21 cells 
transfected with either GFP-pac-WT or GFP-pac-Δ3D replicon RNA were treated with 
a titration of wortmannin (0-2 µM). Graph indicates the percentage of cells 
expressing GFP as an indication of replication when treated with wortmannin when 
compared to an untreated control (0 µM). Levels of GFP expression were measured 




5.6 Chapter discussion 
The PI4K family of enzymes has been shown to be involved in the genome replication 
of many positive-sense RNA viruses, primarily in the formation of intracellular 
membranous compartments by generating PI4P lipids. These compartments are 
proposed to house the viral replication factories to protect the viral RNA from 
degradation and recognition by the host-cell innate immune response. It has also 
been observed that some viruses, such as HCV, upregulate PI4K expression and 
activity. PIK93 is a PI4KIIIβ small molecule inhibitor, but has shown to have an 
additional inhibitory effect on PI4KIIIα and PI3K (Knight et al., 2006). It has been 
demonstrated previously that the treatment of cells with PIK93 down-regulated the 
generation of PI4P lipids by inhibiting the activity of PI4KIIIα and β. Furthermore, 
studies with HCV, CVB3, and PV have shown that treating infected cells with PIK93 
reduced virus genome replication (Altan-Bonnet et al., 2012). However, from the 
studies reported here, it appears that the apparent effect on FMDV genome 
replication is actually due to effects on translation. We have demonstrated that IRES-
mediated translation is sensitive to PIK93. There is an additional effect on genome 
replication for CVB3, but not for FMDV.  
We found no evidence by immunofluorescence microscopy staining for PI4P lipids 
that FMDV replication leads to an accumulation of these lipids. However, in cells 
electroporated with HCV replicon, RNA levels of PI4P were stimulated as expected. 
These data suggest that the PI4K pathway is not the primary pathway involved with 
FMDV genome replication. 
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Membrane reorganisation during HCV infection has been well defined and it has 
been reported that PI4KIIIα plays an essential role in the formation of intracellular 
replication factories required for replication (Trotard et al., 2009; Reiss et al., 2011). 
PI3K has also been implicated in HCV replication by recruiting membranous 
compartments from the endocytic pathway (Sir et al., 2012; Liu et al., 2012; Mohl et 
al., 2016). It has been demonstrated that FMDV induces the formation of 
autophagosomes from the endocytic pathway to facilitate cell entry, but this does 
not appear to be involved in viral replication. In FMDV, autophagosome formation is 
induced in a PI3K-independent manner (Berryman et al., 2012), whereas inhibition 
of both PI3K and PI4KIIIα significantly inhibits HCV replication (Gosert et al., 2003; 
Berger et al., 2009).  
There is evidence from the literature that reorganisation of cellular membranes 
during FMDV infection is different to that seen during infection with other 
picornaviruses. FMDV infection results in a dramatic condensation and relocalisation 
of intracellular organelles to one side of the cytoplasm in the perinuclear region 
(Monaghan et al., 2004) and is unaffected by brefeldin A, a fungal metabolite that 
disrupts retrograde Golgi-ER transport. It has been shown that brefeldin A interacts 
with Arf1/GBF1; interference with GBF1 affects the recruitment of PI4KIIIβ and 
subsequent PI4P-lipid up-regulation. Interestingly, treatment of cells with brefeldin 
A has been shown to enhance FMDV infection (Midgley et al., 2013). Recent studies 
have shown that PV, CVB3, and HRV are able to recruit PI4KIIIβ in an Arf1/GBF1-
independent manner highlighting the complexity of the mechanisms by which 
picornaviruses recruit intracellular membranes. (O’Donnell et al., 2001; Midgley et 
al., 2013; Dorobantu et al., 2014; Dorobantu, Ford-Siltz, et al., 2015). 
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Overall, these studies support the results shown here suggesting that PI4Ks are not 
involved in FMDV replication. The data and conclusions described here are supported 
by a recently published paper (Berryman et al., 2016). Therefore, it can be 
hypothesised that FMDV may subvert an alternative cellular pathway to affect the 
membrane reorganisation required to support virus replication, or may not require 




Concluding Remarks and Future Perspectives 
The primary focus of the work in this thesis was to dissect the role of FMDV 3Dpol in 
viral replication. Although the formation of a classical, discrete intracellular 
membrane-associated replication complex, usually associated with picornavirus 
replication, had yet to be identified within FMDV infected cells, the ability for FMDV 
to form higher-order fibril structures, which appear to require the presence of RNA, 
provide an attractive candidate for the nucleus of a replication complex. The fibrils 
could provide an enclosed, protective environment within which replication can 
occur in an energetically favourable manner. However, there are still outstanding 
questions of how FMDV fibrils form, and what is necessary for these structures to 
form in cells, if indeed, they are involved in whole, or as part of the proposed 
replication complex. 
The studies described in Chapter 3 and 4 provide preliminary results concerning the 
function and structure of the 3Dpol fibrils. The results showed that although WT 3Dpol 
was able to form fibrils, none of the mutants tested here were able to do so. 
Mutations in the polymerase that were located within the catalytic domain of the 
protein (DD388/9NN and DD240/5NN) resulted in non-functional, replication-
deficient replicons and were unable to form any higher-order fibril-like structures. 
The polymerase containing a mutation located in the non-catalytic dsRNA exit site, 
GC216/7AA, was also unable to replicate in context of the FMDV replicon, or form 
any distinctive higher-order fibril-like structures. However, the GC216/7AA mutant 
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was able to bind to RNA with WT affinity, and was able to incorporate radiolabelled 
RNA nucleotides. However, this mutation rendered the replicon non-functional and 
unable to be recovered when co-transfected with WT helper replicon, unlike the 
catalytic mutations, unless both the S-fragment was removed from the 5ʹ UTR, and if 
the cre was inactivated. 
The combination of the ability of the non-catalytic mutant GC216/7AA to incorporate 
RNA nucleotides, along with only being able to be recovered when the regions of the 
5ʹ UTR were removed, points to a novel, necessary cis function for the polymerase in 
addition to its catalytic polymerase activity as suggested in Herod et al., 2016. 
This novel information highlights the importance to undertake further work to 
determine what aspects of polymerase function are important for the formation of 
fibrils. This process of fibril formation identified here is unique to FMDV; PV can form 
fibrils spontaneously even if the polymerase is catalytically inactive. This would 
suggest that the formation of fibrils during FMDV replication has a functional role, as 
opposed to simply acting as a scaffold. The natural progression of this assay would 
be to assess the ability of FMDV 3Dpol to form fibrils if a different non-catalytic site 
were mutated. For example, investigating whether the fibrils are able to form if the 
proposed protein-protein interacting residues were changed, and investigating 
whether these mutations hinder the ability for 3Dpol to bind or incorporate RNA. 
Additionally, it would indicate to further investigate whether these mutations 
affected the replication ability of FMDV in context of the replicon. 
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The hypothesis that the polymerase may have a primary catalytic function and a 
secondary non-catalytic role in replication, both of which involve binding to RNA 
supports the notion that RNA is necessary for the correct formation of fibrils.  
Based on the orientation of the individual polymerase molecules within the fibril 
from the cryo-EM data, it is possible to imagine that the RNA would be replicated by 
the catalytic polymerase, and the newly synthesised negative-strand replicative 
intermediate could become coated by the other polymerase molecules, protecting it 
from degradation by host-cell ribonucleases or detection by the host innate immune 
system. However, proving this hypothesis has been challenging, primarily due to 
being unable to identify density corresponding to RNA associated with the fibrils as 
analysed by cryo-EM. The presence of RNA is necessary for the formation of fibrils 
but so far, no evidence of an interaction has been visualised. 
A reason for the inability to identify RNA density within the fibrils could be due to low 
occupancy levels: if only one of 20 molecules contained RNA, RNA density would not 
be detected. Another reason for the inability to measure any RNA density within the 
fibrils could be due to the RNA primer-template that was used being too unstructured 
and flexible to be visualised by standard negative-stain TEM or cryo-EM as a result of 
the presence of flexible loops extending from the fibril. These loops, if present, could 
be subjected to immunogold labelling and subsequent visualisation by TEM. 
However, the presence of flexible RNA is unlikely as RNA density would be expected 
to be seen within the polymerase active site, and as yet this has not been identified. 
Further work needs to be undertaken to elucidate a potential interaction between 
fibrils and RNA. Methods to determine this interaction include purifying fibrils by 
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gradient densitometry then determining if the protein and RNA appear in the same 
fractions, or alternatively by a particle stability thermal release (PaSTRy)-style assay 
(Walter et al., 2012) where identification of potentially protected RNA can occur by 
disassembling the fibrils and labelling the RNA that may be trapped within.  
Furthermore, identifying whether there are interactions between additional non-
structural proteins and fibrils in vitro would strengthen the hypothesis that the fibrils 
were central for the formation of replication complexes, particularly if there was a 
direct interaction with proteins such as 3A that have a known membrane-associating 
domain. Studies on PV have shown that its polymerase associates with precursor 
proteins 3AB; based on the existing similarities between PV and FMDV, it is 
conceivable that a similar interaction is probable, potentially even with other non-
structural proteins such as 2B and 2C. 
It would also be interesting to see if fibrils can be identified in replicon-containing 
cells. As the 3Dpol is his-tagged, it provides an attractive target for 
immunoprecipitation studies and could provide evidence for potential replication 
complex formation within cells if interactions with other non-structural viral proteins, 
cellular protein or RNA can be identified using this method. Additionally, the use of 
tagged constructs could be used in super-resolution microscopy studies. Preliminary 
confocal studies described in chapter 4 showed that WT and mutant 3Dpol could be 
identified within cells following replicon transfection. A similar process could thus be 
used to try and identify replication complex formation on a single molecule scale. 
Identifying interactions between the P2 non-structural proteins and other non-
structural proteins, particularly 3Dpol, may also provide answers to the apparent 
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importance of 2B in the recovery of replicon RNA in transfected cells. The co-
transfection studies between replicons that contain a WT or a mutant polymerase 
showed that either the presence of 2B, or the presence of a helper RNA of a specific 
length was necessary for recovery to occur. However, studies have pointed to the 
importance of 2B, 2C, and 2BC in virus replication, particularly in the dysregulation 
of the ER- and Golgi-derived membranes. It is highly likely that these proteins are 
necessary in the formation of a replication complex. 
The potential for a large protected replication complex to form involving the 3Dpol 
fibrils and non-structural proteins such as 2BC which results in the dysregulation of 
host-cell intracellular membrane compartments provides an attractive hypothesis for 
the lack of PI4K pathway involvement during replication. Our data has shown that 
the use of this pathway is not required for FMDV replication and that the 
dysregulation of the ER- and Golgi-derived membranes previously observed during 
FMDV replication was not due to the hijacking of the cellular kinase pathway. Further 
work focussing on alternative membrane trafficking pathways needs to be 
undertaken to identify the involvement of other host-cell mechanisms that could be 
involved in the rearrangement of intracellular membranes due to FMDV infection. 
In conclusion, the studies outlined here have provided the scaffold for the 
understanding of the formation of the FMDV replication complex. As a picornavirus, 
the structure and formation of the replication complex is likely to share some 
similarities to other related viruses such as PV and CVB3. However, there are a 
number of key differences not only in the genome structure and organisation, but 
also in the formation of the 3Dpol higher-order complexes, as well as the ability for 
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the virus to replicate independently without the recruitment of host-cell membrane 
rearrangement factors. Therefore, it is likely that predicting the components and 
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